WO2021069705A1 - Isoindolinone compounds - Google Patents

Isoindolinone compounds Download PDF

Info

Publication number
WO2021069705A1
WO2021069705A1 PCT/EP2020/078483 EP2020078483W WO2021069705A1 WO 2021069705 A1 WO2021069705 A1 WO 2021069705A1 EP 2020078483 W EP2020078483 W EP 2020078483W WO 2021069705 A1 WO2021069705 A1 WO 2021069705A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
membered heterocycloalkyl
compound
branched
linear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2020/078483
Other languages
English (en)
French (fr)
Inventor
Alexander Flohr
Olive EIDAM
Bernhard FASCHING
Mirco Meniconi
Amine SADOK
Rajesh Chopra
Hannah ZHU`AI WANG
John Jamieson Caldwell
Ian Collins
Thomas Ryckmans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monte Rosa Therapeutics AG
Original Assignee
Monte Rosa Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monte Rosa Therapeutics AG filed Critical Monte Rosa Therapeutics AG
Priority to JP2022521718A priority Critical patent/JP7724394B2/ja
Priority to EP20789952.7A priority patent/EP4041231A1/en
Publication of WO2021069705A1 publication Critical patent/WO2021069705A1/en
Priority to US17/716,169 priority patent/US20220242846A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Definitions

  • the present disclosure relates to new compounds as modulators of cereblon.
  • the disclosure also relates to methods of preparation of these compounds, compositions comprising these compounds, and methods of using them in the treatment of abnormal cell growth in mammals, especially humans.
  • the ubiquitin proteasome system can be manipulated with different small molecules to trigger targeted degradation of specific proteins of interest. Promoting the targeted degradation of pathogenic proteins using small molecule degraders is emerging as a new modality in the treatment of diseases.
  • One such modality relies on redirecting the activity of E3 ligases such as cereblon (a phenomenon known as E3 reprogramming) using low molecular weight compounds, which have been termed molecular glues (Tan et al. Nature 2007, 446, 640- 645 and Sheard et al. Nature 2010, 468, 400-405) to promote the poly-ubiquitination and ultimately proteasomal degradation of new protein substrates involved in the development of diseases.
  • the molecular glues bind to both the E3 ligase and the target protein, thereby mediating an alteration of the ligase surface and enabling an interaction with the target protein.
  • Particular relevant compounds for the E3 ligase cereblon are the IMiD (immunomodulatory imide drugs) class including Thalidomide, Lenalidomide and Pomalidomide. These IMiDs have been approved by the FDA for use in hematological cancers. However, compounds for efficiently targeting other diseases, in particular other types of cancers, are still required. Summary of disclosure
  • compounds are provided which efficiently target c-Myc dependent cells over non c-Myc dependent cells.
  • compounds are provided for use in therapy of solid tumors, in particular for use in the therapy of breast cancer.
  • the present disclosure is in a first aspect directed towards a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula I: wherein
  • X 1 is linear or branched C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 alkyl C 3.6 cycloalkyl, C 6-10 aryl,
  • X 1 is unsubstituted or substituted with one or more of halogen, linear or branched C 1-6 alkyl, C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , -O- (CH 2 ) 2 -OMe, OCF 3 , C 6-10 alkylamino, -CN, -N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1-6 alkyl, -OC(O)-C 1-4 alkylamino, -C(O)O-C 1-6 alkyl, -COOH, -CHO, -C 1-6 alkylC(O)OH, -C,.
  • X 2 is hydrogen, C 6-10 aryl, 5-10 membered heteroaryl, -0(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -0(4-8 membered heterocycloalkyl), -O-C 1-4 alkyl-(4-8 membered heterocycloalkyl), -OC(O)-C 1-4 alkyl-4-8 membered heterocycloalkyl or C 6 aryloxy, wherein X 2 is unsubstituted or substituted with one or more of linear or branched C 1-6 alkyl, NH 2 , NMe 2 or 5-6 membered heterocycloalkyl; n is 0, 1 or 2.
  • X 1 is linear or branched C 1-4 alkyl, C 3-6 cycloalkyl, -C 1-4 alkyl C 3-6 cycloalkyl, C 6 aryl, 5-10 membered heteroaryl, C 1-6 alkyl C 6 aryl, C 1-6 alkyl 5-10 membered heteroaryl, wherein X 1 is unsubstituted or substituted with one or more of halogen, linear or branched C 1-4 alkyl, C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 1-6 alkylamino, -CN, -N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1-6 alkyl, -OC(O)-C 1-4 alkylamino, -C(O)O- C 1- 6 alkyl, -COOH,
  • Y 1 is hydrogen, C 6 aryl, 5- 10 membered heteroaryl, C 3-6 cycloalkyl, wherein Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1-4 alkyl, C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , -O-(CH 2 ) 2 - OMe, OCF 3 , -CN, -N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1-6 alkyl, -OC(O)-C 1- 4 heteroalkyl, -C(O)O-C 1-6 alkyl, -COOH, -CHO, -C 1-6 alkylC(O)OH, -C,. 6alkylC(O)O-C 1-6 alkyl, NH 2 , C 1-6 alkoxy or C 1-6 alkylhydroxy;
  • Y 2 is hydrogen, C 6 aryl, 5-10 membered heteroaryl, -0(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -0(4-8 membered heterocycloalkyl), -O-C 1-4 alkyl-(4-8 membered heterocycloalkyl), -OC(O)-C 1-4 alkyl-4-8 membered heterocycloalkyl or C 6 aryloxy, wherein Y 2 is unsubstituted or substituted with one or more of linear or branched C 1-6 alkyl, NH 2 , NMe 2 or 5-6 membered heterocycloalkyl.
  • R a , R b each are independently selected from hydrogen and linear or branched C 1-4 alkyl, preferably hydrogen and methyl.
  • n is 1 .
  • the present disclosure is directed towards a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula Ilia, lllb or lllc
  • n is 1 or 2 p is 0, 1 or 2 one of w 1 , w 2 or w 3 is selected from C and N, and the other two of w 1 , w 2 or w 3 are C; one or two of w 4 , w 5 , w 6 , w 7 is selected from C, O, N, NMe, NH, or S while two or three of w 4 , w 5 , w 6 and w 7 are C;
  • R 1 , R 2 , R 3 , R 4 each are independently selected from hydrogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , - O-CHF 2 -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, -N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1- 4 alkylamino, -OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -CHO, -C,.
  • R 6 alkylC(O)OH, -C 1-6 alkylC(O)O-C 1-6 alkyl, NH 2 , C1-4 alkylhydroxy, halogen, preferably F, Cl, Br, more preferably F or Cl; and/or two of R 1 , R 2 , R 3 , R 4 form together a 5-6 membered heterocycloalkyl or a 5-6 membered heteroaryl;
  • R 5 , R 6 each are independently selected from hydrogen, linear or branched C 1-4 alkyl, CF 3 ,
  • CHF 2 halogen, preferably F, Cl, Br, more preferably F or Cl;
  • X 3 is absent, hydrogen or 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membered heterocycloalkyl), -C 1-4 alkoxy-(4-8 membered heterocycloalkyl), 5-10 membered heteroaryl, -0(5-10 membered heteroaryl), -OC(O)-C 1-4 alkyl-4-8 membered heterocycloalkyl, wherein X 3 is unsubstituted or substituted with one or more of linear or branched C 1-6 alkyl, NH 2 , NMe 2 or 5-6 membered heterocycloalkyl;
  • Z is linear or branched C 1-6 alkyl or C 3-6 cycloalkyl or C 1-4 alkoxy, wherein Z is unsubstituted or substituted with C 1-4 alkyl.
  • n is 1 .
  • p is 0 or 1 .
  • R 1 , R 2 , R 3 are defined as above and R 4 is hydrogen such that the aromatic ring contains 4 or 5 substituents which are not hydrogen.
  • R 1 and R 2 are defined as above and R 3 and R 4 each are hydrogen, such that the aromatic ring contains 3 or 4 substituents which are not hydrogen.
  • W, W 1 , W 2 , W 3 are independently selected from
  • the disclosure is directed to a composition
  • a composition comprising a compound according to any one of the embodiments or pharmaceutically acceptable salts or stereoisomers thereof described herein.
  • the composition further comprises a pharmaceutically acceptable carrier.
  • the composition further comprises a second therapeutically active agent.
  • the disclosure is directed to a composition according to any of the embodiments described herein, for use in therapy.
  • certain embodiments comprise a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula I- IV, a pharmaceutical acceptable salt thereof or a composition described herein for use in treatment of diseases associated or caused by GSPTI , in pa rticularthe treatment of cancer associated with GSPT1 , such as glioma, thyroid cancer, lung cancer, colorectal cancer, head and neck cancer, stomach cancer, liver cancer, pancreatic cancer, renal cancer, urothelial cancer, prostate cancer, testis cancer, breast cancer, cervical cancer, endometrial cancer, ovarian cancer, melanoma and multiple myeloma.
  • cancer associated with GSPT1 such as glioma, thyroid cancer, lung cancer, colorectal cancer, head and neck cancer, stomach cancer, liver cancer, pancreatic cancer, renal cancer, urothelial cancer, prostate cancer, testis cancer, breast cancer, cervical cancer, endometrial cancer, ovarian cancer, melanoma and multiple myeloma.
  • Some embodiments comprise the compound or the composition according to any of the embodiments described herein for use in the treatment of breast cancer.
  • the disclosure is directed to a use of a compound or the composition according to any of the embodiments described herein for binding to cereblon comprising administering to a subject a therapeutically-effective amount of the composition.
  • Some embodiments comprise the use of a compound or the composition according to any of the embodiments described herein for treating cancer in particular breast cancer. Certain embodiments comprise the use of a composition according to any of the embodiments described herein for treating cancer associated with GSPT1 , such as glioma, thyroid cancer, lung cancer, colorectal cancer, head and neck cancer, stomach cancer, liver cancer, pancreatic cancer, renal cancer, urothelial cancer, prostate cancer, testis cancer, breast cancer, cervical cancer, endometrial cancer, ovarian cancer, melanoma and multiple myeloma.
  • GSPT1 such as glioma, thyroid cancer, lung cancer, colorectal cancer, head and neck cancer, stomach cancer, liver cancer, pancreatic cancer, renal cancer, urothelial cancer, prostate cancer, testis cancer, breast cancer, cervical cancer, endometrial cancer, ovarian cancer, melanoma and multiple myeloma.
  • the disclosure is directed to a method of treating cancer in a subject, comprising administering to a subject a therapeutically effective amount of the compound or the composition of any of the embodiments as described herein.
  • the method comprises a compound according to any of the embodiments as described herein or pharmaceutically acceptable salts or stereoisomers thereof that binds to cereblon.
  • a dashed line depicts the site of attachment of a residue (i.e. a partial formula).
  • C 6-10 aryl refers to a fully or partially aromatic ring system having 6, 7, 8, 9, 10 ring atoms and includes monocycles and fused bicycles.
  • Examples of C 6-10 aryl include e.g. phenyl, indenyl, naphthyl, 1 , 2, 3, 4-tetrahydronaphthyl.
  • 5 to 10 membered heteroaryl refers to a fully or partially aromatic ring system having 5, 6, 7, 8, 9, 10 ring atoms selected from C, N, O, or S, preferably C, N, or O, more preferably C, N, with the number of N atoms preferably being 0, 1 , 2 or 3 and the number of O and S atoms each being 0, 1 or 2.
  • the term “5-10 membered heteroaryl” comprises monocycles and fused bicycles.
  • Fully aromatic ring systems are preferably monocycles with 5 or 6 ring atoms, selected from C, N, O, or S, preferably C, N, or O, more preferably C, N, with the number of N atoms preferably being 0, 1 , 2 or 3 and the number of O and S atoms each being 0, 1 or 2.
  • Partially aromatic ring systems are preferably fused bicycles with 8 or 9 ring atoms, selected from C, N, O, or S, preferably C, N, or O, more preferably C, O.
  • Examples of "5 to 10 membered heteroaryl” include furyl, imidazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl (pyrazyl), pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, thiazolyl, thienyl, indolyl, quinazolinyl, oxazolinyl, isoxazolinyl, indazolinyl, isothiazolyl, 1 , 3-benzodioxolyl and the like.
  • heteroaryl examples include pyridinyl, isothiazolyl, thiazolyl, pyrazolyl, thienyl, prolyl, isoxazolinyl and 1 , 3-benzodioxolyl.
  • C 3-6 cycloalkyl refers to a saturated alkyl ring system containing 3, 4, 5 or 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
  • 4-8 membered heterocycloalkyl refers to a ring system having 4, 5, 6, 7 or 8 ring atoms selected from C, N, O, or S, preferably C, N, or O, the number of N atoms being 0, 1 , 2 and the number of O and S atoms each being 0, 1 , 2.
  • the term "4-8 membered heterocycloalkyl” preferably comprises fully saturated monocycles, fused bicycles, bridged bicycles or spirobicycles.
  • Examples of 5-6 membered heterocycloalkyl groups include pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiopyranyl, dihydropyranyl, tetrahydropyranyl, 1 ,3-dioxolanyl, 1 ,4-dioxanyl, 1 ,4-oxathianyl 1 ,4-dithianyl, 1 ,3- dioxane, 1 ,3-dithianyl, piperazinyl, thiomorpholinyl, piperidinyl, morpholinyl, and the like.
  • Preferred 4-8 membered heterocycloalkyl include 5-membered heterocycloalkyl having 1 or 2 N-atoms, such as pyrrolidinyl, 6-membered heterocycloalkyl having N and O- atoms, such as morpholinyl, piperidinyl, piperazyinyl , dioxanyl, 7-membered heterocycloalkyl having N and O-atoms, such as 1 N- and 1 O-atom, such as 2-oxa- 5-azabicyclo[2.2.1 ]heptan-5-yl, 1 ,4-diazabicyclo[3.2.1 ]octan-4-yl, 3-methyl-3- azabicyclo[3.1 ,0]hexan-1 -yl; 8-membered heterocycloalkyl having N and O-atoms, such as 1 N- and 1 O-atom, such as 8-oxa-3-azabicyclo[3.2.1 ]octan-3-yl.
  • C 1-4 alkyl 4-8 membered heterocycloalkyl refers to an alkyl as defined below with 1 to 4 carbon atoms, which is bound to a 4-8 membered heterocycloalkyl as defined above.
  • theC 1-4 alkyl may be C 1 , resulting in -(CH 2 )-(4-8 membered heterocycloalkyl) or C 2 , resulting in -(CH 2 ) 2 -(4-8 membered heterocycloalkyl) or C 3 , resulting in -(CH 2 ) 3 -(4-8 membered heterocycloalkyl).
  • Examples include -(CH 2 )-morpholinyl, -(CH 2 ) 2 -morpholinyl, -(CH 2 ) 3 - morpholinyl, -(CH 2 ) 4 -morpholinyl, -(CH 2 )-piperazinyl, -(CH 2 )2-N-methyl-piperazinyl, - (CH 2 ) 3 -piperazinyl or -(CH 2 ) 4 -piperazinyl.
  • C 1-4 alkoxy 4-8 membered heterocycloalkyl refers to a 4-7 membered heterocycloalkyl as described above, which is linked via a C 1-4 alkoxy group to its neighbouring group.
  • the C 1-4 alkoxy may be C 1 , resulting in -(O-CH 2 )-(4-8 membered heterocycloalkyl) or C 2 , resulting in -(O-CH 2 ) 2 -(4-8 membered heterocycloalkyl) orC 3 , resulting in -(O-CH 2 ) 3 -(4-8 membered heterocycloalkyl).
  • Examples include -(O-CH 2 )-(N-morpholinyi), -(O-CH 2 ) 2 -(N-morpholinyi).
  • -O- (4-8 membered heterocycloalkyl) refers to a 4-8 membered heterocycloalkyl as described above, which is linked via a -O-group to its neighbouring group. Examples include -O- morpholinyl, -O-piperazinyl, -O-pyrrolidinyl and the like.
  • -O(CO)-C 1-4 alkyl 4-7 membered heterocycloalkyl refers to a 4-8 membered heterocycloalkyl as described above, which is linked via a -O(CO)-C 1-4 alkyl group to its neighbouring group.
  • the "-O(CO)-C 1-4 alkyl may be C 1 , resulting in -(O(CO)-CH 2 )-(4-8 membered heterocycloalkyl) or C 2 , resulting in -(O(CO)-CH 2 ) 2 -(4-8 membered heterocycloalkyl) or C 3 , resulting in - (O(CO)-CH 2 ) 3 -(4-8 membered heterocycloalkyl).
  • Examples include -(O (CO) -CH 2 )-(N- morpholinyl) or -(O(CO)-CH 2 -CH 2 )-(N-morpholinyl).
  • halogen or “ha I” as used herein may be fluoro, chloro, bromo or iodo preferably fluoro, chloro or bromo, more preferably fluoro or chloro.
  • alkyl refers to a fully saturated branched or unbranched hydrocarbon moiety.
  • C 1-4 alkyl and C 1-6 alkyl refer to a fully saturated branched or unbranched hydrocarbon moiety having 1 , 2, 3 or 4 and 1 , 2, 3, 4, 5 or 6 carbon atoms, respectively.
  • alkyl include, but are not limited to, methyl, ethyl, n- propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, iso-pentyl, neopentyl, n- hexyl, iso-hexyl or neohexyl.
  • C 1 _ 4 alkoxy refers to an unsubstituted or substituted alkyl chain linked to the remainder of the molecule through an oxygen atom, and in particular to methoxy, ethoxy, n- propoxy, iso-propoxy, n-butoxy, iso-butoxy, and t-butoxy.
  • C 1-4 alkyl-C 1-4 alkoxy refers to a C 1-4 alkyl group functionalized with a C 1-4 alkoxy group, such as e.g. -CH 2 -O-CH 3 , -(CH 2 ) 2 -O-CH 3 , -(CH 2 ) 3 -O-CH 3 , -(CH 2 ) 4 -O-CH 3 , -CH 2 -O- CH 2 -CH 3 , -CH 2 -O-(CH 2 ) 2 -CH 3 , -CH 2 -O-(CH 2 ) 3 -CH 3 , and branched isomers thereof.
  • C 1-6 heteroalkyl refers to an alkyl as defined below with 1 , 2, 3, 4, 5 or 6 carbon atoms in which at least one, or at least two, carbon atoms are substituted with a heteroatom, such as N, O, S, preferably N, O. It is understood that the heteroatom may further be substituted with one or two C 1-6 alkyl.
  • substituted includes substitutions at one or more C-atoms (e.g. - CH 2 -CH 2 -) with a heteroatom (e.g. - CH 2 -CH(Het)-) and/or substitutions of one or more C-atoms (e.g.
  • -CH 2 - CH 2 -CH 2 within the alkyl chain (to obtain e.g. - CH 2 -Het-CH 2 -)
  • Examples include -(CH 2 ) 2 -O- Me, -(CH 2 ) 3 -O-Me, -(CH)(OMe)(CH 3 ), -(CH 2 ) 2 -O-CH 2 Me, -(CH 2 ) 2 -NMe 2 ,-(CH 2 )-NMe 2 , -(CH 2 )-NEt 2 ,-(CH 2 )-NEt 2 ,-O-(CH 2 ) 3 -NMe 2 and the like.
  • C 1-4 alkylamino refers to a fully saturated branched or unbranched C 1-4 alkyl, which is substituted with at least one, preferably only one, amino group, alkylamino group or dialkylaminogroup, such as NH 2 , HN(C 1-4 alkyl) or N(C 1-4 alkyl) 2 .
  • a C 1-4 alkylamino refers to C 1-4 alkylamino, C 1-4 alkyl-(C 1-4 alkyl)amino, C 1-4 alkyl-(C 1-4 dialkyl)amino.
  • Examples include but are not limited to dimethylamino, methylaminomethyl, dimethylamonimethyl, aminomethyl, dimethylaminoethyl, aminoethyl, methylaminoethyl, n-propylamino, iso- propylamino, n-butylamino, sec-butylamino, iso-butylamino, tert-butylamino. Based on the definitions given throughout the application the skilled person knows which combinations are synthetically feasible and realistic, e.g. typically combinations of groups leading to heteroatoms directly linked to each other are not contemplated.
  • X 1 is linear or branched C 1-6 alkyl, C 3-6 cycloalkyl, -C 1-6 alkyl C 3-6 cycloalkyl, C 6-10 aryl, 5-10 membered heteroaryl, C 1-6 alkyl C 6-10 aryl, C 1-6 alkyl 5-10 membered heteroaryl, wherein X 1 is unsubstituted or substituted with one or more of halogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF2, -O-(CH 2 ) 2 -OMe, OCF 3 , C 1-6 alkylamino, -CN, -N(H)C(O)-C 1- 6 alkyl, -OC(O)-C 1-6 alkyl, -OC(O)-C 1-4 alkylamino, -C(O)O-C 1-6 alkyl, -COOH
  • X 2 is hydrogen, C 6-10 aryl, 5-10 membered heteroaryl, -0(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -0(4-8 membered heterocycloalkyl), -O-C 1-4 alkyl-(4-8 membered heterocycloalkyl), -OC(O)-C 1-4 alkyl-4-8 membered heterocycloalkyl or C 6 aryloxy, wherein X 2 is unsubstituted or substituted with one or more of linear or branched C 1-6 alkyl, NH 2 , NMe 2 or 5-6 membered heterocycloalkyl; n is O, 1 or 2. In a preferred embodiment of a compound of formula I, n is 1 or 2.
  • n 1 .
  • n is 2.
  • X 1 is linear or branched C 1-6 alkyl, C 3. 6 cycloalkyl, -C 1-6 alkyl C 3-6 cycloalkyl, C 6 aryl, 5-10 membered heteroaryl, C 1-6 alkyl C 6-10 aryl, C 1-6 alkyl 5-10 membered heteroaryl, wherein X 1 is unsubstituted or substituted with one or more of halogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF2, -O-(CH 2 ) 2 -OMe, OCF 3 , C 6-10 alkylamino, -CN, -N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1- 6 alkyl, -OC(O)-C 1-4 alkylamino, -C(O)O-
  • X 2 is hydrogen, C 6-10 aryl, 5- 10 membered heteroaryl, -O-(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C 1-6 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membered heterocycloalkyl), -O-C 1-6 alkyl-(4-8 membered heterocycloalkyl), -OC(O)-C 1-6 alkyl-4-8 membered heterocycloalkyl or C 6 aryloxy, wherein X 2 is unsubstituted or substituted with one or more of linear or branched C 1-6 alkyl, NH 2 , NMe 2 or 5-6 membered heterocycloalkyl; and wherein n is 0, 1 , or 2.
  • X 1 is linear or branched C 1 _ 6 alkyl, C 3-6 cycloalkyl, -C 1 _ 6 alkyl C 3.6 cycloalkyl, C 6-10 aryl, 5-10 membered heteroaryl, C 1 _ 6 alkyl C 6 aryl, wherein X 1 is unsubstituted or substituted with one or more of halogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, -OC(O)-C 1-6 alkylamino, -CHO, -C 1-6 alkylC(O)OH, NH 2 , C 1-6 alkoxy or C 1-6 alkylhydroxy; and X 2 is hydrogen, C 6-10 aryl, 5-10 membere
  • X 1 is linear or branched C 1-4 alkyl, C 3. 6 cycloalkyl, -C 1-4 alkyl C 3-6 cycloalkyl, C 6 aryl, 5-10 membered heteroaryl, C 1-6 alkyl C 6 aryl, C 1- 6 alkyl 5-10 membered heteroaryl, wherein X 1 is unsubstituted or substituted with one or more of halogen, linear or branched C 1-4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 6-10 alkylamino, -CN, -N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1.
  • X 2 is hydrogen, C 6 aryl, 5- 10 membered heteroaryl, -O-(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl,C 1-4 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membered heterocycloalkyl), -O-C 1-4 alkyl-(4-8 membered heterocycloalkyl), -OC(O)-C 1-4 alkyl-4-8 membered heterocycloalkyl or C 6 aryloxy, wherein X 2 is unsubstituted or substituted with one or more of linear or branchedC 1-6 alkyl, NH 2 , NMe 2 or 5-6 membered heterocycloalkyl; and wherein n is 0, 1 , or 2.
  • X 1 is linear or branched C 1-4 alkyl, C 3-6 cycloalkyl, -C 1-4 alkyl C 3.6 cycloalkyl, C 6 aryl, 5-10 membered heteroaryl, C 1-6 alkyl C 6 aryl, wherein X 1 is unsubstituted or substituted with one or more of halogen, linear or branched C 1- 4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, -OC(O)-C 1-4 alkylamino, -CHO, -C 1-6 alkylC(O)OH, NH 2 , C 1-6 alkoxy or C 1-6 alkylhydroxy; and X 2 is hydrogen, C 6 aryl, 5-10 membered heteroaryl, -O
  • X 1 is linear or branched C 1-6 alkyl, C 3. 6 cycloalkyl, -C 1-6 alkyl C 3-6 cycloalkyl, C 6 aryl, 5-10 membered heteroaryl, C 1-6 alkyl C 6-10 aryl,C 1-6 alkyl 5-10 membered heteroaryl, wherein X 1 is unsubstituted or substituted with one or more of halogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF , -O-CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C I -6 alkylamino, -CN, -N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1- 6 alkyl, -OC(O)-C 1-4 alkylamino, -C(O)
  • X 1 is linear or branched C 1-6 alkyl, C 3-6 cycloalkyl, -C 1-6 alkyl C 3.6 cycloalkyl, C 6-10 aryl, 5-10 membered heteroaryl, C 1-6 alkyl C 6 aryl, wherein X 1 is unsubstituted or substituted with one or more of halogen, linear or branched C 1 _ 6 alkyl, linear or branched C 1 _ 6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, -OC(O)-C 1-6 alkylamino, -CHO, -C 1-6 alkylC(O)OH, NH 2 , C 1-6 alkoxy or C 1-6 alkylhydroxy; and X 2 is hydrogen, C 6-10 aryl, 5-10 membered hetero
  • X 1 is linear or branched C 1-4 alkyl, C 3. 6 cycloalkyl, -C 1-4 alkyl C 3.6 cycloalkyl, C 6 aryl, 5-10 membered heteroaryl, C 1-6 alkyl C 6 aryl, C 1-
  • X 1 is unsubstituted or substituted with one or more of halogen, linear or branched C 1 _ 4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF2, -O-(CH 2 ) 2 -OMe, OCF3, C 1-6 alkylamino, -CN, -N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1- 6 alkyl, -OC(O)-C 1-4 alkylamino, -C(O)O-C 1-6 alkyl, -COOH, -CHO, -C 1-6 alkylC(O)OH, -C,.
  • X 2 is hydrogen, C 6 aryl, 5- 10 membered heteroaryl, -O-(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membered heterocycloalkyl), -O-C 1-4 alkyl-(4-8 membered heterocycloalkyl), -OC(O)-C 1-4 alkyl-4-8 membered heterocycloalkyl or C 6 aryloxy, wherein X 2 is unsubstituted or substituted with one or more of linear or branched C 1-6 alkyl, NH 2 , NMe 2 or 5-6 membered heterocycloalkyl; and wherein n is 1 .
  • X 1 is linear or branched C 1-4 alkyl, C3-6 cycloalkyl, -C 1-4 alkyl C 3-6 cycloalkyl, C 6 aryl, 5-10 membered heteroaryl, C 1-6 alkyl C 6 aryl, wherein X 1 is unsubstituted or substituted with one or more of halogen, linear or branched C 1- 4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, -OC(O)-C 1-4 alkylamino, -CHO, -C 1-6 alkylC(O)OH, NH 2 , C 1-6 alkoxy or C 1-6 alkylhydroxy; and X 2 is hydrogen, C 6 aryl, 5-10 membered heteroaryl, -O-
  • the compounds of formula I are compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula l': wherein
  • X is linear or branched C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 alkyl C 3-6 cycloalkyl, C 6-10 aryl, 5-10 membered heteroaryl, C 1-6 alkylaryl, C 1-6 alkyl 5-10 membered heteroaryl, wherein X is unsubsituted or substituted with one or more of halogen, linear or branched C 1-6 alkyl, C 6-10 aryl, 5-10 membered heteroaryl, C 1-6 heteroalkyl, 4-7 membered heterocycloalkyl, C 1-4 alkyl 4-7 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 - OMe, OCF 3 , C I -6 alkylamino, -CN, -OC(O)-C 1-6 alkyl, -N(H)C(O)- C 1-6 alkyl, -C(O)O-
  • n is 1 or 2, more preferably n is 1 .
  • n 1 .
  • X is linear or branched C 1-6 alkyl, C 3. 6 cycloalkyl, -C 1-6 alkyl C 3.6 cycloalkyl, C 6-10 aryl, wherein X is unsubsituted or substituted with one or more of halogen, in particular F, Cl, Br, linear or branched C 1-6 alkyl, C 6-10 aryl, 4-7 membered heterocycloalkyl, C 1-4 alkyl 4-7 membered heterocycloalkyl, CF 3 , CHF 2 , -O- (CH 2 ) 2 -OMe, OCF 3 , C I -6 alkylamino, -CN, -OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C,.
  • halogen in particular F, Cl, Br
  • linear or branched C 1-6 alkyl C 6-10 aryl
  • X is linear or branched C 1-6 alkyl, C 3.
  • n is 1 and X is linear or branched C 1-6 alkyl, C 3-6 cycloalkyl, -C 1-6 alkyl C 3.6 cycloalkyl, C 6-10 aryl, wherein X is unsubstituted or substituted with one or more of halogen, in particular F, Cl, Br, linear or branched C 1-6 alkyl, C 6-10 aryl, 4-7 membered heterocycloalkyl, C 1-4 alkyl 4-7 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 6-10 alkylamino, -CN, -N(H)C(O)- C 1 _ 6 alkyl, -OC(O)-C 1-6 alkyl, - C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkylC(
  • n is 1 and X is linear or branched C 1-6 alkyl, C 3.6 cycloalkyl, -C 1-6 alkyl C 3.6 cycloalkyl, C 6-10 aryl, wherein X is unsubstituted or substituted with one or more of halogen, in particular F, Cl, Br, linear or branched C 1-6 alkyl, C 6-10 aryl, CF 3 , OCF 3 , C 1-6 alkylamino, -CN, C 1-6 alkoxy.
  • halogen in particular F, Cl, Br, linear or branched C 1-6 alkyl, C 6-10 aryl, CF 3 , OCF 3 , C 1-6 alkylamino, -CN, C 1-6 alkoxy.
  • X is linear or branched C 1-4 alkyl, C 3-4 cycloalkyl, C 1-4 alkyl C 3.6 cycloalkyl, C 6 aryl, 5-10 membered heteroaryl, C 1-6 alkylaryl, C 1-
  • X is linear or branched C 1-4 alkyl, C 3-4 cycloalkyl, C 1-4 alkyl C 3.6 cycloalkyl, C 6 aryl, 5-10 membered heteroaryl, C 1-6 alkylaryl, C 1- 6 alkyl 5-10 membered heteroaryl, wherein X is optionally substituted with one or more of halogen, in particular F, Cl, Br, linear or branched C 1 _ 4 alkyl, C 6 aryl, 5-10 membered heteroaryl, CF 3 , OCF 3 , C 1-4 alkylamino, -CN, C 1-4 alkoxy and n is 0, 1 or 2.
  • X is linear or branched C 1-4 alkyl, C 3.4 cycloalkyl, C 1-4 alkyl C 3.6 cycloalkyl, C 6 aryl, 5-10 membered heteroaryl, C 1-6 alkylaryl, C 1- 6 alkyl 5-10 membered heteroaryl, wherein X is optionally substituted with one or more of halogen, in particular F, Cl, Br, linear or branched C 1 _ 4 alkyl, C 6 aryl, 5-10 membered heteroaryl, morpholinyl, -(CH 2 )-morpholinyl, piperazinyl, -(CH 2 )-piperazinyl, CF 3 , CHF 2 , -O- (CH 2 ) 2 -OMe, OCF 3 , C 6-10 alkylamino, -CN, -OC(O)-C 1-6 alkyl, -N(H)C(O)-
  • X is linear or branched C 1-4 alkyl, C 3.4 cycloalkyl, C 1-4 alkyl C 3.6 cycloalkyl, C 6 aryl, 5-10 membered heteroaryl, C 1-6 alkylaryl, C 1- 6 alkyl 5-10 membered heteroaryl, wherein X is optionally substituted with one or more of halogen, in particular F, Cl, Br, linear or branched C 1-4 alkyl, C 6 aryl, 5-10 membered heteroaryl, 4-6 membered heterocycloalkyl, C 1-4 alkyl 4-6 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 6-10 alkylamino, -CN, -N(H)C(O)- C 1-6 alkyl, -OC(O)-C 1-6 alkyl, - C(
  • X is linear or branched C 1-4 alkyl, C 3.4 cycloalkyl, C 1 _ 4 alkyl C 3.6 cycloalkyl, C 6 aryl, 5-10 membered heteroaryl, C 1 _ 6 alkylaryl, C 1-
  • X is linear or branched C 1-4 alkyl, C 3 -4 cycloalkyl, C 1-4 alkyl C 3-6 cycloalkyl, C 6 aryl, 5-10 membered heteroaryl, C 1-6 alkylaryl, C 1- 6 alkyl 5-10 membered heteroaryl, wherein X is optionally substituted with one or more of halogen, in particular F, Cl, Br, linear or branched C 1-4 alkyl, C 6 aryl, 5-10 membered heteroaryl, CF 3 , OCF 3 , C 1-4 alkylamino, -CN, C 1-4 alkoxy and n is 1 .
  • X is linear or branched C 1-4 alkyl, C 3.4 cycloalkyl, C 1-4 alkyl C 3.6 cycloalkyl, C 6 aryl, wherein X is optionally substituted with one or more of halogen, in particular F, Cl, Br, linear or branched C 1-4 alkyl, C 6 aryl, 4-6 membered heterocycloalkyl, C 1-4 alkyl 4-6 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 1-6 alkylamino, -CN, -N(H)C(O)- C 1-6 alkyl, -OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, - COOH, -C 1-6 alkylC(O)OH, -C 1-6 alkylC(O)C(O)OH, -C 1-6 al
  • X is linear or branched C 1-4 alkyl, C 3.4 cycloalkyl, C 1-4 alkyl C 3.6 cycloalkyl, C 6 aryl, wherein X is optionally substituted with one or more of halogen, in particular F, Cl, Br, linear or branched C 1-4 alkyl, C 6 aryl, morpholinyl, - (CH 2 )-morpholinyl, piperazinyl, -(CH 2 )-piperazinyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 1-6 alkylamino, -CN, -OC(O)-C 1-6 alkyl, -N(H)C(O)- C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C, 6 alkylC(O)OH, -C
  • X is linear or branched C 1-4 alkyl, C 3.4 cycloalkyl, C 1-4 alkyl C 3.6 cycloalkyl, C 6 aryl, wherein X is optionally substituted with one or more of halogen, in particular F, Cl, Br, linear or branched C 1-4 alkyl, C 6 aryl, CF 3 , OCF 3 , C 1-4 alkylamino, -CN, C 1-4 alkoxy and n is 1 . More specifically, the present disclosure is directed towards a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula II wherein n is 1 or 2; p is 0, 1 , 2, 3, 4, 5, 6;
  • Y 1 is hydrogen, is C 6 aryl, 5- 10 membered heteroaryl C 3-6 cycloalkyl, wherein Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1-4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O- CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, -N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1-6 alkyl, - OC(O)-C 1 .
  • halogen preferably F, Cl or Br
  • linear or branched C 1-4 alkyl linear or branched C 1-6 heteroalkyl
  • CF 3 CHF 2 , -O- CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , -CN
  • Y 2 is hydrogen, C 6 aryl, 5-10 membered heteroaryl, -0(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -0(4-8 membered heterocycloalkyl), -O-C 1-4 alkyl-(4-8 membered heterocycloalkyl), -OC(O)-C 1-4 alkyl-4-8 membered heterocycloalkyl or C 6 aryloxy, wherein Y 2 is unsubstituted or substituted with one or more of linear or branched C 1-6 alkyl, NH 2 , NMe 2 or 5-6 membered heterocycloalkyl.
  • R a , R b each are independently selected from hydrogen and linear or branched C 1-4 alkyl, preferably hydrogen or methyl.
  • n 1 .
  • p is 0, 1 or 2.
  • p is 0 or 1 .
  • n is 1 and p is 0, 1 or 2. In some specific embodiments of the compound of formula II, n is 1 and p is 0 or 1 .
  • Y 1 is hydrogen, is C 6 aryl, 5- 10 membered heteroaryl C 3-6 cycloalkyl, wherein Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1-4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , OCF 3 , -CN, -OC(O)-C 1-4 heteroalkyl, -CHO, -C,.
  • halogen preferably F, Cl or Br
  • linear or branched C 1-4 alkyl linear or branched C 1-6 heteroalkyl
  • CF 3 CHF 2 , -O-CHF 2 , OCF 3 , -CN, -OC(O)-C 1-4 heteroalkyl, -CHO, -C,.
  • Y 2 is hydrogen C 6 aryl, 5-10 membered heteroaryl, -0(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -0(4-8 membered heterocycloalkyl), -O-C 1-4 alkyl-(4-8 membered heterocycloalkyl), -OC(O)-C 1-4 alkyl-4-8 membered heterocycloalkyl, wherein Y 2 is unsubstituted or substituted with one or more of linear or branched C 1-6 alkyl, NH 2 , NMe 2 or 5-6 membered heterocycloalkyl.
  • n is 1 and Y 1 is hydrogen, is C 6 aryl, 5- 10 membered heteroaryl C 3.6 cycloalkyl, wherein Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1-4 alkyl, linear or branched C 6-10 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, -N(H)C(O)-C,.
  • halogen preferably F, Cl or Br
  • linear or branched C 1-4 alkyl linear or branched C 6-10 heteroalkyl
  • CF 3 CHF 2 , -O-CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, -N(H)C(O)-C,.
  • n is 1 and Y 1 is hydrogen, is C 6 aryl, 5- 10 membered heteroaryl C 3-6 cycloalkyl, wherein Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1 _ 4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , OCF 3 , -CN, -OC(O)-C 1-4 heteroalkyl, -CHO, - C 1-6 alkylC(O)OH, NH 2 , or C 1-6 alkylhydroxy; and Y 2 is hydrogen C 6 aryl, 5-10 membered heteroaryl, -0(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -0(4-8 membere
  • Y 1 is hydrogen, is C 6 aryl, 5- 10 membered heteroaryl C 3.6 cycloalkyl, wherein Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1-4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, - N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1-6 alkyl, -OC(O)-C 1-4 heteroalkyl, -C(O)O-C 1-6 alkyl, -COOH, - CHO, -C 1-6 alkylC(O)OH, -C 1-6 alkylC(O)O-C 1-6 alkyl, -COOH, - CHO, -C 1-6 al
  • Y 1 is hydrogen, is C 6 aryl, 5- 10 membered heteroaryl C 3-6 cycloalkyl, wherein Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1-4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , OCF 3 , -CN, -OC(O)-C 1-4 heteroalkyl, -CHO, -C 1-6 alkylC(O)OH, NH 2 , or C 1-6 alkylhydroxy; and Y 2 is hydrogen C 6 aryl, 5-10 membered heteroaryl, -O-(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C 1- 4 alkyl 4-8 membered heterocycloalkyl, -O-(
  • p is 0 or 1 and Y 1 is hydrogen, is C 6 aryl, 5- 10 membered heteroaryl C 3.6 cycloalkyl, wherein Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1-4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, - N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1-6 alkyl, -OC(O)-C 1-4 heteroalkyl, -C(O)O-C 1-6 alkyl, -COOH, - CHO, -C 1-6 alkylC(O)OH, -C 1-6 alkylC(O)O-C 1-6 alkyl, -COOH, -
  • n is 1
  • p is 0, 1
  • Y 1 is hydrogen
  • Y 1 is C 6 aryl, 5- 10 membered heteroaryl C 3.6 cycloalkyl, wherein Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1-4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, - N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1-6 alkyl, -OC(O)-C 1-4 heteroalkyl, -C(O)O-C 1-6 alkyl, -COOH, - CHO, -C 1-6 alkylC(O)OH, -C 1-6 alkylC
  • n is 1
  • p is 0, 1
  • 2 and Y 1 is hydrogen
  • Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1-4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , OCF 3 , -CN, -OC(O)-C 1-4 heteroalkyl, -CHO, -C 1-6 alkylC(O)OH, NH 2 , or C 1-6 alkylhydroxy; and Y 2 is hydrogen C 6 aryl, 5-10 membered heteroaryl, -O-(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C 1- 4 alkyl 4-8 membered heterocycloalkyl
  • n is 1
  • p is 0 or 1
  • Y 1 is hydrogen
  • Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1-4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, - N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1-6 alkyl, -OC(O)-C 1-4 heteroalkyl, -C(O)O-C 1-6 alkyl, -COOH, - CHO, -C 1-6 alkylC(O)OH, -C 1-6 alkylC(O)C(O)C(O)
  • n is 1
  • p is 0 or 1
  • Y 1 is hydrogen
  • Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1-4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , OCF 3 , -CN, -OC(O)-C 1-4 heteroalkyl, -CHO, -C 1-6 alkylC(O)OH, NH 2 , or C 1-6 alkylhydroxy; and Y 2 is hydrogen C 6 aryl, 5-10 membered heteroaryl, -O-(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C 1- alkyl 4-8 membered heterocycloalkyl,
  • R a and R b each are independently selected from hydrogen, methyl and ethyl.
  • R a and R b is C 1-4 alkyl, preferably methyl or ethyl and all other R a and R b are hydrogen.
  • Y 1 is hydrogen
  • Y 1 is C 6 aryl, 5- 10 membered heteroaryl C 3.6 cycloalkyl, wherein Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1-4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, -N(H)C(O)-C 1-6 alkyl, -
  • halogen preferably F, Cl or Br
  • linear or branched C 1-4 alkyl linear or branched C 1-6 heteroalkyl
  • CF 3 CHF 2 , -O-CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, -N(H)C(O)-C 1-6 alkyl,
  • Y 2 is hydrogen, C 6 aryl, 5-10 membered heteroaryl, -O-(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membered heterocycloalkyl), -O-C1 -4 alkyl-(4-8 membered heterocycloalkyl), -OC(O)-C 1-4 alkyl-4-8 membered heterocycloalkyl or C 6 aryloxy, wherein Y 2 is un
  • Y 1 is hydrogen
  • Y 1 is C 6 aryl, 5- 10 membered heteroaryl C 3-6 cycloalkyl, wherein Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1 _ 4 alkyl, linear or branched C heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , OCF 3 , -CN, -OC(O)-C 1-4 heteroalkyl, -CHO, -C 1- 6 alkylC(O)OH, NH 2 , or C 1-6 alkylhydroxy; and Y 2 is hydrogen C 6 aryl, 5-10 membered heteroaryl, -0(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -0(4-8 membered heterocycloalkyl,
  • n is 1 and Y 1 is hydrogen, is C 6 aryl, 5- 10 membered heteroaryl C 3.6 cycloalkyl, wherein Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1-4 alkyl, linear or branched C 6-10 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, -N(H)C(O)-C,.
  • halogen preferably F, Cl or Br
  • linear or branched C 1-4 alkyl linear or branched C 6-10 heteroalkyl
  • CF 3 CHF 2 , -O-CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, -N(H)C(O)-C,.
  • n is 1 and Y 1 is hydrogen, is C 6 aryl, 5- 10 membered heteroaryl C 3-6 cycloalkyl, wherein Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1-4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , OCF 3 , -CN, -OC(O)-C 1-4 heteroalkyl, -CHO, - C 1 -6 alkylC(O)OH, NH 2 , or C 1-6 alkylhydroxy; and Y 2 is hydrogen C 6 aryl, 5-10 membered heteroaryl, -0(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -0(4-8 membered
  • p is 0, 1 , 2 and Y 1 is hydrogen, is C 6 aryl, 5- 10 membered heteroaryl C 3.6 cycloalkyl, wherein Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1-4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, - N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1-6 alkyl, -OC(O)-C 1-4 heteroalkyl, -C(O)O-C 1-6 alkyl, -COOH, - CHO, -C 1-6 alkylC(O)OH, -C 1-6 alkylC(O)O-C 1-6 alkyl, -COOH, -
  • Y 1 is hydrogen, is C 6 aryl, 5- 10 membered heteroaryl C 3-6 cycloalkyl, wherein Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1-4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , OCF 3 , -CN, -OC(O)-C 1-4 heteroalkyl, -CHO, -C 1-6 alkylC(O)OH, NH 2 , or C 1-6 alkylhydroxy; and Y 2 is hydrogen C 6 aryl, 5-10 membered heteroaryl, -O-(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C 1- 4 alkyl 4-8 membered heterocycloalkyl, -O-(
  • p is 0 or 1 and Y 1 is hydrogen, is C 6 aryl, 5- 10 membered heteroaryl C 3.6 cycloalkyl, wherein Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1-4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, - N(H)C(O)-C 1 _ 6 alkyl, -OC(O)-C 1-6 alkyl, -OC(O)-C 1-4 heteroalkyl, -C(O)O-C 1-6 alkyl, -COOH, - CHO, -C 1-6 alkylC(O)OH, -C 1-6 alkylC(O)O-C 1-6 alkyl, -COOH,
  • Y 1 is hydrogen, is C 6 aryl, 5- 10 membered heteroaryl C 3.6 cycloalkyl, wherein Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1-4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , OCF 3 , -CN, -OC(O)-C 1-4 heteroalkyl, -CHO, -C 1-6 alkylC(O)OH, NH 2 , or C 1-6 alkylhydroxy; and Y 2 is hydrogen C 6 aryl, 5-10 membered heteroaryl, -O-(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C 1- 4 alkyl 4-8 membered heterocycloalkyl, -O-(4
  • n is 1
  • p is 0, 1
  • 2 and Y 1 is hydrogen
  • Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1-4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, - N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1-6 alkyl, -OC(O)-C 1-4 heteroalkyl, -C(O)O-C 1-6 alkyl, -COOH, - CHO, -C 1-6 alkylC(O)OH, -C 1-6 alkylC(O)C(O)OH, -C 1-6 alkylC(
  • n is 1
  • p is 0, 1
  • 2 and Y 1 is hydrogen
  • Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1 _ 4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , OCF 3 , -CN, -OC(O)-C 1-4 heteroalkyl, -CHO, -C 1-6 alkylC(O)OH, NH 2 , or C 1-6 alkylhydroxy; and Y 2 is hydrogen C 6 aryl, 5-10 membered heteroaryl, -O-(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C 1- 4 alkyl 4-8 membered heterocycloal
  • n is 1
  • p is 0 or 1
  • Y 1 is hydrogen
  • Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1-4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, - N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1-6 alkyl, -OC(O)-C 1-4 heteroalkyl, -C(O)O-C 1-6 alkyl, -COOH, - CHO, -C 1-6 alkylC(O)OH, -C 1-6 alkylC(O)C(O)C(O)
  • n is 1
  • p is 0 or 1
  • Y 1 is hydrogen
  • Y 1 is unsubstituted or substituted with one or more of halogen, preferably F, Cl or Br, linear or branched C 1-4 alkyl, linear or branched C 1-6 heteroalkyl, CF 3 , CHF 2 , -O-CHF 2 , OCF 3 , -CN, -OC(O)-C 1-4 heteroalkyl, -CHO, -C 1-6 alkylC(O)OH, NH 2 , or C 1-6 alkylhydroxy; and Y 2 is hydrogen C 6 aryl, 5-10 membered heteroaryl, -O-(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C 1 _ 4 alkyl 4-8 membered heterocycloalkyl,
  • the present disclosure is directed towards a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula IG wherein n is 1 or 2;
  • P is O, 1 , 2, 3, 4, 5, 6;
  • Y is hydrogen, C 6 aryl, 5-10 membered heteroaryl, C 3-5 cycloalkyl, wherein Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, 4- 6 membered heterocycloalkyl, C 1-4 alkyl 4-6 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 6-10 alkylamino, -CN, -N(H)C(O)- C 1-6 alkyl, - OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkylC(O)OH, -C 1-6 alkylC(O)O- C 1-6 alkyl, NH 2 , C 1-4 alkylhydroxy, C 1-4 alkoxy, halogen, preferably F, Cl, Br;
  • R a , R b each are independently selected from hydrogen and linear or branched C 1 -4 alkyl, preferably hydrogen and methyl.
  • n 1 .
  • p is 0, 1 or 2.
  • p is 0 or 1 . In other embodiments of the compound of formula II', n is 1 and p is 0, 1 or 2. In some specific embodiments of the compound of formula II', n is 1 and p is 0 or 1 .
  • Y is hydrogen, C 6 aryl, 5-10 membered heteroaryl or C 3-5 cycloalkyl, wherein Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, 4-6 membered heterocycloalkyl, C 1-4 alkyl 4-6 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 1-6 alkylamino, -CN, - N(H)C(O)- C 1 _ 6 alkyl, -OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkylC(O)OH, -C,. 6 alkylC(O)O-C 1-6 alkyl, NH 2 , C 1-4 alkylhydroxy, C 1-4 alkyl, 4-6 membered heterocycloalky
  • Y is hydrogen, C 6 aryl, 5-10 membered heteroaryl or C 3-5 cycloalkyl, wherein Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, morpholinyl, -(CH 2 )-morpholinyl, piperazinyl, -(CH 2 )- piperazinyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 1-6 alkylamino, -CN, -N(H)C(O)- C 1-6 alkyl, - OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkylC(O)OH, -C, - 6 alkylC(O)O-C 1-6 alkyl, NH 2 , C 1
  • Y is hydrogen, C 6 aryl or C 3-5 cycloalkyl, wherein Y is unsubstituted or substituted with one or more of linear or branched C 1 -4 alkyl, 4-6 membered heterocycloalkyl, C 1-4 alkyl 4-6 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C,- 6 alkylamino, -CN, -N(H)C(O)- C 1-6 alkyl, -OC(O)-C 1-6 alkyl, - C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkylC(O)OH, -C 1-6 alkylC(O)O-C 1-6 alkyl, NH 2 , C,.
  • Y is hydrogen, C 6 aryl or C 3-5 cycloalkyl, wherein Y is unsubstituted or substituted with one or more of linear or branched C 1 - 4 alkyl, morpholinyl, -(CH 2 )-morpholinyl, piperazinyl, -(CH 2 )-piperazinyl, CF 3 , CHF 2 , -O- (CH 2 ) 2 -OMe, OCF 3 , C,- 6 alkylamino, -CN, -N(H)C(O)- C 1-6 alkyl, -OC(O)-C 1-6 alkyl, -C(O)O- C 1-6 alkyl, -COOH, -C 1 -6 alkylC(O)OH, -C 1
  • Y is hydrogen, C 6 aryl or C 3-5 cycloalkyl, wherein Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, CF 3 , OCF 3 , C 1-4 alkylamino, -CN, C 1-4 alkoxy, halogen, preferably F, Cl, Br, more preferably F or Cl.
  • n is 1 and Y is hydrogen, C 6 aryl or C 3-5 cycloalkyl, wherein Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, 4-6 membered heterocycloalkyl, C 1-4 alkyl 4-6 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 1-6 alkylamino, -CN, -N(H)C(O)- C 1- 6 alkyl, -OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkylC(O)OH, -C 1-6 alkylC(O)O-C 1- 6 alkyl, NH 2 , C 1-4 alkylhydroxy, C 1-4 alkoxy, halogen,
  • n is 1 and Y is hydrogen, C 6 aryl or C 3-5 cycloalkyl, wherein Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, CF 3 , OCF 3 , C 1-4 alkylamino, -CN, C 1-4 alkoxy, halogen, preferably F, Cl, Br, more preferably F or Cl.
  • p is 0, 1 or 2 and Y is hydrogen, C 6 aryl or C 3-5 cycloalkyl, wherein Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, 4-6 membered heterocycloalkyl, C 1-4 alkyl 4-6 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 6-10 alkylamino, -CN, -N(H)C(O)- C,.
  • p is 0, 1 or 2 and Y is hydrogen, C 6 aryl or C 3-5 cycloalkyl, wherein Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, CF 3 , OCF 3 , C 1-4 alkylamino, -CN, C 1-4 alkoxy, halogen, preferably F, Cl, Br, more preferably F or Cl.
  • p is 0 or 1 and Y is hydrogen, C 6 aryl or C 3-5 cycloalkyl, wherein Y is unsubstituted or substituted with one or more of linear or branched C 1 _ 4 alkyl, 4-6 membered heterocycloalkyl, C 1 _ 4 alkyl 4-6 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 6-10 alkylamino, -CN, -N(H)C(O)- C,.
  • p is 0 or 1 and Y is hydrogen, C 6 aryl or C 3-5 cycloalkyl, wherein Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, CF 3 , OCF 3 , C 1-4 alkylamino, -CN, C 1-4 alkoxy, halogen, preferably F, Cl, Br, more preferably F or Cl.
  • n is 1 and p is 0, 1 or 2 and
  • Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, 4-6 membered heterocycloalkyl, C 1-4 alkyl 4-6 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 - OMe, OCF 3 , C 1-6 alkylamino, -CN, -N(H)C(O)- C 1-6 alkyl, -OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkylC(O)OH, -C 1-6 alkylC(O)O-C 1 -6 alkyl, NH 2 , C 1-4 alkylhydroxy, C 1-4 alkoxy, halogen, preferably F, Cl, Br, more preferably F or Cl.
  • n is 1 and p is 0, 1 or 2 and
  • Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, CF 3 , OCF 3 , C 1-4 alkylamino, -CN, C 1-4 alkoxy, halogen, preferably F, Cl, Br, more preferably F or Cl.
  • n is 1 and p is 0 or 1 and Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, 4-6 membered heterocycloalkyl, C 1-4 alkyl 4-6 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 - OMe, OCF 3 , C 1-6 alkylamino, -CN, -N(H)C(O)- C 1-6 alkyl, -OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkylC(O)OH, -C 1-6 alkylC(O)O-C 1-6 alkyl, NH 2 , C 1-4 alkylhydroxy, C 1-4 alkoxy, halogen, preferably F, Cl, Br, more preferably F or Cl
  • n is 1 and p is 0 or 1 and Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, CF 3 , OCF 3 , C 1- alkylamino, -CN, C 1-4 alkoxy, halogen, preferably F, Cl, Br, more preferably F or Cl.
  • R a and R b each are independently selected from hydrogen, methyl and ethyl, preferably hydrogen and methyl.
  • R a and a single R b is C 1-4 alkyl, preferably methyl and all other R a and R b are hydrogen.
  • Y is hydrogen, C 6 aryl, C 3-5 cycloalkyl, wherein Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, 4-6 membered heterocycloalkyl, C 1 _ 4 alkyl 4-6 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 6-10 alkylamino, -CN, -N(H)C(O)- C 1 _ 6 alkyl, -OC(O)-C 1-6 alkyl, - C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkylC(O)OH, -C 1-6 alkylC(O)O-C 1-6 alkyl, NH 2 , C,. 4 alkylhydroxy, C 1-4 alkoxy, halogen
  • Y is hydrogen, C 6 aryl, C 3-5 cycloalkyl, wherein Y is unsubstituted or substituted with one or more of linear or branchedC 1-4 alkyl, CF 3 , OCF 3 , C 1 _ 4 alkylamino, -CN, C 1 _ 4 alkoxy, halogen, preferably F, Cl, Br, more preferably F or Cl and R a and R b each are independently selected from hydrogen, methyl and ethyl.
  • n is 1 and Y is hydrogen, C 6 aryl, C 3-5 cycloalkyl, wherein Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, 4-6 membered heterocycloalkyl, C 1-4 alkyl 4-6 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 6-10 alkylamino, -CN, -N(H)C(O)- C,.
  • n is 1 and Y is hydrogen, C 6 aryl, C 3-5 cycloalkyl, wherein Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, CF 3 , OCF 3 , C 1-4 alkylamino, -CN, C 1-4 alkoxy, halogen, preferably F, Cl, Br, more preferably F or Cl and R a and R b each are independently selected from hydrogen, methyl and ethyl.
  • p is 0, 1 or 2 and Y is hydrogen, C 6 aryl, C 3-5 cycloalkyl, wherein Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, 4-6 membered heterocycloalkyl, C 1-4 alkyl 4-6 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 6-10 alkylamino, -CN, -N(H)C(O)- C,.
  • p is 0, 1 or 2 and Y is hydrogen, C 6 aryl, C 3-5 cycloalkyl, wherein Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, CF 3 , OCF 3 , C 1-4 alkylamino, -CN, C 1-4 alkoxy, halogen, preferably F, Cl, Br, more preferably F or Cl and R a and R b each are independently selected from hydrogen, methyl and ethyl.
  • p is 0 or 1 and Y is hydrogen, C 6 aryl, C 3-5 cycloalkyl, wherein Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, 4-6 membered heterocycloalkyl, C 1-4 alkyl 4-6 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 6-10 alkylamino, -CN, -N(H)C(O)- C,.
  • p is 0 or 1 and Y is hydrogen, C 6 aryl, C 3-5 cycloalkyl, wherein Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, CF 3 , OCF 3 , C 1-4 alkylamino, -CN, C 1-4 alkoxy, halogen, preferably F, Cl, Br, more preferably F or Cl and R a and R b each are independently selected from hydrogen, methyl and ethyl.
  • n is 1 and p is 0, 1 or 2 and
  • Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, 4-6 membered heterocycloalkyl, C 1-4 alkyl 4-6 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 - OMe, OCF 3 , C 1-6 alkylamino, -CN, -N(H)C(O)- C 1-6 alkyl, -OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkylC(O)OH, -C 1-6 alkylC(O)O-C 1-6 alkyl, NH 2 , C 1-4 alkylhydroxy, C 1-4 alkoxy, halogen, preferably F, Cl, Br, more preferably F or Cl and R a and R b each are independently selected from hydrogen, methyl and ethyl.
  • n is 1 and p is 0, 1 or 2 and
  • Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, CF 3 , OCF 3 , C 1-4 alkylamino, -CN, C 1 _ 4 alkoxy, halogen, preferably F, Cl, Br, more preferably F or Cl and R a and R b each are independently selected from hydrogen, methyl and ethyl.
  • n is 1 and p is 0 or 1 and Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, 4-6 membered heterocycloalkyl, C 1-4 alkyl 4-6 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 - OMe, OCF 3 , C 1-6 alkylamino, -CN, -N(H)C(O)- C 1 _ 6 alkyl, -OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkylC(O)OH, -C 1-6 alkylC(O)O-C 1 -6 alkyl, NH 2 , C 1-4 alkylhydroxy, C 1-4 alkoxy, halogen, preferably F, Cl, Br, more preferably
  • n is 1 and p is 0 or 1 and Y is unsubstituted or substituted with one or more of linear or branched C 1-4 alkyl, CF 3 , OCF 3 , C 1- alkylamino, -CN, C 1-4 alkoxy, halogen, preferably F, Cl, Br, more preferably F or Cl and R a and R b each are independently selected from hydrogen, methyl and ethyl.
  • the present disclosure is directed towards a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula Ilia, lllb or lllc wherein n is 1 or 2 p is 0, 1 or 2 one of w 1 , w 2 or w 3 is selected from C and N, and the other two of w 1 , w 2 or w 3 are C; one or two of w 4 , w 5 , w 6 , w 7 is selected from C, O, N, NMe, NH, or S while two or three of w 4 , w 5 , w 6 and w 7 are C; R 1 , R 2 , R 3 , R 4 each are independently selected from hydrogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , - O-CHF 2 -O-(CH 2 ) 2 -OMe, OCF 3
  • R 5 , R 6 each are independently selected from hydrogen, linear or branched C 1-4 alkyl, CF 3 , CHF 2 , halogen, preferably F, Cl, Br, more preferably F or Cl
  • X 3 is absent, hydrogen or 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membered heterocycloalkyl), -C 1-4 alkoxy-(4-8 membered heterocycloalkyl), 5-10 membered heteroaryl, -0(5-10 membered heteroaryl), -OC(O)-C 1-4 alkyl-4-8 membered heterocycloalkyl, wherein X 3 is unsubstituted or substituted with one or more of linear or branched C 1-6 alkyl, NH 2 , NMe 2 or 5-6 membered heterocycloalkyl; Z is linear or branched C 1 _ 6 alkyl or C 3.6 cycl
  • the present disclosure is directed towards a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula Ilia, wherein n is 1 or 2 p is 0, 1 or 2 one of w 1 , w 2 or w 3 is selected from C and N, and the other two of w 1 , w 2 or w 3 are C;
  • R 1 , R 2 , R 3 , R 4 each are independently selected from hydrogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , - O-CHF 2 -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, -N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1- 4 alkylamino, -OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -CHO, -C,.
  • the present disclosure is directed towards a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula lllb wherein n is 1 or 2 p is 0, 1 or 2; and Z is linear or branched C 1-6 alkyl or C 3-6 cycloalkyl, C 1-4 alkoxy or C 1-4 alkyl-C 1-4 alkoxy, wherein Z is unsubstituted or substituted with C 1-4 alkyl.
  • n is 1 or 2 p is 0, 1 or 2 one of w 1 , w 2 or w 3 is selected from C and N, and the other two of w 1 , w 2 or w 3 are C; one or two of w 4 , w 5 , w 6 , w 7 is selected from C, O, N, NMe, NH, or S while two or three of w 4 , w 5 , w 6 and w 7 are C;
  • R 1 , R 2 , R 3 , R 4 each are independently selected from hydrogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , - O-CHF2 -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, -N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1- 4 alkylamino, -OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -CHO, -C,.
  • R 5 , R 6 each are independently selected from hydrogen, linear or branched C 1-4 alkyl, CF 3 , CHF 2 , halogen, preferably F, Cl, Br, more preferably F or Cl
  • X 3 is absent, hydrogen or 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membered heterocycloalkyl), -C 1-4 alkoxy-(4-8 membered heterocycloalkyl), 5-10 membered heteroaryl, -0(5-10 membered heteroaryl), -OC(O)-C 1-4 alkyl-4-8 membered heterocycloalkyl, wherein X 3 is unsubstituted or substituted with one or more of linear or branched C 1-6 alkyl,
  • Z is linear or branched C 1-6 alkyl or C 3-6 cycloalkyl, C 1-4 alkoxy or C 1-4 alkyl-C 1-4 alkoxy, wherein Z is unsubstituted or substituted with C 1-4 alkyl.
  • n 1 .
  • p is 0 or 1 .
  • p is 0. In other embodiments of a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula Ilia, lllb or I lie, p is 1 .
  • n is 1 and p is 0 or 1 .
  • n is 1 and p is 0.
  • R 1 , R 2 , R 3 are defined as above and R 4 is hydrogen such that the aromatic ring contains 4 or 5 substituents which are not hydrogen.
  • R 1 and R 2 are defined as above and R 3 and R 4 each are hydrogen, such that the aromatic ring contains 3 or 4 substituents which are not hydrogen.
  • R 1 , R 2 , R 3 and R 4 each are independently selected from hydrogen, linear or branched C 1-6 alkyl, linear or branched C 1 _ 6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , -O-CHF 2 , OCF 3 , -CN, -CHO, -C 1-6 alkylC(O)OH, NH 2 , C,.
  • R 5 , R 6 each are independently selected from hydrogen, linear or branched C 1-4 alkyl and CF 3 ;
  • X 3 is absent, hydrogen or 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -O- (4-8 membered heterocycloalkyl), -C 1-4 alkoxy-(4-8 membered heterocycloalkyl), 5-10 membered heteroaryl, -0(5-10 membered heteroaryl), -OC(O)-C 1-4 alkyl-4-8 membered heterocycloalkyl, wherein X 3 is unsubstituted or substituted with one or more of linear or branched C 1-6 alkyl,
  • R 1 , R 2 , R 3 , R 4 each are independently selected from hydrogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , -O-CHF 2 -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, - N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1-4 alkylamino, -OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, - CHO, -C 1-6 alkylC(O)OH, -C 1-6 alkylC(O)O-C 1-6 alkyl, NH 2 , C 1-4 alkylhydroxy, halogen,
  • R 1 , R 2 , R 3 and R 4 each are independently selected from hydrogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , -O-CHF 2 , OCF 3 , -CN, -CHO, -C 1-6 alkylC(O)OH, NH 2 , C,.
  • R 5 , R 6 each are independently selected from hydrogen, linear or branched C 1-4 alkyl and CF 3 ;
  • X 3 is absent, hydrogen or 4-8 membered heterocycloalkyl, C 1 _ 4 alkyl 4-8 membered heterocycloalkyl, -O- (4-8 membered heterocycloalkyl), -C 1 _ 4 alkoxy-(4-8 membered heterocycloalkyl), 5-10 membered heteroaryl, -0(5-10 membered heteroaryl), -OC(O)-C 1-4 alkyl-4-8 membered heterocycloalkyl, wherein X 3 is unsubstituted or substituted with one or more of linear or branched C 1-6
  • R 1 , R 2 , R 3 , R 4 each are independently selected from hydrogen, linear or branched C 1 _ 6 alkyl, linear or branched C 1 _ 6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , -O-CHF 2 -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, -N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1-4 alkylamino, -OC(O)-C 1-6 alkyl, -C(O)O-C,.
  • R 5 , R 6 each are independently selected from hydrogen, linear or branched C 1-4 alkyl, CF 3 , CHF 2 , halogen, preferably F, Cl, Br, more preferably F or Cl; and X 3 is absent, hydrogen or 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membered heterocycloalkyl), -C 1-4 alkoxy-(4-8 membered heterocyclo
  • R 1 , R 2 , R 3 and R 4 each are independently selected from hydrogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , -O-CHF 2 , OCF 3 , -CN, -CHO, -C 1- 6 alkylC(O)OH, NH 2 , C 1-4 alkylhydroxy, halogen, preferably F, Cl, Br, more preferably F or Cl; and/or two of R 1 , R 2 , R 3 , R 4 form together a 5-6 membered heterocycloalkyl or a 5-6 membered heteroaryl; R 5 , R 6 each are independently selected from hydrogen, linear or branched C 1-4 alkyl and CF 3 ; X 3 is absent, hydrogen or 4-8 membered heterocycloalkyl
  • R 1 , R 2 , R 3 , R 4 each are independently selected from hydrogen, linear or branched C 1 _ 6 alkyl, linear or branched C 1 _ 6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , -O-CHF 2 -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, -N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1-4 alkylamino, -OC(O)-C 1-6 alkyl, -C(O)O-C,.
  • R 5 , R 6 each are independently selected from hydrogen, linear or branched C 1-4 alkyl, CF 3 , CHF 2 , halogen, preferably F, Cl, Br, more preferably F or Cl; and X 3 is absent, hydrogen or 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membered heterocycloalkyl), -C 1-4 alkoxy-(4-8 membered heterocyclo
  • R 1 , R 2 , R 3 and R 4 each are independently selected from hydrogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , -O-CHF 2 , OCF 3 , -CN, -CHO, -C 1- 6 alkylC(O)OH, NH 2 , C 1-4 alkylhydroxy, halogen, preferably F, Cl, Br, more preferably F or Cl; and/or two of R 1 , R 2 , R 3 , R 4 form together a 5-6 membered heterocycloalkyl or a 5-6 membered heteroaryl; R 5 , R 6 each are independently selected from hydrogen, linear or branched C 1-4 alkyl and CF 3 ; X 3 is absent, hydrogen or 4-8 membered heterocycloalkyl
  • R 1 , R 2 , R 3 , R 4 each are independently selected from hydrogen, linear or branched C 1 _ 6 alkyl, linear or branched C 1 _ 6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , -O-CHF 2 -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, -N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1-4 alkylamino, -OC(O)-C 1-6 alkyl, -C(O)O-C,.
  • R 5 , R 6 each are independently selected from hydrogen, linear or branched C 1-4 alkyl, CF 3 , CHF 2 , halogen, preferably F, Cl, Br, more preferably F or Cl; and X 3 is absent, hydrogen or 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membered heterocycloalkyl), -C 1-4 alkoxy-(4-8 membered heterocyclo
  • R 1 , R 2 , R 3 and R 4 each are independently selected from hydrogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , -O-CHF 2 , OCF 3 , -CN, -CHO, -C 1- 6 alkylC(O)OH, NH 2 , C 1-4 alkylhydroxy, halogen, preferably F, Cl, Br, more preferably F or Cl; and/or two of R 1 , R 2 , R 3 , R 4 form together a 5-6 membered heterocycloalkyl or a 5-6 membered heteroaryl; R 5 , R 6 each are independently selected from hydrogen, linear or branched C 1-4 alkyl and CF 3 ; X 3 is absent, hydrogen or 4-8 member
  • R 1 , R 2 , R 3 , R 4 each are independently selected from hydrogen, linear or branched C 1 _ 6 alkyl, linear or branched C 1 _ 6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , -O-CHF 2 -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, -N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1-4 alkylamino, -OC(O)-C 1-6 alkyl, -C(O)O-C,.
  • R 5 , R 6 each are independently selected from hydrogen, linear or branched C 1-4 alkyl, CF 3 , CHF 2 , halogen, preferably F, Cl, Br, more preferably F or Cl; and X 3 is absent, hydrogen or 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membered heterocycloalkyl), -C 1-4 alkoxy-(4-8 membered heterocyclo
  • R 1 , R 2 , R 3 and R 4 each are independently selected from hydrogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , -O-CHF 2 , OCF 3 , -CN, -CHO, -C 1- 6 alkylC(O)OH, NH 2 , C 1-4 alkylhydroxy, halogen, preferably F, Cl, Br, more preferably F or Cl; and/or two of R 1 , R 2 , R 3 , R 4 form together a 5-6 membered heterocycloalkyl or a 5-6 membered heteroaryl; R 5 , R 6 each are independently selected from hydrogen, linear or branched C 1-4 alkyl and CF 3 ; X 3 is absent, hydrogen or 4-8 member
  • C 1-6 alkyl is selected from methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, neopentyl, n- hexyl, iso-hexyl, and neohexyl.
  • C 3.6 cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • C 1-4 alkoxy is selected from methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, and t-butoxy.
  • C 1-4 alkyl-C 1-4 alkoxy is selected from methyl-methoxy, methyl-ethoxy, methyl-n-propoxy, methyl-iso-propoxy, methyl-n-butoxy, methyl-iso-butoxy, methyl-t-butoxy, ethyl-methoxy, ethyl-ethoxy, ethyl-n-propoxy, ethyl- iso-propoxy, ethyl-n-butoxy, ethyl-iso-butoxy, ethyl-t-butoxy, propyl-methoxy, propyl- ethoxy, propyl-n-propoxy, propyl-iso-propoxy, propyl-n-butoxy, propyl- iso-butoxy, and propyl-t-butoxy.
  • Z is methyl, ethyl, n-propyl, iso- propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, neopentyl, n-hexyl, iso-hexyl, neohexyl or cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, wherein Z is unsubstituted or substituted with methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl.
  • Z is methyl, ethyl, n-propyl, iso- propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, neopentyl, n-hexyl, iso-hexyl, neohexyl or cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy.
  • Z is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, neopentyl, n-hexyl, iso-hexyl, neohexyl or cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, wherein Z is unsubstituted or substituted with methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl and n is 1 .
  • Z is methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, neopentyl, n-hexyl, iso-hexyl, neohexyl or cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy and n is 1 .
  • Z is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, neopentyl, n-hexyl, iso-hexyl, neohexyl or cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, wherein Z is unsubstituted or substituted with methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl and p is 0, 1 or 2.
  • Z is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, neopentyl, n-hexyl, iso-hexyl, neohexyl or cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, wherein Z is unsubstituted or substituted with methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl and p is 0 or 1 .
  • Z is methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, neopentyl, n-hexyl, isohexyl, neohexyl or cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, n- propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, wherein Z is unsubstituted or substituted with methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl and n is 1 and p is 0, 1 or 2.
  • Z is methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, neopentyl, n-hexyl, isohexyl, neohexyl or cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, n- propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, wherein Z is unsubstituted or substituted with methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl and n is 1 and p is 0 or 1 .
  • the present disclosure is directed to compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula II la- 1 wherein one of w 1 , w 2 or w 3 is selected from C and N, and the other two of w 1 , w 2 or w 3 are C;
  • R 1 , R 2 , R 3 , R 4 each are independently selected from hydrogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , -O-CHF 2 -O- (CH 2 ) 2 -OMe, OCF 3 , -CN, -N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1-4 alkylamino, -OC(O)-C 1-6 alkyl, -
  • X 3 is absent, hydrogen or 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membered heterocycloalkyl), -C 1-4 alkoxy-(4-8 membered heterocycloalkyl), 5-10 membered heteroaryl, -0(5-10 membered heteroaryl), -OC(O)-C 1- 4 alkyl-4-8 membered heterocycloalkyl, wherein X 3 is unsubstituted or substituted with one or more of linear or branched C 1-6 alkyl, NH 2 , NMe 2 or 5-6 membered heterocycloalkyl.
  • R 1 , R 2 , R 3 and R 4 each are independently selected from0 hydrogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , -O-CHF 2 , OCF 3 , -CN, -CHO, -C 1-6 alkylC(O) 0H, NH 2 , C 1- 4 alkyl hydroxy, halogen, preferably F, Cl, Br, more preferably F or Cl; and/or two of R 1 , R 2 , R 3 , R 4 form together a 5-6 membered heterocycloalkyl or a 5-6 membered heteroaryl;
  • X 3 is absent, hydrogen or 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membered heterocycloalkyl), -C 1-4 al
  • R 1 , R 2 , R 3 are defined as above and R 4 is hydrogen such that the aromatic ring contains 4 or 5 substituents which are not hydrogen.
  • R 1 and R 2 are defined as above and R 3 and R 4 each are hydrogen, such that the aromatic ring contains 3 or 4 substituents which are not hydrogen.
  • the present disclosure is directed to compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula llla-2, llla-3, llla-4 or llla-5
  • R 1 , R 2 , R 3 , R 4 each are independently selected from hydrogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , -O-CHF 2 -O- (CH 2 ) 2 -OMe, OCF 3 , -CN, -N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1-4 alkylamino, -OC(O)-C 1-6 alkyl, -
  • X 3 is absent, hydrogen or 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membered heterocycloalkyl), -C 1-4 alkoxy-(4-8 membered heterocycloalkyl), 5-10 membered heteroaryl, -0(5-10 membered heteroaryl), -OC(O)-C 1- 4 alkyl-4-8 membered heterocycloalkyl, wherein X 3 is unsubstituted or substituted with one or more of linear or branched C 1-6 alkyl, NH 2 , NMe 2 or 5-6 membered heterocycloalkyl.
  • R 1 , R 2 , R 3 and R 4 each are independently selected from hydrogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , -O-CHF 2 , OCF 3 , -CN, -CHO, -C 1-6 alkylC(O) OH, NH 2 , C 1-4 alkylhydroxy, halogen, preferably F, Cl, Br, more preferably F or Cl; and/or two of R 1 , R 2 , R 3 , R 4 form together a 5-6 membered heterocycloalkyl or a 5-6 membered heteroaryl;
  • X 3 is absent, hydrogen or 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membered heterocycl
  • R 1 , R 2 , R 3 and R 4 each are independently selected from hydrogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , -O-CHF 2 , OCF 3 , -CN, -CHO, -C 1-6 alkylC(O)OH, NH 2 , C,.
  • X 3 is absent, hydrogen or 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membered heterocycloalkyl), -C 1-4 alkoxy-(4-8 membered heterocycloalkyl), 5-10 membered heteroaryl, -O-(5-10 membered heteroaryl), -OC(O)-C 1- 4 alkyl-4-8 membered heterocycloalkyl, wherein X 3 is unsubstituted or substituted with one or more of linear or branched C 1-6 alkyl, NH 2 , NMe 2 or 5-6 membered heterocycloalkyl; while in compounds of formula
  • the compound of formula Ilia, 11 la- 1 , llla-2, llla-3, 11 la-4 or llla-5 is given by a compound of formula 11 la- 2a, llla-2b, llla-2c, llla-3a, llla-4a or 11 la- 5a or or pharmaceutically acceptable salts or stereoisomers thereof
  • R 1 , R 2 , R 3 , R 4 each are independently selected from hydrogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , -O-CHF 2 -O- (CH 2 ) 2 -OMe, OCF 3 , -CN, -N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1-4 alkylamino, -OC(O)-C 1-6 alkyl, -
  • X 3 is hydrogen or 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membered heterocycloalkyl), -C 1-4 alkoxy-(4-8 membered heterocycloalkyl), 5-10 membered heteroaryl, -0(5-10 membered heteroaryl), -OC(O)-C 1-4 alkyl-4-8 membered heterocycloalkyl, wherein X 3 is unsubstituted or substituted with one or more of linear or branched C 1-6 alkyl, NH 2 , NMe 2 or 5-6 membered heterocycloalkyl.
  • R 1 , R 2 , R 3 and R 4 each are independently selected from hydrogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , -O-CHF 2 , OCF 3 , -CN, -CHO, -C 1-6 alkylC(O)OH, NH 2 , C 1-4 alkylhydroxy, halogen, preferably F, Cl, Br, more preferably F or Cl; and/or two of R 1 , R 2 , R 3 , R 4 form together a 5-6 membered heterocycloalkyl or a 5-6 membered heteroaryl; X 3 is absent, hydrogen or 4-8 membered heterocycloalkyl, C 1-4 alkyl 4-8 membered heterocycloal
  • R 1 , R 2 , R 3 and R 4 each are independently selected from hydrogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , -O-CHF 2 , OCF 3 , -CN, -CHO, -C 1- 6 alkylC(O)OH, NH 2 , C 1-4 alkylhydroxy, halogen, preferably F, Cl, Br, more preferably F or Cl; and/or two of R 1 , R 2 , R 3 , R 4 form together a 5-6 membered heterocycloalkyl or a 5-6 membered heteroaryl;
  • X 3 is hydrogen or 4-8 membered heterocycloalkyl, C 1 _ 4 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membere
  • R 1 , R 2 , R 3 , R 4 each are independently selected from hydrogen, linear or branched C 1-6 alkyl, linear or branched C 1-6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , -O-CHF 2 -O-(CH 2 ) 2 -OMe, OCF 3 , -CN, -N(H)C(O)-C 1-6 alkyl, -OC(O)-C 1-4 alkylamino, -OC(O)- C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -CHO, -C 1-6 alkylC(O)OH, -C, - 6 a Iky IC(0 )O-C, - 6 a Iky IC(0 )O-C, - 6 a Iky IC(0 )O-C, - 6 a Iky IC(0 )
  • R 1 , R 2 , R 3 and R 4 each are independently selected from hydrogen, linear or branched C 1 _ 6 alkyl, linear or branched C 1 _ 6 heteroalkyl, C 6 aryl, preferably phenyl, CF 3 , CHF 2 , -O-CHF 2 , OCF 3I -CN, -CHO, -C 1-6 alkylC(O)OH, NH 2 , C 1-4 alkylhydroxy, halogen, preferably F, Cl, Br, more preferably F or Cl; and/or two of R 1 , R 2 , R 3 , R 4 form together a 5-6 membered heterocycloalkyl or a 5-6 membered heteroaryl; while one of R 1 , R 2 , R 3 and R 4 is hydrogen; X 3 is absent, hydrogen
  • Z is linear or branched C 1-6 alkyl or C 3-6 cycloalkyl, C 1-4 alkoxy or C 1-4 alkyl-C 1-4 alkoxy, wherein Z is unsubstituted or substituted with C 1-4 alkyl.
  • C 1-6 alkyl is selected from methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, neopentyl, n- hexyl, iso-hexyl, and neohexyl.
  • C 3-6 cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • C 1-4 alkoxy is selected from methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, and t-butoxy.
  • C 1-4 alkyl-C 1-4 alkoxy is selected from methyl-methoxy, methyl-ethoxy, methyl-n-propoxy, methyl-iso-propoxy, methyl-n-butoxy, methyl-iso-butoxy, methyl-t-butoxy, ethyl-methoxy, ethyl-ethoxy, ethyl-n-propoxy, ethyl- iso-propoxy, ethyl-n-butoxy, ethyl-iso-butoxy, ethyl-t-butoxy, propyl-methoxy, propyl- ethoxy, propyl-n-propoxy, propyl-iso-propoxy, propyl-n-butoxy, propyl- iso-butoxy, and propyl-t-butoxy.
  • Z is methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, neopentyl, n-hexyl, iso- hexyl, neohexyl or cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, n- propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, wherein Z is unsubstituted or substituted with methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl and p is 0.
  • Z is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, neopentyl, n-hexyl, iso-hexyl, neohexyl or cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, wherein Z is unsubstituted or substituted with methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl and p is 1 .
  • Z is methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, neopentyl, n-hexyl, isohexyl, neohexyl or cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, n- propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, wherein Z is unsubstituted or substituted with methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl and p is 2.
  • the compounds of formula I lie are of formula I lie- 1 wherein one or two of w 4 , w 5 , w 6 , w 7 is selected from C, O, N, NMe, NH, or S while two or three of w 4 , w 5 , w 6 and w 7 are C;
  • R 5 , R 6 each are independently selected from hydrogen, linear or branched C 1-4 alkyl, CF 3 , CHF 2 , halogen, preferably F, Cl, Br, more preferably F or Cl.
  • R 5 , R 6 each are independently selected from hydrogen, methyl, ethyl and CF 3 .
  • w 5 is N, w 7 is NMe, w 6 and w 4 are C; or w 5 is C, w 7 is S, w 6 and w 4 are C; or w 5 is C, w 7 is NMe, w 6 is N and w 4 is C; or w 5 is C, w 7 is C, w 6 is C and w 4 is S; or w 5 is C, w 7 is C, w 6 is N and w 4 is N; or w 5 is O, w 7 is C, w 6 is C and w 4 is S; or w 5 is NH, w 7 is C, w 6 is C and w 4 is C; or w 5 is C, w 7 is S, w 6 is C and w 4 is N; or w 5 is NH, w 7 is C, w 6 is C and w 4 is N; or w 5 is NH, w 7 is C, w 6 is C and w 4 is N; or
  • R 5 , R 6 each are independently selected from hydrogen, methyl, ethyl and CF 3 and w 5 is N, w 7 is NMe, w 6 and w 4 are C; or w 5 is C, w 7 is S, w 6 and w 4 are C; or w 5 is C, w 7 is NMe, w 6 is N and w 4 is C; or w 5 is C, w 7 is C, w 6 is C and w 4 is S; or w 5 is C, w 7 is C, w 6 is N and w 4 is N; or w 5 is O, w 7 is C, w 6 is C and w 4 is S; or w 5 is NH, w 7 is C, w 6 is C and w 4 is C; or w 5 is C, w 7 is S, w 6 is C and w 4 is N; or w 5 is NH, w 7 is C, w 6 is C and w 4 is C; or
  • the present disclosure is directed towards a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula Ilia' or lllb' wherein n is 1 or 2 p is 0, 1 or 2
  • R 1 , R 2 , R 3 , R 4 each are independently selected from hydrogen, CF 3 , linear or branched C 1-4 alkyl, C 1-4 alkoxy, 4-7 membered heterocycloalkyl, C 1-4 alkyl 4-7 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 1-6 alkylamino, -CN, - OC(O)-C 1-6 alkyl, -N(H)C(O)- C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C,.
  • Z is linear or branched C 1-6 alkyl, C 3.6 cycloalkyl or C 1-4 alkoxy, wherein Z is unsubstituted or substituted with C 1-4 alkyl or C 6 aryl.
  • n 1 .
  • p is 0, 1 or 2. In other embodiments of the compound of formula Ilia' or lllb', p is 0 or 1 .
  • n is 1 and p is 0, 1 or 2.
  • n is 1 and p is 0 or 1 .
  • R 1 , R 2 , R 3 are defined as above and R 4 is hydrogen such that the aromatic ring contains 4 substituents which are not hydrogen.
  • R 1 and R 2 are defined as above and R 3 and R 4 each are hydrogen, such that the aromatic ring contains 3 substituents which are not hydrogen.
  • R 1 and R 2 are independently selected from hydrogen, 4-7 membered heterocycloalkyl, C 1-4 alkyl 4-7 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 1-6 alkylamino, -CN, -OC(O)-C 1-6 alkyl, - N(H)C(O)- C 1 _ 6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkylC(O)OH, -C 1-6 alkylC(O)O-C 1-6 alkyl, NH 2 , C 1-4 alkylhydroxy, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, methoxy, ethoxy, n
  • R 1 and R 2 are independently selected from hydrogen, morpholinyl, -(CH 2 )-morpholinyl, piperazinyl, -(CH 2 )-piperazinyl, CF 3 , CHF 2I -O-(CH 2 ) 2 -OMe, OCF 3 , C 6-10 alkylamino, -CN, -N(H)C(O)- C 1-6 alkyl, -OC(O)-C,.
  • R 1 and R 2 are independently selected from hydrogen, CF 3 , OCF 3 , C 1-4 alkylamino, -CN, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, F, Cl, Br and phenyl.
  • R 1 and R 2 are independently selected from hydrogen, 4-7 membered heterocycloalkyl, C 1-4 alkyl 4-7 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 1-6 alkylamino, -CN, -OC(O)-C 1-6 alkyl, - N(H)C(O)- C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkylC(O)OH, -C 1-6 alkylC(O)O-C 1-6 alkyl, NH 2 , C 1-4 a Iky I hydroxy, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, methoxy, ethoxy,
  • R 1 and R 2 are independently selected from hydrogen, morpholinyl, -(CH 2 )-morpholinyl, piperazinyl, -(CH 2 )-piperazinyl, CF 3 , CHF 2I -O-(CH 2 ) 2 -OMe, OCF 3 , C 6-10 alkylamino, -CN, -N(H)C(O)- C 1 _ 6 alkyl, -OC(O)-C 1.
  • R 1 and R 2 are independently selected from hydrogen, CF 3 , OCF 3 , C 1-4 alkylamino, -CN, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, F, Cl, Br and phenyl and n is 1 .
  • R 1 and R 2 are independently selected from hydrogen, 4-7 membered heterocycloalkyl, C 1-4 alkyl 4-7 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 1-6 alkylamino, -CN, - N(H)C(O)- C 1-6 alkyl, -OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkylC(O)OH, -C,.
  • R 1 and R 2 are independently selected from hydrogen, morpholinyl, -(CH 2 )-morpholinyl, piperazinyl, - (CH 2 )-piperazinyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 6-10 alkylamino, -CN, -N(H)C(O)- C,. 6 alkyl, -OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkylC(O)OH, -C 1-6 alkylC(O)O-C 1.
  • R 1 and R 2 are independently selected from hydrogen, CF 3 , OCF 3 , C 1-4 alkylamino, -CN, methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, methoxy, ethoxy, n-propoxy, iso-propoxy, n- butoxy, iso-butoxy, t-butoxy, F, Cl, Br and phenyl and p is 0, 1 or 2.
  • R 1 and R 2 are independently selected from hydrogen, 4-7 membered heterocycloalkyl, C 1-4 alkyl 4-7 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 1-6 alkylamino, -CN, - OC(O)-C 1-6 alkyl, -N(H)C(O)- C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkylC(O)OH, -C,.
  • R 1 and R 2 are independently selected from hydrogen, morpholinyl, -(CH 2 )-morpholinyl, piperazinyl, - (CH 2 )-piperazinyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 6-10 alkylamino, -CN, -N(H)C(O)- C,.
  • R 1 and R 2 are independently selected from hydrogen, CF 3 , OCF 3 , C 1-4 alkylamino, -CN, methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, methoxy, ethoxy, n-propoxy, iso-propoxy, n- butoxy, iso-butoxy, t-butoxy, F, Cl, Br and phenyl and p is 0 or 1 .
  • R 1 and R 2 are independently selected from hydrogen, 4-7 membered heterocycloalkyl, C 1-4 alkyl 4-7 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 1-6 alkylamino, -CN, - N(H)C(O)- C 1-6 alkyl, -OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkylC(O)OH, -C,.
  • R 1 and R 2 are independently selected from hydrogen, morpholinyl, -(CH 2 )-morpholinyl, piperazinyl, - (CH 2 )-piperazinyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 6-10 alkylamino, -CN, -N(H)C(O)- C,.
  • R 1 and R 2 are independently selected from hydrogen, CF 3 , OCF 3 , C 1-4 alkylamino, -CN, methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, methoxy, ethoxy, n-propoxy, iso-propoxy, n- butoxy, iso-butoxy, t-butoxy, F, Cl, Br and phenyl and n is 1 and p is 0, 1 or 2.
  • R 1 and R 2 are independently selected from hydrogen, 4-7 membered heterocycloalkyl, C 1-4 alkyl 4-7 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 1-6 alkylamino, -CN, - OC(O)-C 1-6 alkyl, -N(H)C(O)- C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkylC(O)OH, -C,.
  • R 1 and R 2 are independently selected from hydrogen, morpholinyl, -(CH 2 )-morpholinyl, piperazinyl, - (CH 2 )-piperazinyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 6-10 alkylamino, -CN, -N(H)C(O)- C,. 6 alkyl, -OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkylC(O)OH, -C 1-6 alkylC(O)O-C 1.
  • R 1 and R 2 are independently selected from hydrogen, CF 3 , OCF 3 , C 1-4 alkylamino, -CN, methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, methoxy, ethoxy, n-propoxy, iso-propoxy, n- butoxy, iso-butoxy, t-butoxy, F, Cl, Br and phenyl and n is 1 and p is 0 or 1 .
  • Z is methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, neopentyl, n-hexyl, iso-hexyl, neohexyl or cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, wherein Z is unsubstituted or substituted with methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl or C 6 aryl.
  • Z is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, neopentyl, n-hexyl, iso-hexyl, neohexyl or cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, wherein Z is unsubstituted or substituted with methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl or C 6 aryl and n is 1 .
  • Z is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, neopentyl, n-hexyl, iso-hexyl, neohexyl or cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, wherein Z is unsubstituted or substituted with methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl or C 6 aryl and p is 0, 1 or 2.
  • Z is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, neopentyl, n-hexyl, iso-hexyl, neohexyl or cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, wherein Z is unsubstituted or substituted with methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl or C 6 aryl and p is 0 or 1 .
  • Z is methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, neopentyl, n-hexyl, isohexyl, neohexyl or cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, n- propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, wherein Z is unsubstituted or substituted with methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl or C 6 aryl and n is 1 and p is 0, 1 or 2.
  • Z is methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, neopentyl, n-hexyl, isohexyl, neohexyl or cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, n- propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, wherein Z is unsubstituted or substituted with methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl or C 6 aryl and n is 1 and p is 0 or 1
  • the present disclosure is directed to compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula IIIa'- 1
  • R 1 , R 2 , R 3 , R 4 each are independently selected from hydrogen, 4-7 membered heterocycloalkyl, C 1-4 alkyl 4-7 membered heterocycloalkyl, CF 3 , linear or branched C 1-4 alkyl, C 1-4 alkoxy, CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 1-6 alkylamino,
  • -CN -OC(O)-C 1-6 alkyl, -N(H)C(O)- C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C,. 6alkylC(O)OH, -C 1-6 alkylC(O)O-C 1-6 alkyl, NH 2 , C 1-4 alkylhydroxy, halogen, preferably F, Cl, Br, more preferably F or Cl, and C 6 aryl, preferably phenyl.
  • R ⁇ R 2 R 3 and R 4 are independently selected from hydrogen, 4-7 membered heterocycloalkyl, C 1-4 alkyl 4-7 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 1-6 alkylamino, -CN, - N(H)C(O)- C 1-6 alkyl, -OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkylC(O)OH, -C,.
  • R 1 , R 2 , R 3 are defined as above and R 4 is hydrogen such that the aromatic ring contains 4 substituents which are not hydrogen.
  • R 3 and R 4 each are hydrogen, such that the aromatic ring contains 3 substituents which are not hydrogen.
  • the compound of formula IIIa'- 1 is defined byformula llla'-1 a, IIIa'- 1 b, IIIa'- 1 c or IIIa'- 1 d wherein R 1 , R 2 each are independently selected from hydrogen, 4-7 membered heterocycloalkyl, C 1 - 4 alkyl 4-7 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 1-6 alkylamino, -CN, -OC(O)-C 1-6 alkyl, -N(H)C(O)- C 1-6 alkyl, -C(O)O-C 1-6 alkyl, - COOH, -C 1-6 alkylC(O)OH, -C 1-6 alkylC(O)O-C 1-6 alkyl, NH 2 , C1 -4 alkylhydroxy, linear or branched C 1 - 4 alkyl,
  • R 1 and R 2 are independently selected from hydrogen, 4-7 membered heterocycloalkyl, C 1- 4 alkyl 4-7 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 1-6 alkylamino, -
  • CN -N(H)C(O)- C 1-6 alkyl, -OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkylC(O)OH, - C 1-6 alkylC(O)O-C 1-6 alkyl, NH , C1 -4 alkylhydroxy, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, F, Cl, Br and phenyl, preferably from hydrogen, CF 3 , methyl, ethyl, t-butyl, methoxy, F, Cl or phenyl.
  • R 1 and R 2 are independently selected from hydrogen, CF 3 , OCF 3 , C 1-4 alkylamino, -CN, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, methoxy, ethoxy, n-propoxy, iso- propoxy, n-butoxy, iso-butoxy, t-butoxy, F, Cl, Br and phenyl, preferably from hydrogen, CF 3 , methyl, ethyl, t-butyl, methoxy, F, Cl or phenyl.
  • the compound of formula IIIa'- 1 is defined by formula IIIa'- 1 e, IIIa'- 1 f, IIIa'- 1 g, IIIa'- 1 h, IIIa'- 1 i or IIIa'- 1 j, in particular by formula IIIa'- 1 h or IIIa'- 1 g wherein R 1 , R 2 and R 3 each are independently selected from hydrogen, 4-7 membered heterocycloalkyl, C 1-4 alkyl 4-7 membered heterocycloalkyl, CF 3 , linear or branched C 1-4 alkyl, C 1-4 alkoxy, CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 1-6 alkylamino, -CN, -N(H)C(O)- C 1-6 alkyl, - OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkyl
  • R 1 , R 2 and R 3 are independently selected from hydrogen, 4-7 membered heterocycloalkyl, C 1-4 alkyl 4-7 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 1-6 alkylamino, -CN, -N(H)C(O)- C 1-6 alkyl, -OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, - COOH, -C 1-6 alkylC(O)OH, -C 1-6 a Iky IC(0 )O-C 1-6 alkyl , NH 2 , C 1-4 alkylhydroxy, methyl, e
  • R 1 , R 2 and R 3 are independently selected from hydrogen, CF 3 , OCF 3 , C 1-4 alkylamino, -CN, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, methoxy, ethoxy, n- propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, F, Cl, Br and phenyl, preferably from hydrogen, CF 3 , methyl, ethyl, t-butyl, methoxy, F, Cl and phenyl.
  • the compound of formula IIIa'- 1 is defined by formula IIIa'- 1 1, IIIa
  • R 1 , R 2 , R 3 and R 4 each are independently selected from hydrogen, 4-7 membered heterocycloalkyl, C 1 _ 4 alkyl 4-7 membered heterocycloalkyl, CF 3 , linear or branched C 1 _ 4 alkyl, C 1-4 alkoxy, CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 6-10 alkylamino, -CN, -N(H)C(O)- C 1 _ 6 alkyl, - OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkylC(O)OH, -C 1-6 alkylC(O)O-C 1-6 alkyl, NH 2 , CI alkylhydroxy, halogen, preferably F, Cl, Br, more preferably F or Cl, and C 6 aryl, preferably phenyl.
  • IIIa'- 1 m or IIIa'- 1 n R 1 , R 2 , R 3 and R 4 are independently selected from hydrogen, 4-7 membered heterocycloalkyl, C 1-4 alkyl 4-7 membered heterocycloalkyl, CF 3 , CHF 2 , -O-(CH 2 ) 2 -OMe, OCF 3 , C 1-6 alkylamino, - CN, -N(H)C(O)- C 1-6 alkyl, -OC(O)-C 1-6 alkyl, -C(O)O-C 1-6 alkyl, -COOH, -C 1-6 alkylC(O)OH, - C 1-6 alkylC(O)O-C 1-6 alkyl, NH 2 , C 1-4 alkylhydroxy, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso
  • IIIa'- 1 m or IIIa'- 1 n R 1 , R 2 , R 3 and R 4 are independently selected from hydrogen, CF 3 , OCF 3 , C 1-4 alkylamino, -CN, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, methoxy, ethoxy, n-propoxy, iso-propoxy, n- butoxy, iso-butoxy, t-butoxy, F, Cl, Br and phenyl, preferably from hydrogen, CF 3 , methyl, ethyl, t-butyl, methoxy, F, Cl and phenyl.
  • the present disclosure is directed towards a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula IV wherein
  • W is selected from
  • W is
  • the present disclosure is directed towards a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula IV' wherein W' is selected from
  • W' is
  • the present disclosure is directed towards a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula V wherein
  • W 1 is selected from In specific embodiments of a compound of formula V, W 1 is selected from In more specific embodiments, the present disclosure is directed towards a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula VI wherein
  • W 2 is selected from
  • W 2 is selected from:
  • the present disclosure is directed towards a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula VII wherein
  • W 3 is selected from
  • W 3 is selected from: In further specific embodiments, the disclosure is directed to the specific examples disclosed in Table 1 .
  • the disclosure is directed to the (S) enantiomer of the compounds of any of formula l-VII. In some embodiments, the disclosure is directed to the (R) enantiomer of the compounds of any of formula l-VII.
  • the disclosure is directed to the racemate of the compounds of any of formula l-VII.
  • the disclosure is directed to a method for producing a compound of any of formula l-VII according to the general procedure A.
  • the compounds of the disclosure can contain one or more asymmetric centers in the molecule.
  • a compound without designation of the stereochemistry is to be understood to include all the optical isomers (e.g., diastereomers, enantiomers, etc.) in pure or substantially pure form, as well as mixtures thereof (e.g. a racemic mixture, or an enantiomerically enriched mixture). It is well known in the art how to prepare such optically active forms (e.g. by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, by chromatographic separation using a chiral stationary phase, and other methods).
  • the compounds can be isotopically-labeled compounds, for example, compounds including various isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, iodine, or chlorine.
  • the disclosed compounds may exist in tautomeric forms and mixtures and separate individual tautomers are contemplated. In addition, some compounds may exhibit polymorphism.
  • the compounds of the disclosure include the free form as well as the pharmaceutically acceptable salts and stereoisomers thereof.
  • the pharmaceutically acceptable salts include all the typical pharmaceutically acceptable salts.
  • the pharmaceutically acceptable salts of the present compounds can be synthesized from the compounds of this disclosure which contain a basic or acidic moiety by conventional chemical methods, see e.g. Berge et al, "Pharmaceutical Salts," J. Pharm. ScL, 1977:66:1 -19.
  • the compounds of the disclosure also include lyophilized and polymorphs of the free form.
  • conventional pharmaceutically acceptable salts for a basic compound include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like, as well as salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxy-benzoic, f umaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, trif luoroacetic and the like.
  • inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like
  • organic acids such as acetic, propi
  • salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc and the like.
  • Salts derived from pharmaceutically acceptable organic bases include salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as arginine, betaine caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2- dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N- ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins,
  • the compounds of the disclosure may exist in solid, i.e. crystalline or noncrystalline form (optionally as solvates) or liquid form. In the solid state, it may exist in, or as a mixture thereof.
  • solvent molecules are incorporated into the crystalline lattice during crystallization.
  • the formation of solvates may include non-aqueous solvents such as, but not limited to, ethanol, isopropanol, DMSO, acetic acid, ethanolamine, or ethyl acetate, or aqueous solvents such as water (also called “hydrates"). It is common knowledge that crystalline forms (and solvates thereof) may exhibit polymorphism, i.e.
  • Polymorphs exist in different crystalline structures known as "polymorphs", that have the same chemical composition but differ in packing, geometrical arrangement, and other descriptive properties of the crystalline solid state. Polymorphs, therefore, may have different physical properties such as shape, density, hardness, deformability, stability, and dissolution properties, and may display different melting points, IR spectra, and X-ray powder diffraction patterns, which may be used for identification. Such different polymorphs may be produced, for example, by changing or adjusting the reaction conditions or reagents, during preparation of the compound of the disclosure.
  • the disclosure also provides methods of preparation of the compounds of the disclosure. Typically, they are prepared according to the syntheses shown in the experimental section.
  • the disclosure further provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically-effective amount of one or more of the compounds of the disclosure or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers and/or excipients (also referred to as diluents).
  • the excipients are acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof (i.e., the patient).
  • the term "therapeutically-effective amount” as used herein refers to the amount of a compound (as such or in form of a pharmaceutical composition) of the present disclosure which is effective for producing some desired therapeutic effect.
  • Pharmaceutical compositions may be in unit dose form containing a predetermined amount of a compound of the disclosure per unit dose.
  • Such a unit may contain a therapeutically effective dose of a compound of the disclosure or salt thereof or a fraction of a therapeutically effective dose such that multiple unit dosage forms might be administered at a given time to achieve the desired therapeutically effective dose.
  • Preferred unit dosage formulations are those containing a daily dose or sub-dose, or an appropriate fraction thereof, of a compound of the disclosure or salt thereof.
  • the compounds of the disclosure may be administered by any acceptable means in solid or liquid form, including ( 1 ) oral administration, for example, drenches (aqueous or non- aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (3) topical application, for example, as a cream, ointment, or a controlled- release patch or spray applied to the skin; (4) intravag inally or intrarectally, for example, as a pessary, cream or foam; (5) sublingually; (6) ocularly; (7) transdermally; (8) nasally; (9) pulmonary; or (10) intrathecally.
  • oral administration for example, drenches (aqueous or non-
  • pharmaceutically-acceptable carrier means a pharmaceutically- acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body.
  • manufacturing aid e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid
  • solvent encapsulating material involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body.
  • Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
  • materials which can serve as pharmaceutically-acceptable carriers include: (1 ) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; ( 1 1 ) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; ( 1 2) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydro
  • compositions may contain further components conventional in pharmaceutical preparations, e.g. wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants, pH modifiers, bulking agents, and further active agents.
  • wetting agents e.g. sodium lauryl sulfate and magnesium stearate
  • coloring agents e.g., coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants, pH modifiers, bulking agents, and further active agents.
  • antioxidants examples include: (1 ) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil- soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citricacid, ethylenediaminetetraaceticacid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
  • water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like
  • oil- soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (
  • compositions may be prepared by any method known in the art, for example, by bringing into association the active ingredient with one or more carriers and/or excipients.
  • Different compositions and examples of carriers and/or excipients are well known to the skilled person and are described in detail in, e.g., Remington: The Science and Practice of Pharmacy. Pharmaceutical Press, 2013; Rowe, Sheskey, Quinn: Handbook of Pharmaceutical Excipients. Pharmaceutical Press, 2009.
  • Excipients that may be used in the preparation of the pharmaceutical compositions may include one or more of buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide a composition suitable for an administration of choice.
  • the compounds of the present disclosure may be in solid or liquid form and administered by various routes in any convenient administrative form, e.g., tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc.
  • a compound is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: ( 1 ) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds and surfactants, such as
  • the pharmaceutical compositions may also comprise buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecularweight polyethyleneglycols and the like.
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
  • Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets, and other solid dosage forms of the pharmaceutical compositions of the present disclosure such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres.
  • compositions may be formulated for rapid release, e.g., freeze-dried. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
  • Liquid dosage forms for oral administration of the compounds of the disclosure include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • An oral composition can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening
  • a compound may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
  • suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
  • Dosage forms for rectal or vaginal administration of a compound of the disclosure include a suppository, which may be prepared by mixing one or more compounds of the disclosure with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
  • suitable forms include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
  • Dosage forms for the topical or transdermal administration of a compound of the disclosure include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
  • the active compound may be mixed under sterile conditions with a pharmaceutically-acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
  • Such ointments, pastes, creams and gels may contain, in addition to a compound of the disclosure, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Dosage for s such as powders and sprays for administration of a compound of the disclosure may contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
  • Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
  • Dosageforms such astransdermal patchesfor administration of a compound of thedisclosure may include absorption enhancers or retarders to increase or decrease the flux of the compound across the skin.
  • the rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.
  • Other dosage forms contemplated include ophthalmicformulations, eye ointments, powders, solutions and the like. It is understood that all contemplated compositions must be stable under the conditions of manufacture and storage, and preserved against the contaminating action of microorganisms, such as bacteria and fungi.
  • the dosage levels of a compound of the disclosure in the pharmaceutical compositions of the disclosure may be adjusted in order to obtain an amount of a compound of the disclosure which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being deleterious to the patient.
  • the dosage of choice will depend upon a variety of factors including the nature of the particular compound of the present disclosure used, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound used, the rate and extent of absorption, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
  • a medical practitioner having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
  • a suitable daily dose of a compound of the disclosure will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, oral, intravenous, intracerebroventricular and subcutaneous doses of the compounds of this disclosure for a patient, when used for the indicated analgesic effects, will rangefrom about 0.0001 to about 100 mg, more usual 0.1 to 100 mg/kg per kilogram of body weight of recipient (patient, mammal) per day. Acceptable daily dosages may be from about 1 to about 1000 mg/day, and for example, from about 1 to about 100 mg/day.
  • the effective dose of a compound of the disclosure may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout a specified period (per day or per week or per month), optionally, in unit dosage forms. Preferred dosing also depends on factors as indicated above, e.g. on the administration, and can be readily arrived at by one skilled in medicine or the pharmacy art.
  • the compounds of the disclosure modulate the activity of cereblon.
  • the compounds and compositions of the disclosure can be useful as a medicament, i.e. as a medicament in therapy, more specifically for the treatment of cancer, as detailed below.
  • the present disclosure provides a method of treatment of a mammal, for example, a human, suffering from cancer, as detailed below.
  • treatment is intended to encompass prophylaxis, therapy and cure.
  • Such treatment comprises the step of administering a therapeutically effective amount of a compound of Formula I or salt thereof (or of a pharmaceutical composition containing a compound of Formula I or salt thereof) to said mammal, for example, a human.
  • the disclosure is directed towards the use of the compounds of the disclosure or pharmaceutically acceptable salts or stereoisomers thereof or a pharmaceutical composition thereof for the treatment of a disease associated or caused with GSPT1 , in particular the treatment of cancer, as detailed below, in a mammal, for example a human.
  • the compounds of the disclosure or pharmaceutically acceptable salts or stereoisomers thereof or a pharmaceutical composition thereof are used for the treatment of cancer associated with GSPT1 , such as glioma, thyroid cancer, lung cancer, colorectal cancer, head and neck cancer, stomach cancer, liver cancer, pancreatic cancer, renal cancer, urothelial cancer, prostate cancer, testis cancer, breast cancer, cervical cancer, endometrial cancer, ovarian cancer, melanoma and multiple myeloma.
  • cancer associated with GSPT1 such as glioma, thyroid cancer, lung cancer, colorectal cancer, head and neck cancer, stomach cancer, liver cancer, pancreatic cancer, renal cancer, urothelial cancer, prostate cancer, testis cancer, breast cancer, cervical cancer, endometrial cancer, ovarian cancer, melanoma and multiple myeloma.
  • Such a use (or method of treatment) of a subject comprises administering to a subject in need of such treatment a therapeutically effective amount of a compound of the disclosure or pharmaceutically acceptable salts thereof or a pharmaceutical composition thereof by targeting cereblon.
  • the present disclosure contemplates administration of a compound of the disclosure alone or in combination with one or more additional therapeutic agents, such as other Tyrosine kinase inhibitors: Erlotinib hydrochloride (e.g. Tarceva(R) by Genentech/Roche), Linifanib (or ABT 869, by Genentech), sunitinib malate (e.g.
  • Sutent(R) by Pfizer bosutinib (or SKI-606, described in US 6,780,996 ), dasatinib (e.g. Sprycel(R) by Bristol-Myers Squibb), armala (e.g. pazopanib, e.g. Votrient(R) by GlaxoSmithKline), imatinib and imatinib mesylate (e.g.
  • VEG Vascular Endothelial Growth Factor
  • Bevacizumab or Avastin(R) by Genentech/Roche
  • axitinib or AG013736, described in WO 01 /002369
  • Brivanib Alaninate or BMS-582664
  • motesanib or AMG- 706, described in PCT WO 02/066470
  • pasireotide e.g. SOM230, described in WO 02/010192
  • sorafenib e.g. Nexavar(R)
  • HER2 receptor inhibitors Trastuzumab (e.g.
  • Herceptin(R) by Genentech/Roche Herceptin(R) by Genentech/Roche), neratinib (or HKI-272, described WO 05/028443), lapatinib or lapatinib ditosylate (e.g. Tykerb(R) by GlaxoSmithKline); CD20 antibodies: Rituximab (e.g. Riuxan(R) and MabThera(R) by Genentech/Roche), tositumomab (e.g. Bexxar(R) by GlaxoSmithKline), ofatumumab (e.g. Arzerra(R) by GlaxoSmithKline); Bcr/Abl kinase inhibitors: nilotinib hydrochloride (e.g.
  • Tasigna(R) by Novartis DNA Synthesis inhibitors: Capecitabine (e.g. Xeloda(R) by Roche), gemcitabine hydrochloride (e.g. Gemzar(R) by Eli Lilly and Company), nelarabine (or Arranon(R) and Atriance(R) by GlaxoSmithKline); Antineoplastic agents: oxaliplatin (e.g.
  • Eloxatin(R) ay Sanofi-Aventis described in US 4,169,846 ); Epidermal growth factor receptor (EGFR) inhibitors: Gefitinib (or Iressa(R)), Afatinib (orTovok(R) by Boehringer Ingelheim), cetuximab (e.g. Erbitux(R) by Bristol-Myers Squibb), panitumumab (e.g. Vectibix(R) by Amgen); HER dimerization inhibitors: Pertuzumab (e.g. Omnitarg(R), by Genentech); Human Granulocyte colony- stimulatingfactor (G-CSF) modulators: Filgrastim (e.g.
  • Immunomodulators Afutuzumab (by Roche(R)), pegfilgrastim (e.g. Neulasta(R) by Amgen), lenalidomide (e.g. CC-501 3, e.g. Revlimid(R)), thalidomide (e.g. Thalomid(R)); (m) CD40 inhibitors: Dacetuzumab (e.g. SGN-40 or huS2C6, by Seattle Genetics, Inc); Pro- apoptotic receptor agonists (PARAs): Dulanermin (e.g.
  • AMG-951 by Amgen/Genentech
  • Hedgehog antagonists Vismodegib (or GDC-0449, described in WO 06/028958)
  • PI3K inhibitors Pictilisib (or GDC-0941 described in WO 09/036082 and WO 09/055730 ), Dactolisib (or BEZ 235 or NVP-BEZ 235, described in WO 06/1 22806)
  • Phospholipase A2 inhibitors Anagrelide (e.g.
  • Hycamtin(R) by GlaxoSmithKline Topoisomerase II inhibitors: etoposide (e.g. VP-16 and Etoposide phosphate, e.g. Toposar(R), VePesid(R) and Etopophos(R)), teniposide (e.g. VM-26, e.g. Vumon(R)); mTOR inhibitors: Temsirolimus (e.g. Torisel(R) by Pfizer), ridaforolimus (formally known as deferolimus, (or AP23573 and MK8669, described in WO 03/064383), everolimus (e.g.
  • etoposide e.g. VP-16 and Etoposide phosphate, e.g. Toposar(R), VePesid(R) and Etopophos(R)
  • teniposide e.g. VM-26, e.g. Vumon(R)
  • octreotide acetate e.g. Sandostatin(R) and Sandostatin LAR(R)
  • Nplate(R) by Amgen Nplate(R) by Amgen
  • Cell growth stimulators Palifermin (e.g. Kepivance(R) by Amgen);
  • Elotuzumab (HuLuc63, CAS No. 91 5296-00-3); CD52 antibodies: Alemtuzumab (e.g. Campath(R)); CTLA-4 inhibitors: Tremelimumab ( IgG 2 monoclonal antibody by Pfizer, formerly known as ticilimumab, CP-675,206), ipilimumab (CTLA-4 antibody, e.g. MDX- 010, CAS No. 477202-00-9); Histone deacetylase inhibitors (HDI): Voninostat (e.g. Zolinza(R) by Merck); Alkylating agents: Temozolomide (e.g.
  • Temodar(R) and Temodal(R) by Schering-Plough/Merck Temodar(R) and Temodal(R) by Schering-Plough/Merck
  • dactinomycin e.g. actinomycin-D and e.g. Cosmegen(R)
  • melphalan e.g. L-PAM, L-sarcolysin, and phenylalanine mustard, e.g. Alkeran(R)
  • altretamine e.g. hexamethylmelamine (HMM), e.g. Hexalen(R)
  • carmustine e.g. BiCNU(R)
  • bendamustine e.g. Treanda(R)
  • busulfan e.g.
  • Busulfex(R) and Myleran(R) carboplatin (e.g. Paraplatin(R)), lomustine (e.g. CCNU, e.g. CeeNU(R)), cisplatin (e.g. CDDP, e.g. Platinol(R) and Platinol(R)-AQ), chlorambucil (e.g. Leukeran(R)), cyclophosphamide (e.g. Cytoxan(R) and Neosar(R)), dacarbazine (e.g. DTIC, DIC and imidazole carboxamide, e.g. DTIC-Dome(R)), altretamine (e.g.
  • carboplatin e.g. Paraplatin(R)
  • lomustine e.g. CCNU, e.g. CeeNU(R)
  • cisplatin e.g. CDDP, e.g. Platinol(R) and
  • HMM hexamethylmelamine
  • ifosfamide e.g. Ifex(R)
  • procarbazine e.g. Matulane(R)
  • mechlorethamine e.g. nitrogen mustard, mustine and mechloroethamine hydrochloride, e.g. Mustargen(R)
  • streptozocin e.g. Zanosar(R)
  • thiotepa e.g. thiophosphoamide, TESPA and TSPA, e.g. Thioplex(R
  • Biologic response modifiers bacillus calmette-guerin (e.g.
  • theraCys(R) and TICE(R) BCG denileukin diftitox
  • denileukin diftitox e.g. Ontak(R)
  • Anti-tumor antibiotics doxorubicin (e.g. Adriamycin(R) and Rubex(R)), bleomycin (e.g. lenoxane(R)), daunorubicin (e.g. dauorubicin hydrochloride, daunomycin, and rubidomycin hydrochloride, e.g. Cerubidine(R)), daunorubicin liposomal (daunorubicin citrate liposome, e.g. DaunoXome(R)), mitoxantrone (e.g.
  • DHAD e.g. Novantrone(R)
  • epirubicin e.g. EllenceTM
  • idarubicin e.g. Idamycin(R), Idamycin PFS(R)
  • mitomycin C e.g. Mutamycin(R)
  • Anti-microtubule agents Estramustine (e.g. Emcyl(R)); Cathepsin K inhibitors: Odanacatib (or MK-0822, by Lanzhou Chon Chemicals, ACC Corp., and ChemieTek, described in WO 03/075836); Epothilone B analogs: Ixabepilone (e.g.
  • HSP Heat Shock Protein
  • Tanespimycin 17-allylamino- 17-demethoxygeldanamycin, e.g. KOS-953 and 17-AAG, by SIGMA, described in US 4,261 ,989)
  • TpoR agonists Eltrombopag (e.g. Promacta(R) and Revolade(R) by GlaxoSmithKline)
  • Anti-mitotic agents Docetaxel (e.g. Taxotere(R) by Sanofi-Aventis);
  • Adrenal steroid inhibitors aminoglutethimide (e.g.
  • GnRH Gonadotropin releasing hormone receptor agonists: Leuprolide or leuprolide acetate (e.g. Viadure(R) by Bayer AG, Eligard(R) by Sanofi-Aventis and Lupron(R) by Abbott Lab); Taxane anti-neoplastic agents: Cabazitaxel, larotaxel; 5HT1 a receptor agonists: Xaliproden (or SR57746, described in US 5,266,573); HPC vaccines: Cervarix(R) sold by GlaxoSmithKline, Gardasil(R) sold by Merck; Iron Chelating agents: Deferasinox (e.g.
  • Claribine (2-chlorodeoxyadenosine, e.g. leustatin(R)), 5-fluorouracil (e.g. Adrucil(R)), 6-thioguanine (e.g. Purinethol(R)), pemetrexed (e.g. Alimta(R)), cytarabine (e.g. arabinosylcytosine (Ara-C), e.g. Cytosar-U(R)), cytarabine liposomal (e.g. Liposomal Ara-C, e.g. DepoCytTM), decitabine (e.g.
  • Dacogen(R) hydroxyurea (e.g. Hydrea(R), DroxiaTM and MylocelTM), fludarabine (e.g. Fludara(R)), floxuridine (e.g. FUDR(R)), cladribine (e.g. 2-chlorodeoxyadenosine (2-CdA) e.g. LeustatinTM), methotrexate (e.g. amethopterin, methotrexate sodim (MTX), e.g. Rheumatrex(R) and TrexallTM), pentostatin (e.g. Nipent(R)); Bisphosphonates: Pamidronate (e.g.
  • Aredia(R)), zoledronic acid e.g. Zometa(R)
  • Demethylating agents 5-azacitidine (e.g. Vidaza(R)), decitabine (e.g. Dacogen(R));
  • Plant Alkaloids Paclitaxel protein-bound (e.g. Abraxane(R)), vinblastine (e.g. vinblastine sulfate, vincaleukoblastine and VLB, e.g. Alkaban-AQ(R) and Velban(R)), vincristine (e.g. vincristine sulfate, LCR, and VCR, e.g. Oncovin(R) and Vincasar Pfs(R)), vinorelbine (e.g.
  • Glucocorticosteroids Hydrocortisone (e.g. cortisone, hydrocortisone sodium succinate, hydrocortisone sodium phosphate, and e.g. Ala-Cort(R), Hydrocortisone Phosphate, Solu-Cortef(R), Hydrocort Acetate(R) and Lanacort(R)), dexamethasone, prednisolone (e.g.
  • Prednisone e.g. Deltasone(R), Liquid Red(R), Meticorten(R) and Orasone(R)
  • methylprednisolone e.g. 6-Methylprednisolone, Methylprednisolone Acetate, Methylprednisolone Sodium Succinate, e.g. Duralone(R), Medralone(R), Medrol(R), M-Prednisol(R) and Solu- Medrol(R)
  • Cytokines interleukin-2 (e.g.
  • aldesleukin and IL-2 e.g. Proleukin(R)), interleukin-1 1 (e.g. oprevelkin, e.g. Neumega(R)), alpha interferon alfa (e.g. IFN-alpha, e.g. Intron(R) A, and Roferon-A(R)); Lutinizing hormone releasing hormone (LHRH) agonists: Goserelin (e.g. Zoladex(R)); Progesterones: megestrol (e.g. megestrol acetate, e.g. Megace(R)); Miscellaneous cytotoxic agents: Arsenic trioxide (e.g.
  • Trisenox(R) Trisenox(R)
  • asparaginase e.g. L-asparaginase, Erwinia L-asparaginase, e.g. Elspar(R) and Kidrolase(R)
  • Anti-nausea drugs NK-1 receptor antagonists: Casopitant (e.g. Rezonic(R) and Zunrisa(R) by GlaxoSmithKline); and Cy to protective agents: Am if ostine (e.g. Ethyol(R)), leucovorin (e.g. calcium leucovorin, citrovorum factor and folinic acid).
  • Variant iii) To a solution of 3-(6-(aminomethyl)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride VI (0.8-1 .3 eq, hydrochloride) and triethylamine (1 .2-20 eq) in a polar aprotic solvent (dimethylformamide, dichloromethane, or tetrahydrofuran, 0.03-0.71 M) was added the O-phenylcarbamate R-N(CO)O-Ph (0.8-2 eq). The reaction was stirred at a temperature range of 20 to 60°C for 1 to 24 h.
  • a polar aprotic solvent dimethylformamide, dichloromethane, or tetrahydrofuran, 0.03-0.71 M
  • the reaction was extracted (the mixture was diluted with water and extracted with ethyl acetate, and the combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure) or it was directly concentrated under reduced pressure (with or without prior dilution with DMSO and/or filtration) to give a residue.
  • the obtained residue was purified by reversed phase preparative HPLC or by trituration (ethyl acetate was added, and the mixture was cooled to 1 5°C for 5 min; the precipitate was filtered and dried). The purified compounds were lyophilized to afford the final urea compounds VII as solids.
  • Step 1 3-chloro-2-methyl-5-nitrobenzoic acid.
  • 3-chloro-2-methylbenzoic acid 10.0 g, 58.6 mmol, 1 .00 eg
  • sulfuric 50.0 mL
  • nitric acid 4.1 9 g, 64.5 mmol, 2.99 mL, 1 .10 eg
  • the reaction mixture was poured into ice water (about 200 ml) and stirred, the precipitated solid was collected by filtration and washed with water.
  • Step 2 3-chloro-2-methyl-5-nitrobenzoic acid (1 6.0 g, crude) as a white solid was used for the next step without purification.
  • Step 2 (3-chloro-2-methyl-5-nitrophenyl)methanol.
  • Step 3 1 -chloro-3-(chloromethyl)-2-methyl-5-nitrobenzene.
  • thionyl chloride 5.90 g, 49.6 mmol, 3.60 mL, 5.00 eg
  • the reaction mixture was concentrated under reduced pressure to afford 1 -chloro-3-(chloromethyl)-2-methyl-5-nitrobenzene (2.20 g, crude) as yellow oil.
  • Step 4 1 -(3-chloro-2-methyl-5-nitrophenyl) -N,N-dimethylmethanamine.
  • 1 -chloro-3-(chloromethyl)-2-methyl-5-nitrobenzene (2.18 g, 9.92 mmol, 1.00 eg) and triethylamine (2.51 g, 24.8 mmol, 3.45 mL, 2.50 eg) in acetonitrile (20.0 mL) was added dimethylamine hydrochloride (1 .01 g, 12.4 mmol, 1 .25 eg). Then the mixture was stirred at 25 °C for 10 h. The reaction mixture was concentrated under reduced pressure to give a residue.
  • Step 5 3-chloro-5-((dimethylamino)methyl)-4-methylaniline.
  • Step 6 1 -(3-chloro-5-isocyanato-2-methylphenyl)-N,N-dimethylmethanamine.
  • Step 1 1 -chloro-4-methoxy-2-methyl-5-nitrobenzene.
  • acetonitrile 50.0 mL
  • dimethyl sulfate 3.71 g, 29.4 mmol, 2.79 mL, 1 .20 eg
  • potassium carbonate 6.78 g, 49.1 mmol, 2.00 eg.
  • the reaction was stirred at 80 °C for 1 2 h.
  • the reaction mixture was quenched with water (50 .0 mL), extracted with ethyl acetate (3 x 100 mL).
  • Step 2 5-chloro-2-methoxy-4-methylaniline.
  • 1 -chloro-4-methoxy-2- methyl-5-nitrobenzene (5.00 g, 24.8 mmol, 1 .00 eg) in ethanol (30.0 mL) and water ( 10.0 mL) was added iron powder (4.1 5 g, 74.4 mmol, 3.00 eg) and ammonium chloride (6.63 g, 1 24 mmol, 5.00 eg).
  • the reaction was stirred at 80 °C for 1 2 h.
  • the reaction mixture was filtered and concentrated in vacuo.
  • the residue was suspended in water (50.0 mL) and extracted with ethyl acetate (3 x 100 mL).
  • Step 3 1 -chloro-5-isocyanato-4-methoxy-2-methylbenzene.
  • 5-chloro-2- methoxy-4-methylaniline 1 .00 g, 5.83 mmol, 1 .00 eg
  • triphosgene 1 .73 g, 5.83 mmol, 1 .00 eg
  • Step 1 To a solution of 2,5-dichloro-4-methyl-benzoic acid ( 1 .00 g, 4.88 mmol, 1 .00 eq) and triethylamine (523 mg, 5.17 mmol, 720 uL, 1 .06 eq) in toluene (50.0 mL) was added diphenyl phosphorazidate (1 .37 g, 4.97 mmol, 1 .08 mL, 1 .02 eq) at 20 °C. The reaction mixture was stirred 1 20 °C for 2 h. The reaction mixture was concentrated in vacuo.
  • Step 1 To a solution of 4-(dimethylamino)benzoic acid (1 .00 g, 6.05 mmol, 1 .00 eg) in toluene (50.0 mL) was added triethylamine (0.89 mL, 6.42 mmol, 1 .06 eg) and diphenylphosphoryl azide (1 .34 mL, 6.17 mmol, 1 .02 eg). The reaction was stirred at 20°C for 0.5 h, then at 1 20°C for 2 h. The mixture was concentrated under reduced pressure to give a residue. Dichloromethane (4.00 mL) was added to the residue to afford the 4- isocyanato-/V,/V-dimethylaniline (982 mg, crude) as red oil.
  • Step 1 To a solution of 3-((tert-butoxycarbonyl)amino)benzoic acid (500 mg, 2.1 1 mmol, 1 .00 eq) in toluene (25.0 mL) was added triethylamine (0.31 mL, 2.23 mmol, 1 .06 eq) and diphenyl phosphorazidate (0.47 mL, 2.15 mmol, 1 .02 eq). The reaction was stirred at 20°C for 0.5 h, then at 1 20°C for 2 h. The mixture was concentrated under reduced pressure to afford tert-butyl-(3-isocyanatophenyl)carbamate (490 mg, 2.09 mmol, 99% yield) as a yellow oil.
  • Step 2 To a solution of 3-(6-(aminomethyl)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride VI (1.00 eq, hydrochloride) in dimethylformamide (2.00 mL) was added triethylamine (0.1 1 mL, 0.77 mmol, 1 .20 eq) and tert-butyl (3-isocyanatophenyl)carbamate (182 mg, 0.77 mmol, 1 .20 eq) at 0°C. The reaction was stirred at 20°C for 1 h.
  • Step 3 To a solution of tert- butyl (3-(3-((2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5- yl)methyl)ureido) phenyl)carbamate (150 mg, 0.30 mmol, 1 .00 eq) in methanol (1 .00 mL) was added 4N of hydrochloric acid in methanol (1 .00 mL). The reaction was stirred at 20°C for 0.5 h. The mixture was concentrated under reduced pressure to give a residue, which was purified by preparative HPLC and lyophilized to afford Compound 80 (77.8 mg, 0.17 mmol, 59% yield) as an off-white solid.
  • Step 1 To a solution of 3-(6-(aminomethyl)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride VI ( 1 .00 eq, hydrochloride) in dimethylformamide (2.00 mL) was added triethylamine (0.09 ml, 645 ⁇ mol, 1 .00 eq) and 1 -isocyanato-4-nitro-benzene (106 mg, 0.65 mmol, 1 .00 eq) at 0°C. The reaction was stirred 20°Cfor 1 h. The mixture was quenched with water (10.0 mL) and extracted with ethyl acetate (2 x 50 mL).
  • Step 2 To a solution of 1 -[[2-(2,6-dioxo-3-piperidyl)-3-oxo-isoindolin-5-yl]methyl]-3-(4- nitrophenyl)urea (1 50 mg, 343 ⁇ mol, 1 .00 eq) in methanol (3.00 mL) was added Pd/C 10.0% weight on C (5 mg,) and hydrochloric acid 4M (8.57 ⁇ L, 0.10 eq). The reaction was stirred at 20°Cfor 2 h under hydrogen atmosphere (1 5 psi). The mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue.
  • Step 1 To a solution of (3-chloro-2-methyl-5-nitrophenyl)methanol (2.00 g, 9.92 mmol, 1 .00 eq) in dichloromethane (20.0 mL) was added thionyl chloride (3.60 mL, 49.6 mmol, 5.00 eq). The reaction was stirred at 25°C for 2 h. The mixture was concentrated under reduced pressure to afford 1 -chloro-3-(chloromethyl)-2-methyl-5-nitro-benzene (2.20 g, 10.0 mmol, crude) as a yellow oil. It was used directly in the next step.
  • Step 2 To a solution of 1 -chloro-3-(chloromethyl)-2-methyl-5-nitrobenzene (2.20 g, 10.0 mmol, 1 .00 eq) and triethylamine (3.48 mL, 25.0 mmol, 2.50 eq) in acetonitrile (20.0 mL) was added morpholine (1 .14 mL, 13.0 mmol, 1 .30 eq). The reaction was stirred at 25°C for 10 h.
  • Step 3 To a mixture of ethanol (8.00 mL) and water (4.00 mL) was added 4-(3-chloro-2- methyl-5-nitrobenzyl)morpholine (0.500 g, 1 .85 mmol, 1 .00 eq), ammonium chloride (98.8 mg, 1 .85 mmol, 1 .00 eq) and ferrous powder (516 mg, 9.23 mmol, 5.00 eq). The reaction was stirred at 90°C for 10 h. The mixture was filtered and washed with ethyl acetate (20.0 mL).
  • Step 4 To a solution of 3-chloro-4-methyl-5-(morpholinomethyl)aniline (0.100 g, 0.41 mol, 1 .00 eq) in tetrahydrofuran (1 .00 mL) was added 1 , V-carbonyldiimidazole (74.1 mg, 0.46 mmol, 1 .10 eq). The mixture was stirred at 25°C for 2 h, then 3-(6-(aminomethyl)-1 - oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride VI ( 1 29 mg, 0.41 mmol, 1 .00 eq, hydrochloride) was added. The reaction was stirred at 25°C for 10 h.
  • Step 1 To a mixture of 1 -methyl-1 H-pyrazole-4-carboxylic acid (400 mg, 3.17 mmol, 1 .00 eq) and triethylamine (0.55 mL, 3.96 mmol, 1.25 eq) in toluene (5.00 mL) was added diphenylphosphoryl azide (0.83 mL, 3.81 mmol, 1 .20 eq) in one portion at 20°C. The mixture was stirred at 105°C under nitrogen for 3 h. The mixture was cooled to 20°C, then concentrated under reduced pressure to afford 4-isocyanato-1 -methyl- 1 H-pyrazole (1 .80 g, crude) as black oil. It was used directly in the next step.
  • Step 1 To a suspension of thiophene-3-carboxylic acid (300 mg, 2.34 mmol, 1 .00 eq) and triethylamine (407 ⁇ L, 2.93 mmol, 1 .25 eq) in dry toluene (5.00 mL) was added diphenylphosphoryl azide (609 ⁇ L, 2.81 mmol, 1 .20 eq) at 25°C under nitrogen. The reaction was stirred at 25°C for 30 min, then heated to 100°C for 2 h. The mixture was concentrated under reduced pressure to afford 3-isocyanatothiophene (300 mg, crude) as a white solid, which was used directly in the next step.
  • Step 1 To a solution of 2,4-dimethyl-5-nitroaniline (500 mg, 3.01 mmol, 1 .00 eq) in concentrated hydrochloric acid (9.00 mL) was added a solution of sodium nitrite (208 mg, 3.01 mmol, 1 .00 eq) in water (0.60 mL) at 0°C. The reaction was stirred at 0°C for 1 h, then cuprous chloride (477 mg, 4.81 mmol, 1 .60 eq) was added at 0°C. The reaction was stirred at 20°C for 1 1 h.
  • Step 2 To a solution of 1 -chloro-2,4-dimethyl-5-nitrobenzene (350 mg, 1 .89 mmol, 1 .00 eq) in ethanol (1 2.0 mL) and water (3.00 mL) was added iron powder (31 5 mg, 5.66 mmol, 3 eq) and ammonium chloride (504 mg, 9.43 mmol, 5.00 eq). The reaction was stirred at 80°C for 2 h. The mixture was filtered and concentrated under reduced pressure to give a residue.
  • Step 3 To a solution of 5-chloro-2,4-dimethylaniline (270 mg, 1 .73 mmol, 1 .00 eq) in toluene (10.0 mL) was added triphosgene (51 5 mg, 1 .73 mmol, 1 .00 eq). The reaction was stirred at 100°C for 2 h. The mixture was concentrated under reduced pressure to afford 1 - chloro-5-isocyanato-2,4-dimethylbenzene (31 5 mg, 1 .73 mmol, 99.0% yield) as yellow oil.
  • Step 1 To a solution of 3-chloro-2-methoxy-4-methylbenzoic acid (300 mg, 1.50 mmol, 1 .00 eq) in toluene (15.0 mL) was added triethylamine (0.22 mL, 1 .59 mmol, 1 .06 eq) and diphenyl phosphorazidate (0.33 mL, 1 .53 mmol, 1 .02 eq). The reaction was stirred at 20°C for 0.5 h, then at 1 20°C for 2 h. The mixture was concentrated under reduced pressure to give a residue. Dichloromethane (4.00 mL) was added to afford 2-chloro-4-isocyanato-3- methoxy-1 -methylbenzene (296 mg, crude) as a yellow oil.
  • Step 1 To a solution of 3-chloro-4-methylaniline (5.00 g, 35.3 mmol, 1 .00 eq) in N, Ni di methyformamide (50.0 mL) at 0°C was added 1 -chloropyrrolidine-2, 5-dione (5.00 g, 37.4 mmol, 1 .06 eq) in dimethyformamide (20.0 mL) dropwise. The reaction was stirred at
  • Step 1 To a solution of 1 -methyl-1 H-pyrazole-3-carboxylic acid (500 g, 3.96 mmol, 1 .00 eq), triethylamine (0.55 mL, 3.96 mmol, 1 .00 eq) in toluene (5.00 mL) was added diphenyl phosphorazidate (0.86 mL, 3.96 mmol, 1 .00 eq) at 25°C. The reaction was stirred at 25°C for 30 min. The mixture was concentrated under reduced pressure to afford 1 -methyl-1 H- pyrazole-3-carbonyl azide (600 mg, crude) as a black solid. It was used directly in the next step.
  • Step 2 To a solution of phenol (2.96 mL, 33.7 mmol, 1 1 .3 eq) in toluene (22.0 mL) was added 1 -methyl- 1 H-pyrazole- 3 -carbonyl azide (450 mg, 2.98 mmol, 1 .00 eq) at 100°C. The reaction was stirred at 100°C for 3 hr. The mixture was concentrated under reduced pressure to give a residue.
  • Step 1 To a solution of 3-(dimethylamino)benzoic acid (1 .00 g, 6.05 mmol, 1 .00 eq) in toluene (50.0 mL) was added triethylamine (0.89 mL, 6.42 mmol, 1.06 eq) and diphenylphosphoryl azide (1 .34 mL, 6.17 mmol, 1 .02 eq). The reaction was stirred at 20°C for 0.5 h, then at 1 20°C for 2 h. The mixture was concentrated under reduced pressure to give a residue. Dichloromethane (4.00 mL) was added to the residue to afford 4-isocyanato-N,N-dimethylaniline (982 mg, crude) as red oil.
  • Step 1 To a solution of thiophene-2-carboxylic acid (300 mg, 2.34 mmol, 1 .00 eq), triethylamine (0.33 mL, 2.34 mmol, 1 .00 eq) in toluene ( 1 .50 mL) was added diphenyl phosphorazidate (0.51 mL, 2.34 mmol, 1 .00 eq) at 25°C. The reaction was stirred at 25°C for 30 min.
  • Step 2 Thiophene-2-carbonyl azide (400 mg, 2.61 mmol, 1 .00 eq) in toluene (4.00 mL) was stirred at 1 20°C for 30 min to afford 2-isocyanatothiophene. It was used directly in the next step.
  • Step 1 To a solution of thiazol-2-amine (1 .00 g, 9.99 mmol, 1 .00 eq) in dichloromethane (5.00 mL) was added pyridine (4.84 mL, 60.0 mmol, 6.00 eq) and phenyl chloroformate ( 1 .50 mL, 1 2.0 mmol, 1 .20 eq). The reaction was stirred at 20°C for 1 2 h. The mixture was concentrated under reduced pressure to give a residue.
  • Step 1 Nitric acid (1 .50 mL, 33.4 mmol, 1 .00 eq) was added dropwise to a solution of 2- chloro-1 ,3-dimethylbenzene (4.43 mL, 33.4 mmol, 1 .00 eq) in sulfuric acid (20.0 mL) at 0°C. The reaction was stirred at 20°C for 2 h. The mixture was poured into ice water (20.0 mL) and extracted with ethyl acetate (2 x 20.0 mL). The combined organic layers were washed with brine (30.0 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give a residue.
  • Step 2 To a solution of 2-chloro-1 ,3-dimethyl -4-nitrobenzene (2.10 g, 1 1 .3 mmol, 1 .00 eq) in ethanol (24.0 mL) and water (8.00 mL) was added ammonium chloride (6.05 g, 1 13 mmol, 10.0 eq) and Fe (3.79 g, 67.9 mmol, 6.00 eq). The reaction was stirred at 80°C for 2 h. The mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue.
  • Step 3 To a solution of 3-chloro-2,4-dimethylaniline (300 mg, 1 .93 mmol, 1 .00 eq) in toluene (1 2.0 mL) was added bis(trichloromethyl) carbonate (572 mg, 1 .93 mmol, 1 .00 eq). The reaction was stirred at 100°C for 3 h. The mixture was concentrated under reduced pressure to give a residue. Dichloromethane ( 1 .00 mL) was added to the residue to afford 2- chloro-4-isocyanato-1 ,3-dimethylbenzene (350 mg, crude) as a yellow oil.
  • Step 1 To a solution of isoxazol-3-amine (500 mg, 5.95 mmol, 1 .00 eq) in tetrahydrofuran (20.0 mL) were added phenyl chloroformate (1 .02 g, 6.54 mmol, 1 .10 eq) and triethylamine ( 1 .20 g, 1 1 .9 mmol, 2.00 eq) dropwise at 20°C. The reaction was stirred at 25°C for 1 2 h. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by reversed phase column chromatography to afford phenyl isoxazol-3-ylcarbamate ( 130 mg, 598 p/mol, 10% yield) as a yellow solid.
  • Step 1 To a mixture of nicotinic acid (500 mg, 4.06 mmol, 1 .00 eq) and triethylamine (534 mg, 5.28 mmol, 1 .30 eq) in toluene (5 mL) was added diphenylphosphoryl azide ( 1 .68 g, 6.09 mmol, 1 .50 eq) dropwise at 20°C. The reaction was stirred at 20°Cfor 1 h.
  • nicotinic acid 500 mg, 4.06 mmol, 1 .00 eq
  • triethylamine 534 mg, 5.28 mmol, 1 .30 eq
  • diphenylphosphoryl azide 1 .68 g, 6.09 mmol, 1 .50 eq
  • Triethylamine 1 .64 g, 16.3 mmol, 4.00 eq
  • 3-(6-(aminomethyl)-1 -oxoisoindolin-2-yl)piperidine- 2,6-dione hydrochloride VI 555 mg, 1 .79 mmol, 0.44 eq, hydrochloride
  • the reaction was stirred at 100°C for 2 h.
  • the mixture was diluted with ethyl acetate (50 mL) and poured into saturated aqueous sodium bicarbonate (50 mL).
  • the organic layer was separated, and the aqueous layer was extracted with ethyl acetate ( 10 x 50 mL).
  • Step 1 To a solution of 3-chloro-2,4-dimethylaniline (780 mg, 5.01 mmol, 1 .00 eq) in dimethylformamide (10.5 mL) was added a solution of 1 -chloropyrrolidine-2,5-dione (709 mg, 5.31 mmol, 1 .06 eq) in dimethylformamide (7.00 mL). The reaction was stirred at 20°C for 1 2 h, then it was concentrated under reduced pressure to give a residue.
  • Step 1 To a mixture of 5-methylisoxazole-3-carboxylic acid (700 mg, 5.51 mmol, 1 .00 eq) and triethylamine (725 mg, 7.16 mmol, 1 .30 eq) in toluene (5 mL) was added diphenylphosphoryl azide (2.58 g, 9.36 mmol, 1 .70 eq) dropwise at 20°C. The mixture was stirred at 20°Cfor 1 h.
  • Triethylamine (836 mg, 8.26 mmol, 1 .5 eq) and 3-(6-(aminomethyl)- 1 -oxo-isoindolin-2-yl)piperidine-2,6-dione hydrochloride VI (500 mg, 1 .61 mmol, 0.293 eq, hydrochloride) were added, and the reaction was stirred at 100°C for 2 h.
  • the mixture was cooled to 20°C and diluted with ethyl acetate (50.0 mL).
  • the mixture was poured into saturated aqueous sodium bicarbonate ( 100 mL), the organic layer was separated, and the aqueous layer was extracted with ethyl acetate (5 x 50 mL).
  • Step 1 To a solution of 1 H-pyrrole-3-carboxylic acid (500 mg, 4.50 mmol, 1.00 eq), triethylamine (0.63 mL, 4.50 mmol, 1.00 eq) in toluene (1.00 mL) was added diphenyl phosphorazidate (0.97 mL, 4.50 mmol, 1.00 eq) at 25°C. The reaction was stirred at 25°C for 1 hr. The mixture was used in the next step directly.
  • 1 H-pyrrole-3-carboxylic acid 500 mg, 4.50 mmol, 1.00 eq
  • triethylamine (0.63 mL, 4.50 mmol, 1.00 eq
  • diphenyl phosphorazidate 0.97 mL, 4.50 mmol, 1.00 eq
  • Step 1 To a solution of thiazole-4-carboxylic acid (0.50 g, 3.87 mmol, 1 .00 eq), triethylamine (0.54 mL, 3.87 mmol, 1 .00 eq) in toluene (4.00 mL) was added diphenyl phosphorazidate (0.84 mL, 1 .07 g, 3.87 mmol, 1 .00 eq) at 25°C. The mixture was stirred at 25°C for 30 min. The mixture was used in the next step directly.
  • Step 1 To a solution of 5-chloro-2,4-dimethylaniline (1 .50 g, 9.64 mmol, 1 .00 eq) in dimethyformamide ( 1 5.00 mL) was added a solution of 1 -chloropyrrolidine-2,5-dione (1 .36 g, 10.2 mmol, 1 .06 eq) in dimethyformamide (6.00 mL). The reaction was stirred at 20°C for 1 2 h. Water (20.0 mL) was added to the mixture and it was extracted with ethyl acetate (2 x 100 mL).
  • Step 2 To a solution of 2,3-dichloro-4,6-dimethylaniline (500 mg, 2.63 mmol, 1 .00 eq) in toluene (10.0 mL) was added triphosgene (781 mg, 2.63 mmol, 1 .00 eq). The reaction was stirred at 100°C for 2 h. The mixture was concentrated under reduced pressure to give 2,3- dichloro-4-isocyanato-1 ,5-dimethylbenzene (560 mg, 2.59 mmol, 99% yield) as a yellow oil.
  • Step 2 To a mixture of (2-methyl-5-nitrophenyl)methanol (1 .00 g, 5.98 mmol, 1 .00 eq) in dichloromethane ( 10.0 mL) were added thionyl chloride (4.34 mL, 59.8 mmol, 10.0 eq) and /V-methyl pyrrolidone (0.58 mL, 5.98 mmol, 1 .00 eq) dropwise at 20°C. The reaction was stirred at 25°C for 4 h. The reaction was carefully quenched with water (50.0 ml) and extracted with ethyl acetate (4 x 20.0 mL).
  • Step 3 To a mixture of 2-(chloromethyl)-1 -methyl-4-nitrobenzene (500 mg, 2.69 mmol, 1 .00 eq) in dimethylformamide (1 .50 mL) and acetonitrile ( 1 .50 mL) were added N,N- diisopropylethylamine (1 .04 g, 8.08 mmol, 3.00 eq) and morpholine (258 mg, 2.96 mmol, 1 .10 eq) dropwise at 20°C. The reaction was stirred at 60°Cfor 10 h.
  • Step 4 To a mixture of 4-(2-methyl-5-nitrobenzyl)morpholine (584 mg, 2.47 mmol, 1 .00 eq) in ethanol (5.00 mL) and water (5.00 mL) were added ammonium chloride ( 132 mg, 2.47 mmol, 1 .00 eq) and ferrous powder (690 mg, 1 2.4 mmol, 5.00 eq). The reaction was stirred at 90°C for 10 h. The mixture was cooled to 20°C and filtered. The filter cake was washed with methanol (2 x 20.0 mL). The filtrate was concentrated under reduced pressure to give a slurry.
  • Step 5 To a mixture of 4-methyl-3-(morpholinomethyl)aniline (200 mg, 0.969 mmol, 1 .50 eq) and triethylamine (98.0 mg, 0.969 mmol, 1 .50 eq) in tetrahydrofuran ( 10.0 mL) was added 1 ,1 '-carbonyldiimidazole (1 57 mg, 0.969 mmol, 1 .50 eq). The reaction was stirred at 20°C for 1 h.
  • Step 1 To a solution of 3-nitro- 1 H-pyrazole (5.00 g, 44.2 mmol, 1 .00 eq) intetrahydrofuran ( 100 mL) was added sodium hydride 60% purity (2.13 g, 53.3 mmol, 1 .20 eq) at 0°C. The reaction was stirred for 10 min, and 2-(trimethylsilyl)ethoxymethyl chloride (8.60 mL, 48.6 mmol, 1 .10 eq) was added dropwise. The reaction was stirred at 20°C for 1 h. The mixture was quenched with ice water ( 1 50 mL) and extracted with ethyl acetate (2 x 200 mL).
  • Step 2 To a solution of trimethyl-[2-[(3-nitropyrazol-1 -yl)methoxy]ethyl]silane (3.00 g, 1 2.3 mmol, 1 .00 eq) in methanol (50.0 mL) was added Pd/C 10% weight on C (0.50 g). The reaction was stirred at 30°C for 4 h under hydrogen atmosphere ( 1 5 psi). The mixture was filtered, and the filtrate was concentrated under reduced pressure to afford 1 -(2- trimethylsilylethoxymethyl)pyrazol-3-amine (2.40 g, 1 1 .2 mmol, 91 % yield) as a white solid.
  • Step 3 To a solution of 1 -(2-trimethylsilylethoxymethyl)pyrazol-3-amine (1 .00 g, 4.69 mmol, 1 .00 eq) and pyridine (0.76 mL, 9.37 mmol, 2.00 eq) in acetonitrile (8.00 mL) was added phenyl chloroformate (0.70 mL, 5.62 mmol, 1 .20 eq) in acetonitrile (2.00 mL) at 0°C. The reaction was stirred at 25°C for 3 h. The mixture was diluted with water (20.0 mL) and extracted with ethyl acetate (2 x 20.0 mL).
  • Step 4 To a solution of 3-[6-(aminomethyl)-1 -oxo-isoindolin-2-yl]piperidine-2,6-dione hydrochloride VI (200 mg, 645 ⁇ mol, 1 .00 eq, hydrochloride) and triethylamine (196 mg, 1 .94 mmol, 267 ⁇ L, 3.00 eq) in dimethylformamide (3.00 mL) was added phenyl ( 1 -((2- (trimethylsilyl)ethoxy)methyl)-1 H-pyrazol-3-yl)carbamate (258 mg, 775 ⁇ mol, 1 .20 eq). The reaction was stirred at 25°C for 1 2 h.
  • Step 5 A mixture of 1 -((2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)methyl)-3-(1 - ( ( 2-(trimethylsilyl)ethoxy) methyl)-1 H-pyrazol-3-yl)urea (360 g, 702 ⁇ mol , 1.00 eq) in trifluoroacetic acid ( 1 .00 mL) and dichloromethane ( 1 .00 mL) was stirred at 20°C for 12 h. The mixture was concentrated under reduced pressure to give a residue.
  • Step 1 To a vigorously stirred suspension of ethyl thiazole-5-carboxylate ( 1 .84 g, 1 1.7 mmol, 1 .00 eq) in methanol (1 1 .0 mL) was added sodium hydroxide (1 .40 g, 35.1 mmol, 3.00 eq).
  • Step 2 To a solution of thiazole-5-carboxylic acid (1 .31 g, 10.2 mmol, 1 .00 eq) in 1 ,4- dioxane (33.0 mL) was added triethylamine (1 .61 mL, 1 1 .59 mmol, 1 .14 eq) and diphenylphosphoryl azide (2.51 mL, 1 1 .6 mmol, 1 .14 eq). The reaction was stirred at 20°C for 3 h. Phenol ( 10.2 mL, 1 16.21 mmol, 1 1 .43 eq) was added dropwise, and the reaction was stirred at 100°C for 3 h.
  • Step 1 To a solution of 3-(morpholinomethyl)aniline (279 mg, 1 .45 mmol, 1 .50 eq) and triethylamine ( 196 mg, 1 .94 mmol, 2.00 eq) in dimethylformamide (5.00 mL) was added di(1 H-imidazol-1 -yl)methanone (236 mg, 1 .45 mmol, 1 .50 eq).
  • Step 1 To a solution of 3-(difluoromethyl)aniline (416 mg, 2.91 mmol, 3.00 eq) and triethylamine (392 mg, 3.87 mmol, 4.00 eq) in dimethylformamide (10.0 mL) was added di(1 H-imidazol-1 -yl)methanone (518 mg, 3.20 mmol, 3.30 eq) in one portion at 20°C.
  • Step 3 To a solution of 3-chloro-2,4,6-trimethylaniline (300 mg, 1 .77 mmol, 1 .00 eq) in toluene (10.0 mL) was added triphosgene (525 mg, 1 .77 mmol, 1 .00 eq). The reaction was stirred at 100°C for 2 h. The mixture was concentrated under reduced pressure to afford 2- chloro-4-isocyanato-1 ,3,5-trimethylbenzene (345 mg, 1 .76 mmol, 99% yield) as a yellow oil.
  • Step 1 To a solution of tert-butyl 4-aminopyrazole-1 -carboxylate (500 mg, 2.73 mmol, 1 .00 eq), pyridine (0.44 mL, 5.46 mmol, 2.00 eq) in acetonitrile (5.00 mL) was added phenyl chloroformate (0.41 mL, 3.27 mmol, 1 .20 eq) at 0°C. The reaction was stirred at 30°C for 2 h. The mixture was diluted with water (1 5.0 mL) and extracted with ethyl acetate (2 x 20.0 mL).
  • Step 2 To a mixture of 3-[6-(aminomethyl)-1 -oxo-isoindolin-2-yl]piperidine-2,6-dione hydrochloride VI (500 mg, 1 .61 mmol, 1 .00 eq, hydrochloride) and triethylamine (674 ⁇ L, 4.84 mmol, 3.00 eq) in dimethylformamide (5.00 mL) was added tert- butyl 4- (phenoxycarbonylamino)pyrazole-l -carboxylate (587 mg, 1 .94 mmol, 1 .20 eq). The reaction was stirred at 30°C for 6 h.
  • Step 3 To a solution of tert- butyl 4-[[2-(2,6-dioxo-3-piperidyl)-3-oxo-isoindolin-5-yl] methylcarbamoylamino]pyrazole-1 -carboxylate (500 mg, 1 .04 mmol, 1 .00 eq) in dioxane (5.00 mL) was added hydrochloric acid/dioxane (4 M, 2.5 mL, 9.65 eq). The reaction was stirred at 25°C for 1 h. The mixture was concentrated under reduced pressure to give a residue.
  • Step 1 To a solution of (3-chloro-2-methyl-5-nitrophenyl)methanol (1 .50 g, 7.44 mmol, 1 .00 eq) in dichloromethane (20.0 mL) was added thionyl chloride (2.70 mL, 37.2 mmol,
  • Step 2 To a solution of 1 -chloro-3-(chloromethyl)-2-methyl-5-nitrobenzene (900 mg, 4.09 mmol, 1 .00 eq) in dimethylformamide (2.00 mL) was added potassium carbonate ( 1 .13 g, 8.18 mmol, 2.00 eq), potassium iodide (67.9 mg, 0.41 mmol, 0.100 eq) and 2-oxa-6- azaspiro[3.3]heptane (81 1 mg, 8.18 mmol, 2.00 eq). The reaction was stirred at 20°C for 1 2 h. The mixture was filtered and concentrated under reduced pressure to give a residue.
  • Step 3 To a solution of 6-(3-chloro-2-methyl-5-nitrobenzyl)-2-oxa-6-azaspiro[3.3]heptane (600 mg, 2.1 2 mmol, 1 .00 eq) in ethanol (6.00 mL) and water (2.00 mL) was added iron powder (356 mg, 6.37 mmol, 3.00 eq) and ammonium chloride (568 mg, 10.6 mmol, 5.00 eq). The reaction was stirred at 80°Cfor 2 h. The mixture was filtered and concentrated under reduced pressure to give a residue.
  • Step 4 To a solution of 3-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl)-5-chloro-4- methylaniline ( 140 mg, 554 ⁇ mol, 1 .00 eq) in dichloromethane (2.00 mL) was added pyridine (0.27 mL, 3.32 mmol, 6.00 eq) and a solution of phenyl chloroformate (69.4 ⁇ L, 554 ⁇ mol, 1 .00 eq) in dichloromethane (2.00 mL) dropwise at 0°C. The reaction was stirred at 0°C for 1 h. The mixture was concentrated under reduced pressure to give a residue.
  • Step 1 To a mixture of 3-aminophenol ( 1 .00 g, 9.16 mmol, 1 .00 eq) and sodium bicarbonate (0.43 mL, 1 1 .0 mmol, 1 .20 eq) in tetrahydrofuran ( 10.0 mL) and water ( 1 .00 mL) was added phenyl chloroformate (1 .21 mL, 9.62 mmol, 1 .05 eq) at 0°C. The reaction was stirred at 0°C for 2 h. The mixture was quenched with water (10.0 mL) and extracted with ethyl acetate (10.0 mL). The organic phase was dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford phenyl N-(3-hydroxyphenyl)carbamate (2.00 g, 8.72 mmol, 95% yield) as white solid.
  • Step 2 A mixture of 3-[6-(aminomethyl)-1 -oxo-isoindolin-2-yl]piperidine-2,6-dione hydrochloride VI (0.800 g, 2.58 mmol, 1 .00 eq, hydrochloride), phenyl N-(3- hydroxyphenyl)carbamate (651 mg, 2.84 mmol, 1 .10 eq) and triethylamine (1 .08 mL, 7.75 mmol, 3.00 eq) in dimethyl formamide (10.0 mL) was heated to 50°C for 2 h.
  • Step 3 To a mixture of 2-morpholinoacetic acid (89 mg, 61 2 ⁇ mol, 1 .00 eq) and N,N- dimethylpyridin-4-amine (7.5 mg, 61 .2 ⁇ mol, 0.10 eq) in dimethyl formamide (3.00 mL) was added N,N'-methanediylidenedicyclohexanamine (136 ⁇ L, 673 ⁇ mol, 1 .10 eq) at 0°C.
  • Step 1 A mixture of tert-butyl 4-((methylsulfonyl)oxy)piperidine-1 -carboxylate (2.41 g, 8.63 mmol, 1 .20 eq), 3-nitrophenol (1 .43 mL, 7.19 mmol, 1 .00 eq), potassium carbonate
  • Step 2 To a solution of tert-butyl 4-(3-nitrophenoxy)piperidine-1 -carboxylate (500 mg, 1 .55 mmol, 1 .00 eq) in ethanol (10.0 mL) was added Pd/C 10% weight on C (400 mg, 1 .00 eq) under hydrogen atmosphere (1 5 psi). The reaction was stirred at 25°C for 6 h. The mixture was filtered, and the filtrate was concentrated under reduced pressure to afford tert- butyl 4-(3-aminophenoxy)piperidine-1 -carboxylate (428 mg, 1 .46 mmol, 94% yield) as yellow oil.
  • Step 3 To a solution of tert- butyl 4-(3-aminophenoxy)piperidine-1 -carboxylate (428 mg, 1 .46 mmol, 1 .00 eq) in dichloromethane (5.00 mL) was added pyridine (0.15 mL, 1 .90 mmol, 1 .30 eq) and phenyl chloroformate (0.20 mL, 1 .61 mmol, 1 .10 eq) at 0°C. The reaction was stirred at 25°C for 3 h. The mixture was diluted with water (5.00 mL) and extracted with ethyl acetate (3 x 5.00 mL).
  • Step 4 To a solution of tert- butyl 4-(3-((phenoxycarbonyl)amino)phenoxy)piperidine-1 - carboxylate (399 mg, 968 ⁇ mol, 1 .20 eq) in dimethyl formamide (4.00 mL) was added 3- [6-(aminomethyl)-1 -oxo-isoindolin-2-yl]piperidine-2,6-dione hydrochloride VI (250 mg, 807 ⁇ mol, 1 .00 eq, hydrochloride) and triethylamine (727 mg, 7.18 mmol, 1 .00 mL, 8.90 eq). The reaction was stirred at 40°C for 2 h under nitrogen.
  • Step 5 A solution of tert- butyl 4-(3-(3-((2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5- yl)methyl)ureido)phenoxy)piperidine-1 -carboxylate (210 mg, 354 ⁇ mol, 1.00 eq) in hydrochloric acid/ethyl acetate (4.00 mL) was stirred at 20°C for 0.5 h. The mixture was concentrated under reduced pressure to give a residue. The residue was triturated with acetonitrile at 20°Cfor 20 min to afford Compound 111 (75.0 mg, 152 ⁇ mol, 43% yield) as a white solid.
  • Step 1 To a mixture of 2-(3-nitrophenyl)-1 H-imidazole (900 g, 4.76 mmol, 1 .00 eq), di- tert- butyl dicarbonate (1 .64 mL, 7.14 mmol, 1 .50 eq), and 4-dimethylaminopyridine (58.1 mg, 475 ⁇ mol, 0.10 eq) in dichloromethane (9.00 mL) was added triethylamine (993 ⁇ L, 7.14 mmol, 1 .50 eq) and the reaction was stirred for 16 h at 25°C. The mixture was diluted with water ( 10.0 mL) and extracted with dichloromethane (3 x 10.0 mL).
  • Step 2 To a solution of tert- butyl 2-(3-nitrophenyl)-1 H-imidazole- 1 -carboxylate (500 mg, 1 .73 mmol, 1 .00 eq) in ethyl alcohol (10.0 mL) was added Pd/C 10% weight on C (400 mg, 1 .73 mmol, 1 .00 eq), and the mixture was stirred at 25°Cfor 3 h under hydrogen atmosphere
  • Step 3 To a solution of tert- butyl 2-(3-aminophenyl)-1 H-imidazole- 1 -carboxylate (790 mg, 3.05 mmol, 1 .00 eq) in dichloromethane ( 10.0 mL) was added pyridine (0.32 mL, 3.96 mmol, 1 .30 eq) and phenyl chloroformate (524 mg, 3.35 mmol, 419 ⁇ L, 1 .10 eg) at 0°C. The reaction was stirred for 3 h at 25°C. The mixture was diluted with water (50.0 mL) and extracted with dichloromethane (3 x 50.0 mL).
  • Step 1 To a solution of 3-(2-methylimidazol-1 -yl)aniline (90.0 mg, 520 pmol, 1 .00 eq) in dichloromethane (3.00 mL) was added pyridine (84 ⁇ L, 1 .04 mmol, 2.00 eq). Phenyl chloroformate (72 ⁇ L, 572 pmol, 1 .10 eq) was added to the mixture portion-wise. The reaction was stirred at 20°C for 2 h. The mixture was poured into water (5.00 mL) and extracted with dichloromethane (2 x 5.00 m). The combined organic layers were concentrated under reduced pressure to give a residue.
  • Step 1 To a solution of 4-(difluoromethyl)aniline hydrochloride (400 mg, 2.23 mmol, 1 .00 eq) in tetrahydrofuran (8.00 mL) was added triethylamine (0.62 mL, 4.45 mmol, 2.00 eq) and phenyl chloroformate (0.31 mL, 2.45 mmol, 1 .10 eq). The reaction was stirred at 20°C for 1 h. The mixture was filtered and concentrated under reduced pressure to give a residue.
  • Step 1 To a mixture of 5-bromo-1 -methyl-pyrazole (0.500 g, 3.1 1 mmol, 1 .00 eq) and (3- aminophenyl)boronic acid (510 mg, 3.73 mmol, 1 .20 eq) in dioxane (10.0 mL) and water (1 .00 mL) was added tetrakis(triphenylphosphine)palladium (359 mg, 31 1 ⁇ mol, 0.10 eq) and potassium phosphate (1 .98 g, 9.32 mmol, 3.0 eq).
  • Step 2 To a solution of 3-(2-methylpyrazol-3-yl)aniline (0.400 g, 2.31 mmol, 1 .00 eq) in dichloromethane (5.00 mL) was added pyridine (0.34 mL, 4.62 mmol, 2.00 eq). The mixture was cooled to 0°C, and phenyl chloroformate (0.32 mL, 2.54 mmol, 1 .10 eq) was added dropwise. The reaction was stirred at 20°Cfor 1 h. Water (5.00 mL) was added to the mixture.
  • Step 1 A mixture of 3-bromo-1 -methyl-pyrazole (0.550 g, 3.42 mmol, 1 .00 eq), (3- aminophenyl)boronic acid (561 mg, 4.10 mmol, 1 .20 eq), potassium phosphate (2.18 g, 10.3 mmol, 3.00 eq) and tetrakis(triphenylphosphine)palladium ( 197 mg, 171 ⁇ mol, 0.05 eq) in dioxane ( 10.0 mL) and water ( 1 .00 mL) was heated to 1 10°Cfor 1 6 h under nitrogen.
  • Step 2 To a solution of 3-(1 -methylpyrazol-3-yl)aniline (0.380 g, 2.19 mmol, 1 .00 eq) and pyridine (0.53 mL, 6.58 mmol, 3.00 eq) in dichloromethane (10.0 mL) at 0°C was added phenyl chloroformate (0.30 mL, 2.41 mmol, 1 .10 eq). The mixture was allowed to warm to 20°C and stirred for 2 h.
  • Step 1 A mixture of methyl 3-chloro-5-hydroxy-4-methyl-benzoate ( 1 .00 g, 4.98 mmol, 1 .00 eq), 3-chloro-N,N-dimethyl-propan-1 -amine hydrochloride (709 mg, 4.49 mmol, 0.90 eq, hydrochloride) and potassium carbonate (2.07 g, 14.9 mmol, 3.00 eq) in acetonitrile (20.0 mL) was stirred at 85°Cfor 1 2 h. The mixture was diluted with water (50.0 mL) and extracted with ethyl acetate (3 x 20.0 mL).
  • Step 2 To a solution of methyl 3-chloro-5-(3-(dimethylamino)propoxy)-4-methylbenzoate (900 mg, 3.1 5 mmol, 1 .00 eq) in water ( 10.0 mL) and methanol (20.0 mL) was added sodium hydroxide (252 mg, 6.30 mmol, 2.00 eq). The reaction was stirred at 60°C for 2 h. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by reversed phase preparative HPLC to afford 3-chloro-5-(3- (dimethylamino)propoxy)-4-methylbenzoic acid (750 mg, 2.76 mmol, 87% yield) as a yellow solid.
  • Step 3 To a mixture of 3-chloro-5-(3-(dimethylamino)propoxy)-4-methylbenzoic acid (600 g, 2.21 mmol, 1 .00 eq) and triethylamine (614 ⁇ L, 4.42 mmol, 2.00 eq) in 2- methylpropan-2-ol ( 10.0 mL) was added diphenyl phosphoryl azide (0.96 mL, 4.42 mmol, 2.00 eq). The reaction was stirred at 100°C for 1 2 h. The mixture was concentrated under reduced pressure to give a residue.
  • Step 4 A solution of tert- butyl (3-chloro-5-(3-(dimethylamino)propoxy)-4- methylphenyl)carbamate (350 mg, 1 .02 mmol, 1 .00 eq) in hydrogen chloride/ethyl acetate (4.00 M, 10.0 mL, 39.2 eq) was stirred at 25°C for 0.5 h. The mixture was concentrated under reduced pressure to give 3-chloro-5-(3-(dimethylamino)propoxy)-4-methylaniline (360 mg, crude, hydrogen chloride) as a yellow solid. It was used directly in the next step.
  • Step 5 To a solution of 3-chloro-5-(3-(dimethylamino)propoxy)-4-methylaniline (300 mg, 1 .07 mmol, 1 .00 eq, hydrogen chloride) and triethylamine (326 mg, 3.22 mmol, 3.00 eq) in dichloromethane (5.00 mL) was added phenyl chloroformate (252 mg, 1 .61 mmol, 1 .50 eq) at 25°C. The mixture was stirred at 25°C for 0.5 h. The mixture was concentrated under reduced pressure to give a residue.
  • Step 2 To a solution of 2,3-dimethylbenzoic acid (2.50 g, 16.6 mmol, 1 .00 eq) in sulfuric acid (25.0 mL) was added potassium nitrate (2.02 g, 19.98 mmol, 1 .20 eq) in portions at 0°C. The reaction was warmed to 1 5°C and stirred for 1 2 h. The mixture was poured into ice- water (200 mL), filtered, and the filter cake was washed with water (2 x 50.0 mL). The filter cake was dried under reduced pressure to afford 2,3-dimethyl-5-nitro-benzoic acid (3.00 g, 1 5.4 mmol, 92% yield) as a white solid.
  • Step 3 To a solution of 2,3-dimethyl-5-nitro-benzoic acid (4.50 g, 23.1 mmol, 1 .00 eq) in tetrahydrofuran ( 100 mL) was added dimethyl sulfide borane ( 10.0 M, 4.61 mL, 2.00 eq) dropwise at 20°C. The reaction was heated to 60°C and stirred for 5 h. The mixture was cooled to 0°C, then quenched with methanol (5.00 mL) and water (5.00 mL), and stirred at 20°C for 0.5 h. The mixture was concentrated under reduced pressure and poured into saturated aqueous sodium bicarbonate (50.0 mL).
  • Step 4 To a solution of (2,3-dimethyl-5-nitro-phenyl)methanol (2.50 g, 13.8 mmol, 1 .00 eq) in dichloromethane (20.0 mL) was added thionyl chloride (10.0 mL, 138 mmol, 10.0 eq) and N-methyl pyrrolidone ( 1 .34 mL, 13.8 mmol, 1 .00 eq) dropwise at 0°C. The reaction was stirred at 20°C for 1 2 h. The mixture was concentrated under reduced pressure to give a residue.
  • Step 5 To a solution of 4-[(2,3-dimethyl-5-nitro-phenyl)methyl]morpholine (2.50 g, 10.0 mmol, 1 .00 eq) in ethanol (30.0 mL) and water (1 5.0mL) were added ammonium chloride (534 mg, 10.0 mmol, 1 eq) and iron powder (2.79 g, 50.0 mmol, 5.00 eq) in portions at 20°C. The reaction was stirred at 90°C for 1 2 h. The mixture was filtered, and the filter cake was washed with methanol (50.0 mL). The filtrate was concentrated under reduced pressure to give a residue.
  • ammonium chloride 534 mg, 10.0 mmol, 1 eq
  • iron powder 2.79 g, 50.0 mmol, 5.00 eq
  • Step 1 To a solution of (3-chloro-5-nitro-phenyl)methanol (880 mg, 4.69 mmol, 1 .00 eq) and N-methyl pyrrolidone ( 1 .50 mL) in dichloromethane (10.0 mL) was added thionyl chloride (3.4 mL, 46.9 mmol, 10.0 eq) at 0°C. The reaction was stirred at 25° C for 2 h. The mixture was concentrated under reduced pressure to give a residue.
  • Step 2 To a solution of 1 -chloro-3-(chloromethyl)-5-nitro-benzene (1 .40 g, 6.80 mmol, 1 .00 eq) in acetonitrile (17.0 mL) were added triethylamine (2.36 mL, 17.0 mmol, 2.50 eq) and morpholine (0.78 mL, 8.83 mmol, 1 .30 eq). The reaction was stirred at 25°C for 1 2 h. The mixture was concentrated under reduced pressure to give a residue.
  • Step 3 To a solution of 4-[(3-chloro-5-nitro-phenyl)methyl]morpholine (980 mg, 3.82 mmol, 1 .00 eq) in ethanol ( 16.0 mL) and water (8.00 mL) were added ammonium chloride (204 mg, 3.82 mmol, 1 .00 eq) and iron powder (1 .07 g, 19.1 mmol, 5.00 eq). The reaction was stirred at 90°C for 1 2 h. The mixture was filtered and washed with ethyl acetate (20.0 mL), and the filtrate was extracted with ethyl acetate (3 x 20.0 mL).
  • Step 4 To a solution of phenyl chloroformate (0.21 mL, 1 .70 mmol, 1 .10 eq) in tetrahydrofuran (20.0 mL) was added triethylamine (0.43 mL, 3.09 mmol, 2.00 eq) and 3- chloro-5-(morpholinomethyl)aniline (350 mg, 1 .54 mmol, 1 .00 eq).
  • Step 1 To a solution of 3-chloro-4-methyl-benzoic acid (20.0 g, 1 17 mmol, 1 .00 eq) in sulfuric acid (80.0 mL) was added 1 -iodopyrrolidine-2,5-dione (29.0 g, 1 29 mmol, 1 .10 eq). The reaction was stirred at 25°C for 1 h. The mixture was poured slowly into stirred ice water (300 mL). The resulting suspension was filtered, and the filter cake was washed with water ( 100 mL) and dried under reduced pressure. Methanol (200 mL) was added, and the mixture was concentrated under reduced pressure to afford 3-chloro-5-iodo-4-methyl- benzoic acid (36.0 g, crude) as a white solid. It was used directly in the next step.
  • Step 2 To a solution of 3-chloro-5-iodo-4-methyl-benzoic acid (34.8 g, 1 17 mmol, 1 .00 eq) in methanol (500 mL) was added thionyl chloride (27.9 g, 234 mmol, 17.0 mL, 2.00 eq) dropwise at 0°C. The reaction was stirred at 60°C for 1 2 h. The mixture was concentrated to 100 mL under reduced pressure, and the resulting suspension was filtered.
  • Step 3 A solution of methyl 3-chloro-5-iodo-4-methyl-benzoate (10.0 g, 32.2 mmol, 1 .00 eq), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,3,2- dioxaborolane (16.4 g, 64.4 mmol, 2.00 eq), potassium acetate (9.48 g, 96.6 mmol, 3.00 eq) and (1 ,1 -bis(diphenylphosphino)ferrocene) dichloropalladium(ll) (2.36 g, 3.22 mmol, 0.10 eq) in dioxane (200 mL) was stirred at 1 10°C for 1 2 h.
  • the mixture was concentrated under reduced pressure to give a residue.
  • the residue was diluted with water (200 mL) and extracted with ethyl acetate (2 x 200 mL). The combined organic layers were washed with water (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to afford a residue.
  • Step 4 To a solution of tert- butyl 2-bromoacetate (0.79 mL, 5.37 mmol, 1 .00 eq), palladium acetate (36.1 mg, 161 ⁇ mol, 0.03 eq), potassium phosphate (5.70 g, 26.8 mmol, 5.00 eq) and tris-o-tolylphosphane (147 mg, 483 ⁇ mol, 0.09 eq) in tetrahydrofuran (40.0 mL) was added methyl 3-chloro-4-methyl-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- yl)benzoate (2.00 g, 6.44 mmol, 1 .20 eq).
  • Step 5 To a solution of methyl 3-(2-tert-butoxy-2-oxo-ethyl)-5-chloro-4-methyl-benzoate (400 mg, 1 .34 mmol, 1 .00 eq) in methanol (3.00 mL) was added a solution of sodium hydroxide ( 107 mg, 2.68 mmol, 2.00 eq) in water (3.00 mL). The reaction was stirred at 25°C for 1 2 h. The mixture was concentrated under reduced pressure to give a residue. The residue was diluted with 1 M hydrochloric acid (3.00 mL) and extracted with ethyl acetate (50.0 mL).
  • Step 6 To a solution of 3-(2-tert-butoxy-2-oxo-ethyl)-5-chloro-4-methyl-benzoic acid (300 mg, 1 .05 mmol, 1 .00 eq) and triethylamine (0.16 mL, 1 .16 mmol, 1 .10 eq) in toluene (3.00 mL) was added diphenylphosphoryl azide (0.25 mL, 1 .16 mmol, 1 .10 eq). The reaction was stirred at 20°C for 10 min, then phenol (0.46 mL, 5.27 mmol, 5.00 eq) was added. The reaction was stirred at 100°C for 30 min.
  • Step 7 To a solution of 3-(6-(aminomethyl)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride VI (150 mg, 484 gmol, 1 .00 eq, hydrochloride) and triethylamine (135 mI_, 969 ⁇ mol , 2.00 eq) in dimethylforma ide (2.00 mL) was added tert-butyl 2-(3-chloro-2- methyl-5-((phenoxycarbonyl)amino)phenyl)acetate (182 g, 484 ⁇ mol, 1.00 eq). The reaction was stirred at 25°C for 12 h.
  • Step 8 To a solution of tert- butyl 2-(3-chloro-5-(3-((2-(2,6-dioxopiperidin-3-yl)-3- oxoisoindolin-5-yl)methyl)ureido)-2-methylphenyl)acetate (240 mg, 432 ⁇ mol, 1 .00 eq) in dichloromethane (5.00 mL) was added trifluoroacetic acid (5.00 mL). The reaction was stirred at 20°C for 1 h. The mixture was concentrated under reduced pressure to give a residue.
  • Step 1 To a solution of 3-(pyridin-2-yloxy)aniline (0.250 g, 1 .34 mmol, 1 .00 eq) and triethylamine (0.56 mL, 4.03 mmol, 3.00 eq) in dichloromethane (5.00 mL) was added phenyl chloroformate ( 185 ⁇ L, 1 .48 mmol, 1 .10 eq) dropwise at 0°C. The reaction was stirred at 20°C for 3 h. Water (5.00 mL) was added, and the organic layer was separated, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a residue.
  • phenyl chloroformate 185 ⁇ L, 1 .48 mmol, 1 .10 eq
  • Step 1 To a solution of methyl 3-chloro-5-iodo-4-methylbenzoate (4.00 g, 1 2.9 mmol, 1 .00 eq) in toluene (40.0 mL) under nitrogen was added morpholine ( 1 .36 mL, 1 5.5 mmol, 1 .20 eq) and cesium carbonate (21 .0 g, 64.4 mmol, 5.00 eq).
  • Step 3 To a solution of 3-chloro-4-methyl-5-morpholinobenzoic acid (600 mg, 2.35 mmol, 1 .00 eq) and triethylamine (0.36 mL, 2.58 mmol, 1 .10 eq) in toluene (6.00 mL) was added diphenylphosphoryl azide (0.56 mL, 2.58 mmol, 1 .10 eq). The reaction was stirred at 20°C for 10 min.
  • Step 1 To a solution of (3-chloro-2-methyl-5-nitrophenyl)methanol (2.00 g, 9.92 mmol, 1 .00 eq) in dichloromethane (20.0 mL) was added thionyl chloride (5.90 g, 49.6 mmol, 3.60 mL, 5.00 eq) dropwise. The reaction was stirred at 25°C for 2 h. The mixture was concentrated under reduced pressure to afford 1 -chloro-3-(chloromethyl)-2-methyl-5- nitrobenzene (2.20 g, 10.0 mmol, crude) as a gray solid.
  • Step 2 A mixture of 1 -(3-chloro-2-methyl-5-nitrobenzyl)-4-methylpiperazine (0.70 g, 2.47 mmol, 1 .00 eq), ammonium chloride (1 32 mg, 2.47 mmol, 1 .00 eq) and ferrous powder (689 mg, 1 2.3 mmol, 5.00 eq) in ethanol ( 10.0 mL) and water (5.00 mL) was stirred at 90°C for 10 h. The reaction was filtered and concentrated under reduced pressure to give a residue.
  • Step 3 To a solution of 3-chloro-4-methyl-5-((4-methylpiperazin-1 -yl)methyl)aniline (0.30 g, 1 .18 mmol, 1 .00 eq) and potassium carbonate (326 mg, 2.36 mmol, 2.00 eq) in acetone (5.00 mL) was added phenyl chloroformate (0.22 mL, 1 .77 mmol, 1 .50 eq) dropwise at 0°C.
  • Step 1 A mixture of methyl 3-chloro-5-hydroxy-4-methyl-benzoate (1.00 g, 4.98 mmol, 1 .00 eq), 1 -bromo-2-methoxy-ethane (0.94 mL, 9.97 mmol, 2.00 eq) and potassium carbonate (2.76 g, 19.9 mmol, 4.00 eq) in acetonitrile (20.0 mL) was stirred at 85°C for 12 h. The mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue.
  • Step 2 A mixture of methyl 3-chloro-5-(2-methoxyethoxy)-4-methyl-benzoate (1.00 g, 3.87 mmol, 1 .00 eq) and sodium hydroxide (309 mg, 7.73 mmol, 2.00 eq) in methanol (10.0 mL) and water (10.0 mL) was stirred at 70°C for 1 2 h.
  • Step 3 A solution of 3-chloro-5-(2-methoxyethoxy)-4-methyl-benzoic acid (650 mg, 2.66 mmol, 1.00 eq), diphenyl phosphoryl azide (0.86 mL, 3.98 mmol, 1.50 eq), and triethylamine (0.74 mL, 5.31 mmol, 2.00 eq) in 2-methylpropan-2-ol (10.0 mL) was stirred at 100°C for 1 2 h. The mixture was diluted with water (50.0 mL) and extracted with ethyl acetate (3 x 20.0 mL).
  • Step 4 To a solution of tert-butyl (3-chloro-5-(2-methoxyethoxy)-4- methylphenyl)carbamate (650 mg, 2.06 mmol, 1 .00 eq) in hydrogen chloride/ethyl acetate (2.00 mL) was stirred at 25°Cfor 1 h. The mixture was concentrated under reduced pressure to afford 3-chloro-5-(2-methoxyethoxy)-4-methyl-aniline hydrochloride (500 mg, 1 .98 mmol, 96% yield, hydrochloride) as a yellow solid.
  • Step 5 To a solution of 3-chloro-5-(2-methoxyethoxy)-4-methyl-aniline hydrochloride (430 mg, 1 .99 mmol, 1 .00 eq, hydrochloride) and triethylamine (555 ⁇ L, 3.99 mmol, 2.00 eq) in dichloromethane (10.0 mL) was added phenyl chloroformate (0.30 mL, 2.39 mmol, 1 .20 eq) dropwise at 0°C. The reaction was stirred at 25°C for 0.5 h. The mixture was concentrated under reduced pressure to give a residue.
  • Step 1 To a solution of (3-chloro-2-methyl-5-nitrophenyl)methanol (1 .00 g, 4.96 mmol, 1 .00 eq) in dichloromethane (1 5.0 mL) was added thionyl chloride (2.95 g, 24.8 mmol, 1 .80 mL, 5.00 eq) at 0°C. Then the reaction was stirred at 25°C for 2 h. The mixture was concentrated under reduced pressure to give 1 -chloro-3-(chloromethyl)-2-methyl-5- nitrobenzene ( 1 .10 g, 4.96 mmol, crude) as yellow oil. It was used directly in the next step.
  • Step 2 To a solution of 1 -chloro-3-(chloromethyl)-2-methyl-5-nitrobenzene ( 1 .10 g, 5.00 mmol, 1 .00 eq) and triethylamine (1 .26 g, 1 2.5 mmol, 1 .74 mL, 2.50 eq) in acetonitrile ( 10.0 mL) was added 4-(piperidin-4-yl)morpholine ( 1 .06 g, 6.25 mmol, 1 .25 eq). The reaction was stirred at 25°C for 10 h. The mixture was concentrated under reduced pressure to give a residue.
  • Step 3 A mixture of 4-( 1 -(3-chloro-2-methyl-5-nitrobenzyl)piperidin-4-yl)morpholine ( 1 .00 g, 2.83 mmol, 1 .00 eq), ammonium chloride (1 51 mg, 2.83 mmol, 1 .00 eq) and ferrous powder (789 mg, 14.1 mmol, 5.00 eq) in ethanol (20.0 mL) and water ( 10.0 mL) was stirred at 90°C for 10 h. The mixture was filtered and concentrated under reduced pressure to afford 3-chloro-4-methyl-5-((4-morpholinopiperidin-1 -yl)methyl)aniline (0.950 g, 2.83 mmol, crude) as yellow oil. It was used directly in the next step.
  • Step 4 To a solution of 3-chloro-4-methyl-5-((4-morpholinopiperidin-1 -yl)methyl)aniline (0.92 g, 2.84 mmol, 1 .00 eq) and potassium carbonate (785 mg, 5.68 mmol, 2.00 eq) in acetone ( 10.0 mL) was added phenyl chloroformate (0.53 mL, 4.26 mmol, 1 .50 eq) dropwise. The reaction was stirred at 25°Cfor 10 h. The mixture was diluted with water (10.0 mL) and extracted with ethyl acetate (3 x 35.0 mL).
  • Step 1 To a solution of methyl 3-chloro-5-hydroxy-4-methylbenzoate (600 mg, 3.00 mmol, 1 .00 eq) in acetonitrile (6.00 mL) was added potassium iodide (49.7 mg, 0.30 mmol, 0.10 eq), potassium carbonate (1 .65 g, 12.0 mmol, 4.00 eq) and 4-(2-chloroethyl)morpholine hydrochloric acid (1.1 1 g, 5.98 mmol, 2.00 eq, hydrochloric acid).
  • Step 2 To a solution of methyl 3-chloro-4-methyl-5-(2-morpholinoethoxy)benzoate (770 mg, 2.45 mmol, 1 .00 eq) in tetrahydrofuran (3.00 mL) and water (1 .00 mL) was added lithium hydroxide monohydrate (309 mg, 7.36 mmol, 3.00 eq). The reaction was stirred at 20°C for 1 2 h. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by reversed phase column chromatography and lyophilized to give a residue.
  • Step 3 To a solution of 3-chloro-4-methyl-5-(2-morpholinoethoxy)benzoic acid (600 mg, 2.00 mmol, 1 .00 eq) in toluene (6.00 mL) was added triethylamine (446 mg, 4.40 mmol, 2.20 eq) and diphenylphosphoryl azide (606 mg, 2.20 mmol, 1 .10 eq). The reaction was stirred at 20°C for 10 min, then phenol (942 mg, 10.0 mmol, 5.00 eq) was added. The reaction was stirred at 100°C for 30 min. The mixture was concentrated under reduced pressure to give a residue.
  • Step 1 To a solution of 1 -methyl-1 H-pyrrole-3-carboxylic acid (700 mg, 5.59 mmol, 1.00 eq) in toluene (7.00 mL) was added diphenylphosphoryl azide (1.33 mL, 6.15 mmol, 1.10 eq) and triethylamine (0.86 mL, 6.15 mmol, 1.10 eq). The reaction was stirred at 20°C for 10 min, then phenol (2.46 mL, 28.0 mmol, 5.00 eq) was added and the reaction was stirred at 100°Cfor 30 min.
  • Step 1 To a solution of methyl 3-chloro-5-iodo-4-methylbenzoate (9.00 g, 29.0 mmol, 1 .00 eq) in toluene ( 180 mL) was added 2,2'-bis(diphenylphosphino)-1 , 1 '-binaphthalene (5.41 g, 8.70 mmol, 0.30 eq), diphenylmethanimine (5.84 mL, 34.8 mmol, 1 .20 eq), sodium tert- butoxide (3.90 g, 40.6 mmol, 1 .40 eq) and tris(dibenzylideneacetone)dipalladium (2.65 g, 2.90 mmol, 0.10 eq).
  • 2,2'-bis(diphenylphosphino)-1 , 1 '-binaphthalene 5.41 g, 8.70 mmol, 0.30 eq
  • diphenylmethanimine 5.
  • Step 3 To a solution of methyl 3-amino-5-chloro-4-methylbenzoate (2.86 g, 14.3 mmol, 1 .00 eq) in dimethylformamide (30.0 mL) was added iodomethane (2.68 mL, 43.0 mmol, 3.00 eq) and potassium carbonate (7.92 g, 57.3 mmol, 4.00 eq).
  • Step 5 To a solution of 3-chloro-5-(dimethylamino)-4-methylbenzoic acid (700 mg, 3.28 mmol, 1 .00 eq) and triethylamine (0.50 mL, 3.60 mmol, 1 .10 eq) in toluene (7.00 mL) was added diphenylphosphoryl azide (0.78 mL, 3.60 mmol, 1 .10 eq). The reaction was stirred at 20°C for 10 min, then phenol (1 .44 mL, 16.4 mmol, 5.00 eq) was added. The reaction was stirred at 100°C for 30 min. The mixture was concentrated under reduced pressure to give a residue.
  • Step 1 A solution of tert-butyl 4-(3-nitrophenoxy)piperidine-1 -carboxylate (800 mg, 2.48 mmol, 1 .00 eq) in hydrochloric acid/ethyl acetate (10.0 mL) was stirred at 25°C for 0.5 h. The mixture was concentrated under reduced pressure to afford 4-(3- nitrophenoxy)piperidine (630 mg, crude) as a white solid. It was used directly in the next reaction.
  • Step 2 To a solution of 4-(3-nitrophenoxy)piperidine (500 mg, 2.25 mmol, 1.00 eq) in methanol (20.0 mL) was added formaldehyde (37% purity, 0.50 mL, 6.75 mmol, 3.00 eq) and sodium cyanoborohydride (424 g, 6.75 mmol, 3.00 eq). The reaction was stirred at 25°C for 4 h. The mixture was concentrated under reduced pressure to give a residue. Water ( 10.0 mL) was added and the solution was extracted with dichloromethane (3 x 20.0 mL).
  • Step 3 To a solution of 1 -methyl-4-(3-nitrophenoxy)piperidine (320 mg, 1 .35 mmol, 1 .00 eq) in tetrahydrofuran (5.00 mL) was added Pd/C 10% weight on C ( 100 mg, 1 .00 eq). The reaction was stirred under hydrogen atmosphere ( 1 5 psi) at 20°C for 4 h. The mixture was filtered, and the filtrate was concentrated under reduced pressure to afford 3-[(1 -methyl-4- piperidyl)oxy]aniline (270 mg, 1 .31 mmol, 97% yield) as a yellow solid.
  • Step 4 To a solution of 3-[(1 -methyl-4-piperidyl)oxy]aniline (270 mg, 1 .31 mmol, 1 .00 eq) in dichloromethane (10.0 mL) was added pyridine (0.32 mL, 3.93 mmol, 3.00 eq) at 0°C, then phenyl chloroformate (0.18 mL, 1 .44 mmol, 1 .10 eq) was added. The reaction was stirred at 20°C for 6 h. The mixture was concentrated under reduced pressure to give a residue. The residue was diluted with water ( 1 5.0 mL) and extracted with dichloromethane (3 x 20.0 mL).
  • Step 1 To a mixture of 1 -(4-nitrophenyl)ethanone (2.00 g, 1 2.1 mmol, 1 .00 eq) in ethanol ( 18.0 mL) and water (9.00 mL) was added ammonium chloride (648 mg, 1 2.1 mmol, 1 .00 eq) and ferrous powder (3.38 g, 60.6 mmol, 5.00 eq). The reaction was stirred at 90°C for 10 h. The mixture was filtered, and the filtrate was extracted with ethyl acetate (3 x 30.0 mL).
  • Step 2 To a solution of 1 -(4-aminophenyl)ethanone (1 .60 g, 1 1 .8 mmol, 1 .00 eq) in tetrahydrofuran (20.0 mL) was added methylmagnesium bromide (3.00 M, 1 1 .8 mL, 3.00 eq) dropwise at 0°C. Then the reaction was stirred at 25°C for 10 h. The mixture was quenched by addition saturated ammonium chloride (1 5.0 mL), diluted with water (10.0 mL), and extracted with ethyl acetate (3 x 55.0 mL).
  • Step 3 To a solution of 2-(4-aminophenyl)propan-2-ol (0.45 g, 2.98 mmol, 1 .00 eq) and 2,6-dimethylpyridine (0.38 mL, 3.27 mmol, 1.10 eq) in tetrahydrofuran (3.00 mL) and trichloromethane (3.00 mL) was added phenyl chloroformate (0.37 mL, 2.98 mmol, 1 .00 eq) at 0°C. The reaction was stirred at 0°C for 1 h. The mixture was diluted with water ( 10.0 mL) and extracted with dichloromethane (3 x 35.0 mL).
  • Step 1 To a solution of 3-chloro-2-methylbenzoic acid (41 .0 g, 240 mmol, 1 .00 eq) in sulfuric acid (200 mL) was added nitric acid ( 1 2.3 mL, 264 mmol, 1 .10 eq) dropwise at - 10°C. The reaction was stirred at -10°C for 1 h. The mixture was poured into stirred ice water (200 mL). The resulting precipitate was collected by filtration and washed with water to afford 3-chloro-2-methyl-5-nitrobenzoic acid (52.0 g, 241 mmol, crude) as a white solid. It was used directly in the next step.
  • Step 2 To a solution of 3-chloro-2-methyl-5-nitrobenzoic acid (52.0 g, 67.5 mmol, 1 .00 eq) in tetrahydrofuran (400 mL) was added borane dimethyl sulfide complex (10.0 M, 13.5 mL, 2.00 eq) at 0°C. The reaction was stirred at 25°C for 10 h. Water (25.0 mL) was added at
  • Step 3 To a solution of (3-chloro-2-methyl-5-nitrophenyl)methanol (1 .10 g, 5.46 mmol, 1 .00 eq) in dichloromethane (10.0 mL) was added thionyl chloride (3.25 g, 27.3 mmol, 1 .98 mL, 5.00 eq) at 0°C. The reaction was stirred at 25°C for 2 h. The mixture was concentrated under reduced pressure to give a residue. The residue was diluted with water ( 10.0 mL) and extracted with ethyl acetate (3 x 35.0 mL).
  • Step 4 To a solution of sodium hydride 60% purity (473 mg, 1 1 .8 mmol, 2.00 eq) in tetrahydrofuran (1 5.0 mL) was added diethyl malonate ( 1 .79 mL, 1 1 .8 mmol, 2.00 eq) slowly at 0°C. After 1 h, 1 -chloro-3-(chloromethyl)-2-methyl-5-nitrobenzene (1 .30 g, 5.91 mmol, 1 .00 eq) was added, and the reaction was stirred at 25°C for 10 h. Water ( 10.0 mL) was added, and the mixture was extracted with ethyl acetate (3 x 35.0 mL).
  • Step 5 To a solution of diethyl 2-(3-chloro-2-methyl-5-nitrobenzyl)malonate (2.00 g, 5.82 mmol, 1 .00 eq) in tetrahydrofuran (16.0 mL) was added sodium borohydride ( 1 .10 g, 29.1 mmol, 5.00 eq) in portions at 0°C. Methanol (4.00 mL) was added, and the reaction was stirred at 25°C for 10 h. Water ( 10.0 mL) was added, and the organic solvents were removed under reduced pressure.
  • Step 6 To a solution of 2-(3-chloro-2-methyl-5-nitrobenzyl)propane-1 ,3-diol ( 1 .40 g, 5.39 mmol, 1 .00 eq) in dichloromethane (10.0 mL) were added dimethoxymethane (71 5 ⁇ L, 8.09 mmol, 1 .50 eq) and boron trifluoride diethyl etherate (1 mL, 8.09 mmol, 1 .50 eq). The reaction was stirred at 25°C for 1 .5 h. The mixture was diluted with water (10.0 mL) and extracted with dichloromethane (3 x 35.0 mL).
  • Step 7 A mixture of 5-(3-chloro-2-methyl-5-nitrobenzyl)-1 ,3-dioxane (1 .00 g, 3.68 mmol, 1 .00 eq), ammonium chloride (197 mg, 3.68 mmol, 1 .00 eq) and ferrous powder ( 1 .03 g, 18.4 mmol, 5.00 eq) in ethanol (1 5.0 mL) and water (7.00 mL) was stirred at 90°C for 10 h. The mixture was filtered and concentrated under reduced pressure to give a residue. Water ( 10.0 mL) was added, and the mixture was extracted with ethyl acetate (3 x 35.0 mL).
  • Step 8 To a solution of 3-((1 ,3-dioxan-5-yl) methyl)- 5-chloro-4-methylaniline (0.20 g, 827 ⁇ mol, 1 .00 eq) and potassium carbonate (229 mg, 1 .65 mmol, 2.00 eq) in acetone (5.00 mL) was added phenyl chloroformate ( 1 24 ⁇ L, 993 ⁇ mol, 1 .20 eq). The reaction was stirred at 25°C for 10 h. The mixture was diluted with water (10.0 mL) and extracted with ethyl acetate (3 x 30.0 mL).
  • Step 1 To a solution of (3-chloro-2-methyl-5-nitrophenyl)methanol (0.80 g, 3.97 mmol, 1 .00 eq) in dichloromethane (10.0 mL) was added thionyl chloride (1 .44 mL, 19.8 mmol, 5.00 eq) at 0°C. The reaction was stirred at 25°Cfor 2 h. The mixture was concentrated under reduced pressure to afford 1 -chloro-3-(chloromethyl)-2-methyl-5-nitrobenzene (0.90 g, 4.09 mmol, crude) as yellow oil. It was used directly in the next step.
  • Step 2 To a solution of 1 -chloro-3-(chloromethyl)-2-methyl-5-nitrobenzene (0.90 g, 4.09 mmol, 1 .00 eq) and triethylamine (1 .42 mL, 10.2 mmol, 2.50 eq) in acetonitrile (10.0 mL) was added N,N-dimethylpiperidin-4-amine (655 mg, 5.1 1 mmol, 1 .25 eq). The reaction was stirred at 25°C for 10 h.
  • Step 3 A mixture of 1 -(3-chloro-2-methyl-5-nitrobenzyl)-N,N-dimethylpiperidin-4-amine ( 1 .30 g, 4.17 mmol, 1 .00 eq), ammonium chloride (223 mg, 4.17 mmol, 1 .00 eq) and ferrous powder ( 1 .16 g, 20.9 mmol, 5.00 eq) in ethanol (20.0 mL) and water (10.0 mL) was stirred at 90°C for 10 h. The mixture was filtered and concentrated under reduced pressure to give a residue.
  • Step 4 To a solution of 1 -(5-amino-3-chloro-2-methylbenzyl)-N,N-dimethylpiperidin-4- amine (0.60 g, 2.1 3 mmol, 1 .00 eq) and potassium carbonate (588 mg, 4.26 mmol, 2.00 eq) in acetone (10.0 mL) was added phenyl chloroformate (400 mg, 2.55 mmol, 320 ⁇ L, 1 .20 eq). The reaction was stirred at 25°C for 1 h. The mixture was filtered and concentrated under reduced pressure to give a residue.
  • Step 1 To a solution of methyl 3-chloro-5-hydroxy-4-methylbenzoate (600 mg, 2.99 mmol, 1 .00 eq) in acetonitrile (6.00 mL) was added potassium iodide (49.7 mg, 299 ⁇ mol, 0.10 eq), potassium carbonate ( 1 .65 g, 1 2.0 mmol, 4.00 eq) and 2-chloro-N,N- dimethylethanamine (862 mg, 5.98 mmol, 2.00 eq, hydrochloric acid). The reaction was stirred at 80°C for 1 2 h. The mixture was filtered and concentrated under reduced pressure to give a residue.
  • potassium iodide 49.7 mg, 299 ⁇ mol, 0.10 eq
  • potassium carbonate 1 .65 g, 1 2.0 mmol, 4.00 eq
  • 2-chloro-N,N- dimethylethanamine 862 mg, 5.98 mmol, 2.00 eq, hydrochloric acid
  • Step 2 To a solution of methyl 3-chloro-5-(2-(dimethylamino)ethoxy)-4-methylbenzoate (500 mg, 1 .84 mmol, 1 .00 eq) in tetrahydrofuran (1 .50 mL) and water (0.50 mL) was added lithium hydroxide monohydrate (232 mg, 5.52 mmol, 3.00 eq). The reaction was stirred at 20°C for 1 2 h. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by reversed phase column chromatography and lyophilized to give solid.
  • Step 3 To a solution of 3-chloro-5-(2-(dimethylamino)ethoxy)-4-methylbenzoic acid (300 mg, 1 .1 6 mmol, 1 .00 eq) in toluene (1 .00 mL) was added triethylamine (259 mg, 2.56 mmol, 2.20 eq) and diphenylphosphoryl azide (352 mg, 1 .28 mmol, 1 .10 eq). The reaction was stirred at 20°C for 10 min, then phenol (548 mg, 5.82 mmol, 5.00 eq) was added. The reaction was stirred at 100°C for 30 min. The mixture was concentrated under reduced pressure to give a residue.
  • Step 1 A mixture of 1 -(3-nitrophenyl)ethanone (2.00 g, 1 2.1 mmol, 1 .00 eq), ammonium chloride (648 mg, 1 2.1 mmol, 1 .00 eq) and ferrous powder (3.38 g, 60.6 mmol, 5.00 eq) in ethanol (20.0 mL) and water ( 10.0 mL) was stirred at 90°C for 10 h. The mixture was filtered, and the filtrate was extracted with ethyl acetate (3 x 50.0 mL).
  • Step 2 To a solution of 1 -(3-aminophenyl)ethanone (1 .50 g, 1 1 .1 mmol, 1 .00 eq) in tetrahydrofuran ( 1 5.0 mL) was added methylmagnesium bromide (3.00 M, 1 1 .1 mL, 3.00 eq) dropwise at 0°C. The reaction was stirred at 25°C for 2 h. The mixture was quenched by addition saturated ammonium chloride (8.00 mL), and then diluted with water (5.00 mL) and extracted with ethyl acetate (3 x 30.0 mL).
  • Step 3 To a solution of 2-(3-aminophenyl)propan-2-ol (0.10 g, 661 ⁇ mol, 1 .00 eq) and 2,6-dimethylpyridine (84.7 ⁇ L, 727 ⁇ mol, 1 .10 eq) in tetrahydrofuran (0.50 mL) and trichloromethane (0.50 mL) was added phenyl chloroformate (82.8 ⁇ L, 661 ⁇ mol, 1 .00 eq) slowly at 0°C. The reaction was stirred at 25°C for 2 h. The mixture was diluted with water (5.00 mL) and extracted with dichloromethane (3 x 25.0 mL).
  • Compound 136 Scheme for the preparation of Compound 136.
  • Step 1 A mixture of 2-(dimethylamino)acetic acid (75.7 mg, 734 ⁇ mol, 1.50 eq), 4- dimethylaminopyridine (6.0 mg, 48.9 ⁇ mol, 0.10 eq) and N,N'- methanediylidenedicyclohexanamine (148 ⁇ L, 734 ⁇ mol, 1.50 eq) in dimethylformamide (5.00 mL) was stirred at 20°C for 30 min, then 1 -( (2-( 2,6-dioxopiperidin-3-yl)-3- oxoisoindolin-5-yl)methyl)-3-(3-hydroxyphenyl)urea (described in example 110) (200 mg, 489 ⁇ mol, 1 .00 eq) was added. The reaction was stirred at 20°C for 12h, then at 40°C for
  • Step 1 To a solution of 6-chloro-5-methyl-pyridin-2-amine (300 mg, 2.10 mmol, 1 .00 eq) in dichloromethane (15.0 mL) was added pyridine (0.25 mL, 3.16 mmol, 1.50 eq) and phenyl chloroformate (0.26 mL, 2.10 mmol, 1 .00 eq) at 0°C. The reaction was stirred at 20°C for 2 h. The mixture was diluted with water (20.0 mL) and extracted with ethyl acetate (3 x 30.0 mL).
  • Step 1 To a solution of 1 -(bromomethyl)-3-chloro-2-methyl-5-nitrobenzene (500 g, 1 .89 mmol, 1 .00 eq) in acetonitrile (10.0 mL) was added 3-oxa-8-azabicyclo[3.2.1 ]octane hydrochloride (283 mg, 1.89 mmol, 1.00 eq, hydrochloride), potassium carbonate (523 mg, 3.78 mmol, 2.00 eq) and potassium iodide (31 .4 mg, 189 ⁇ mol, 0.10 eq).
  • Step 3 To a solution of 3-(3-oxa-8-azabicyclo[3.2.1 ]octan-8-ylmethyl)-5-chloro-4- methylaniline (230 mg, 862 ⁇ mol, 1 .00 eq) and potassium carbonate (1 19 mg, 862 ⁇ mol, 1 .00 eq) in acetone (3.00 mL) was added phenyl chloroformate (0.1 1 mL, 862 ⁇ mol, 1 .00 eq) dropwise. The reaction was stirred at 20°C for 1 h. The mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue.
  • Step 1 To a solution of 2-oxa-5-azabicyclo[2.2.1 ]heptane hydrochloride (308 mg, 2.27 mmol, 1 .00 eq, hydrochloride) in acetonitrile (10.0 mL) was added 1 -(bromomethyl)-3- chloro-2-methyl-5-nitrobenzene (600 mg, 2.27 mmol, 1 .00 eq), potassium carbonate (627 mg, 4.54 mmol, 2.00 eq) and potassium iodide (37.6 mg, 227 ⁇ mol, 0.10 eq). The reaction was stirred at 80°C for 1 2 h.
  • Step 2 To a solution of 5-(3-chloro-2-methyl-5-nitrobenzyl)-2-oxa-5- azabicyclo[2.2.1 ]heptane (500 mg, 1 .77 mmol, 1 .00 eq), ammonium chloride (662 mg, 1 2.4 mmol, 7.00 eq) in methanol (8.00 mL) and water (2.00 mL) was added iron powder (691 mg, 1 2.4 mmol, 7.00 eq) in portions. The reaction was stirred at 70°C for 2 h. The mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue.
  • ammonium chloride 662 mg, 1 2.4 mmol, 7.00 eq
  • iron powder 691 mg, 1 2.4 mmol, 7.00 eq
  • Step 3 To a solution of 3-(2-oxa-5-azabicyclo[2.2.1 ]heptan-5-ylmethyl)-5-chloro-4- methylaniline (300 mg, 1 .19 mmol, 1 .00 eq) and phenyl chloroformate (0.1 5 mL, 1 .19 mmol, 1 .00 eq) in acetone (3.00 mL) was added potassium carbonate (492 mg, 3.56 mmol, 3.00 eq) in portions. The reaction was stirred at 1 5°C for 2 h. Water (30.0 mL) was added, and the mixture was extracted with ethyl acetate (3 x 30.0 mL).
  • Step 1 To a solution of 8-oxa-3-azabicyclo[3.2.1 ]octane (400 mg, 3.53 mmol, 1 .00 eq) and triethylamine (0.74 mL, 5.30 mmol, 1 .50 eq) in tetrahydrofuran (1 5.0 mL) was added 1 - (bromomethyl)-3-chloro-2-methyl-5-nitrobenzene (842 mg, 3.18 mmol, 0.90 eq). The reaction was stirred at 20°C for 6 h. The mixture was concentrated under reduced pressure to afford a residue.
  • Step 2 A mixture of 3-(3-chloro-2-methyl-5-nitrobenzyl)-8-oxa-3-azabicyclo[3.2.1 ]octane (750 g, 2.53 mmol, 1 .00 eq), ammonium chloride (1 35 mg, 2.53 mmol, 1 .00 eq) and iron powder (706 mg, 1 2.6 mmol, 5.00 eq) in ethanol (20.0 mL) and water ( 10.0 mL) was stirred at 90°C for 3 h. The mixture was filtered and concentrated under reduced pressure to give a residue.
  • Step 3 To a solution of 3-(8-oxa-3-azabicyclo[3.2.1 ]octan-3-ylmethyl)-5-chloro-4- methylaniline (300 mg, 1 .1 2 mmol, 1 .00 eq) and potassium carbonate (466 mg, 3.37 mmol, 3.00 eq) in acetone (3.00 mL) was added phenyl chloroformate (0.14 mL, 1 .1 2 mmol, 1 .00 eq) dropwise. The reaction was stirred at 15°C for 2 h. Water (50.0 mL) was added, and the mixture was extracted with ethyl acetate (3 x 40.0 mL).
  • Step 1 To a solution of 2-(3-chloro-2-methyl-5-nitrobenzyl)propane-1 ,3-diol ( 1 .00 g, 3.85 mmol, 1 .00 eq) (described in example 132) and 1 , 1 -dimethoxyethane (61 1 ⁇ L, 5.78 mmol, 1 .50 eq) in dichloromethane (10.0 mL) was added boron trifluoride diethyl etherate (713 ⁇ L, 5.78 mmol, 1 .50 eq).
  • Step 2 A mixture of 5-(3-chloro-2-methyl-5-nitrobenzyl)-2-methyl-1 ,3-dioxane ( 1 .10 g, 3.85 mmol, 1 .00 eq), ferrous powder (1 .07 g, 19.3 mmol, 5.00 eq) and ammonium chloride

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/EP2020/078483 2019-10-09 2020-10-09 Isoindolinone compounds Ceased WO2021069705A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022521718A JP7724394B2 (ja) 2019-10-09 2020-10-09 イソインドリノン化合物
EP20789952.7A EP4041231A1 (en) 2019-10-09 2020-10-09 Isoindolinone compounds
US17/716,169 US20220242846A1 (en) 2019-10-09 2022-04-08 Isoindolinone compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH01281/19 2019-10-09
CH12812019 2019-10-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/716,169 Continuation US20220242846A1 (en) 2019-10-09 2022-04-08 Isoindolinone compounds

Publications (1)

Publication Number Publication Date
WO2021069705A1 true WO2021069705A1 (en) 2021-04-15

Family

ID=68242216

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2020/078483 Ceased WO2021069705A1 (en) 2019-10-09 2020-10-09 Isoindolinone compounds

Country Status (4)

Country Link
US (1) US20220242846A1 (enExample)
EP (1) EP4041231A1 (enExample)
JP (1) JP7724394B2 (enExample)
WO (1) WO2021069705A1 (enExample)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022153220A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Methods for the identification of degrons
WO2022152821A1 (en) * 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
WO2022152822A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Treatment of myc-driven cancers with gspt1 degraders
WO2022200857A1 (en) * 2021-03-22 2022-09-29 Monte Rosa Therapeutics Ag Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons
WO2022256623A1 (en) 2021-06-04 2022-12-08 Monte Rosa Therapeutics, Inc. E3 ligase fusion proteins for proximity detection
WO2022268066A1 (zh) * 2021-06-22 2022-12-29 苏州开拓药业股份有限公司 一种蛋白降解剂
CN115636811A (zh) * 2022-08-17 2023-01-24 成都分迪药业有限公司 异吲哚啉苄胺衍生物的合成方法
JP2023507590A (ja) * 2019-12-17 2023-02-24 オリオニス バイオサイエンシズ，インコーポレイテッド タンパク質の動員および／または分解を調節する化合物
WO2023069720A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
WO2023069708A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and uses thereof
WO2023069700A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
WO2023069731A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
WO2023091567A1 (en) 2021-11-17 2023-05-25 Monte Rosa Therapeutics, Inc. Degron and neosubstrate identification
CN116583509A (zh) * 2020-10-07 2023-08-11 上海睿跃生物科技有限公司 治疗癌症的化合物和方法
WO2023201282A1 (en) * 2022-04-14 2023-10-19 Bristol-Myers Squibb Company Novel gspt1 compounds and methods of use of the novel compounds
CN117242060A (zh) * 2021-01-13 2023-12-15 蒙特罗萨医疗公司 异吲哚啉酮化合物
WO2024015855A1 (en) 2022-07-13 2024-01-18 Monte Rosa Therapeutics, Inc. COMBINATION THERAPY COMPRISING GSPT1-DIRECTED MOLECULAR GLUE DEGRADERS AND PI3K/AKT/mTOR PATHWAY INHIBITORS
WO2024015565A1 (en) * 2022-07-14 2024-01-18 Monte Rosa Therapeutics, Inc. Methods of preparing an isoindolinone derivative and crystal forms thereof
WO2024027795A1 (zh) * 2022-08-04 2024-02-08 苏州开拓药业股份有限公司 包含Myc蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
WO2024054832A1 (en) 2022-09-09 2024-03-14 Innovo Therapeutics, Inc. CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS
JP2024527628A (ja) * 2021-07-19 2024-07-25 メッドシャイン ディスカバリー インコーポレイテッド ヘテロアリール－３－ピペリジンジオン化合物その使用
WO2024201248A1 (en) * 2023-03-24 2024-10-03 Pin Therapeutics, Inc. Compounds and methods for degrading gspt1
WO2025051180A1 (zh) * 2023-09-06 2025-03-13 上海超阳药业有限公司 内酰胺类衍生物及其应用
WO2025085416A1 (en) * 2023-10-16 2025-04-24 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the compounds
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025146112A1 (en) * 2024-01-05 2025-07-10 Primelink Biotherapeutics (Shenzhen) Co., Ltd. Gspt1 degrading compounds and compositions and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059106A1 (en) * 2000-12-27 2002-08-01 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
WO2008027542A2 (en) * 2006-08-30 2008-03-06 Celgene Corporation 5-substituted isoindoline compounds
WO2019148055A1 (en) * 2018-01-26 2019-08-01 Yale University Imide-based modulators of proteolysis and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG195613A1 (en) 2008-10-29 2013-12-30 Celgene Corp Isoindoline compounds for use in the treatment of cancer
TWI696615B (zh) 2016-05-05 2020-06-21 瑞士商伊蘭科動物健康公司 雜芳基-1,2,4-三唑及雜芳基-三唑化合物
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
KR20250044800A (ko) 2016-10-11 2025-04-01 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적 분해용 화합물 및 방법
KR20230051120A (ko) * 2020-03-31 2023-04-17 오름테라퓨틱 주식회사 신규분해약물 접합체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059106A1 (en) * 2000-12-27 2002-08-01 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
WO2008027542A2 (en) * 2006-08-30 2008-03-06 Celgene Corporation 5-substituted isoindoline compounds
WO2019148055A1 (en) * 2018-01-26 2019-08-01 Yale University Imide-based modulators of proteolysis and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DANIEL P. BONDESON ET AL: "Targeted Protein Degradation by Small Molecules", ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY., vol. 57, no. 1, 12 October 2016 (2016-10-12), US, pages 107 - 123, XP055588533, ISSN: 0362-1642, DOI: 10.1146/annurev-pharmtox-010715-103507 *
GANG LU ET AL: "A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase (inlcudes methods)", vol. 535, 14 July 2016 (2016-07-14), pages 252 - 257, 17pp, XP002784903, ISSN: 0028-0836, Retrieved from the Internet <URL:https://www.nature.com/articles/nature18611> [retrieved on 20160622], DOI: 10.1038/NATURE18611 *
PHILIP P. CHAMBERLAIN ET AL: "Cereblon modulators: Low molecular weight inducers of protein degradation", DRUG DISCOVERY TODAY: TECHNOLOGIES, vol. 31, 1 April 2019 (2019-04-01), AMSTERDAM, NL, pages 29 - 34, XP055758408, ISSN: 1740-6749, DOI: 10.1016/j.ddtec.2019.02.004 *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023507590A (ja) * 2019-12-17 2023-02-24 オリオニス バイオサイエンシズ，インコーポレイテッド タンパク質の動員および／または分解を調節する化合物
CN116583509A (zh) * 2020-10-07 2023-08-11 上海睿跃生物科技有限公司 治疗癌症的化合物和方法
WO2022152821A1 (en) * 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
WO2022152822A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Treatment of myc-driven cancers with gspt1 degraders
US12391663B2 (en) 2021-01-13 2025-08-19 Monte Rosa Therapeutics Ag Isoindolinone compounds
WO2022153220A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Methods for the identification of degrons
US11912682B2 (en) 2021-01-13 2024-02-27 Monte Rosa Therapeutics, Inc. Isoindolinone compounds
CN117242060A (zh) * 2021-01-13 2023-12-15 蒙特罗萨医疗公司 异吲哚啉酮化合物
WO2022200857A1 (en) * 2021-03-22 2022-09-29 Monte Rosa Therapeutics Ag Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons
WO2022256623A1 (en) 2021-06-04 2022-12-08 Monte Rosa Therapeutics, Inc. E3 ligase fusion proteins for proximity detection
WO2022268066A1 (zh) * 2021-06-22 2022-12-29 苏州开拓药业股份有限公司 一种蛋白降解剂
JP2024527628A (ja) * 2021-07-19 2024-07-25 メッドシャイン ディスカバリー インコーポレイテッド ヘテロアリール－３－ピペリジンジオン化合物その使用
WO2023069731A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
WO2023069700A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
WO2023069708A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and uses thereof
WO2023069720A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
WO2023091567A1 (en) 2021-11-17 2023-05-25 Monte Rosa Therapeutics, Inc. Degron and neosubstrate identification
US12187699B2 (en) 2022-04-14 2025-01-07 Bristol-Myers Squibb Company GSPT1 compounds and methods of use of the novel compounds
WO2023201282A1 (en) * 2022-04-14 2023-10-19 Bristol-Myers Squibb Company Novel gspt1 compounds and methods of use of the novel compounds
WO2024015855A1 (en) 2022-07-13 2024-01-18 Monte Rosa Therapeutics, Inc. COMBINATION THERAPY COMPRISING GSPT1-DIRECTED MOLECULAR GLUE DEGRADERS AND PI3K/AKT/mTOR PATHWAY INHIBITORS
WO2024015565A1 (en) * 2022-07-14 2024-01-18 Monte Rosa Therapeutics, Inc. Methods of preparing an isoindolinone derivative and crystal forms thereof
WO2024027795A1 (zh) * 2022-08-04 2024-02-08 苏州开拓药业股份有限公司 包含Myc蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
CN115636811A (zh) * 2022-08-17 2023-01-24 成都分迪药业有限公司 异吲哚啉苄胺衍生物的合成方法
WO2024054832A1 (en) 2022-09-09 2024-03-14 Innovo Therapeutics, Inc. CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS
WO2024201248A1 (en) * 2023-03-24 2024-10-03 Pin Therapeutics, Inc. Compounds and methods for degrading gspt1
WO2025051180A1 (zh) * 2023-09-06 2025-03-13 上海超阳药业有限公司 内酰胺类衍生物及其应用
WO2025085416A1 (en) * 2023-10-16 2025-04-24 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the compounds
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds

Also Published As

Publication number Publication date
US20220242846A1 (en) 2022-08-04
EP4041231A1 (en) 2022-08-17
JP2022551185A (ja) 2022-12-07
JP7724394B2 (ja) 2025-08-18

Similar Documents

Publication Publication Date Title
US20220242846A1 (en) Isoindolinone compounds
US11912682B2 (en) Isoindolinone compounds
US11034672B1 (en) Tyrosine kinase inhibitor compositions, methods of making and methods of use
US20240051936A1 (en) Isoindolinone compounds
RU2699546C2 (ru) Комбинированная терапия для лечения рака
JP7649289B2 (ja) アルキニルキナゾリン化合物
KR102534028B1 (ko) 트리아졸로피리미딘 화합물 및 그의 용도
US20240051937A1 (en) Isoindolinone amide compounds useful to treat diseases associated with gspt1
US9562019B2 (en) Substituted pyridazines as EGFR and/or KRAS inhibitors
US20220041613A1 (en) Tyrosine kinase inhibitor compositions, methods of making and methods of use
WO2022026935A1 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
WO2022015670A1 (en) Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors
WO2022170052A1 (en) Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
CN117242060A (zh) 异吲哚啉酮化合物
EA048940B1 (ru) Соединения алкинилхиназолина

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20789952

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022521718

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020789952

Country of ref document: EP

Effective date: 20220509